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Chapter 1  General Introduction       
 
Leprosy is a chronic infectious disease that affects hundreds of thousands of people every 
year. Its prevalence has dramatically reduced from millions in the 1980s to hundreds of 
thousands in the last 30 years as a result of the introduction of multidrug treatment (MDT) 
which is a combination of dapsone, clofazimine and rifampicin [7;204]. However, since the 
last decade, the annual numbers of new leprosy cases have become consistent indicating the 
continuing disease transmission [183;203;205]. The numbers of new cases in children, and 
the numbers of patients with grade 2 disability (visible deformity in hands/feet and/or visual 
impairment) reported every year are good indicators of the ongoing transmission and the 
delayed detection of cases, respectively. This is mainly due to the lack of early diagnostic 
tools [83] as well as poor awareness and knowledge of the signs and symptoms of the disease 
among the public and health professionals. 
 
Leprosy primarily affects the peripheral nerves and skin and its cardinal signs are skin lesions, 
loss of sensation and nerve thickenings. The disease manifests itself in different clinical 
forms. For treatment purposes, WHO classifies leprosy cases as multi-bacillary (MB) and 
pauci-bacillary (PB) where cases with more than 5 skin lesions and high bacterial load are 
considered as MB and those with less than 5 skin lesions and low bacterial load as PB [1]. 
The clinical forms are further classified in to five groups based on the host’s immunological 
responses, bacterial load and histopathological features of the lesions into tuberculoid leprosy 
(TT), borderline tuberculoid leprosy (BT), borderline borderline leprosy (BB), borderline 
lepromatous leprosy (BL) and lepromatous leprosy (LL). The TT and LL are stable forms 
whereas the borderlines are immunologically unstable. The cell mediated immunity decreases 
from TT to LL whereas the bacterial load and antibody level increase [181]. 
 
The discovery of Mycobacterium leprae (M. leprae) as an etiologic agent of leprosy a century 
ago, and later the development of efficient treatment regimens have proven that leprosy is a 
curable infectious disease [157;158;247]. The recent whole M. leprae genome sequencing 
project [39] has further opened the way for new avenues in leprosy research. Hence, there are 
currently more opportunities than ever before to better understand M. leprae and leprosy.  
 
Following the availability of the whole genome sequence of M. leprae, several unique M. 
leprae proteins have been identified [81;191;218]. These were tested in different endemic 
sites in Asia, Africa and South America for their immunogenicity and for their discriminating 
potential of those infected and at risk of becoming infected, such as household contacts 
[22;86]. The M. leprae unique proteins identified as well as the host biomarkers induced by 
stimulation of blood cells by these proteins (including cytokines, chemokines, growth factors 
and others) provide important new tools for leprosy disease control, and are currently being 
validated in large-scale studies for their potential application in the early detection of leprosy 
(before the onset of clinical signs and symptoms of the disease) [65;68;83].  
 
1.1. The Global Leprosy burden 
 
“We can endure losing fingers and toes, eyes and nose, but what we cannot endure is to be 
rejected by those nearest and dearest”;  a leprosy victim from Nepal [174].  
The disfiguring character of leprosy and the wrong perception on the cause and transmission 
of the disease are the main reasons for stigmatizing leprosy affected people [43;174;230]. 
Leprosy is a curable chronic infectious disease; however this scientific fact is not yet well 
perceived in minds of many people irrespective of their level of knowledge [15;92]. Some 
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studies have also shown the strong stigma in leprosy compared to other diseases and its 
devastating impact on the lives of patients and their close relatives [177].  
 
The dramatic reduction in leprosy prevalence and number of new cases in the post MDT era 
is undeniable, which has been the result of the determined efforts to eliminate leprosy. 
However, in the last couple of years, more than 200,000 new leprosy cases including children 
have been registered each year. Among the 5 WHO regions, the South-East-Asia region has 
the largest number of new cases (166,445) per year, followed by the Americas (36,000) and 
the African countries (20,599). Multi-bacillary (MB) new cases dominated in most of the 
regions and percentages of children affected ranges from 0.6% in Argentina to 24.5% in 
Cameroon and disabilities from 0.7 % in Marshall Islands to 25.4% in Uganda [7]. Here the 
major concerns are the considerable number of children and the grade 2 disabilities among 
new leprosy cases. 
 
Number of new cases per given period of time and death or disability adjusted life years 
(DALY) are among the many ways to express a disease burden [178]. The disability together 
with self and society driven psychological distresses leave leprosy affected persons with a life 
time of misery and pain [212]. Despite the fact that leprosy is the leading cause of disability, 
leprosy associated DALYs are not registered in many high burden countries except the recent 
assessment in 3 states in India which showed the loss of 13.4 productive working years due to 
disability (DAWLY) of the 42 years estimated productive years [178]. Unlike TB or malaria, 
mortality due to leprosy is not a major concern although some deaths may occur from  
indirect effects of leprosy [72;138] and there were also a few reports showing the higher risk 
of death in lepromatous leprosy (LL) patients compared with the general population in pre 
MDT era [156]. However, the chain of disability to poor quality of life, to inevitable 
economic and physical dependence on family and society, to noticeable stigma, to mental 
distress greatly affects the lives of leprosy patients [132;201;235].   
 
Leprosy control activities have been integrated with other health services since 1997 with the 
intention of better management of leprosy and reducing stigma [5]. However, the emergence 
of TB in the 1990s [3] and its co-infection with HIV diverted the focus of TB-leprosy control 
programs in most countries for the last two decades heavily towards TB/HIV. As a result 
leprosy has been left as poorly managed disease due to lack of knowledge, interest and 
commitment. The integration of leprosy management in the general health services has had 
its own advantages [173] and disadvantages. The service is meant to be easily accessible as 
long as there are health facilities in the vicinity of the patients, but its use depends on their 
health seeking behavior and the attitude of the community, since active case detection has not 
been part of the control programs so far. The knowledge, attitude and practice (KAP) of the 
health professionals at each facility are also main factors determining the quality of the 
leprosy management. This includes the focus of the control program to keep health 
professionals updated and committed as there is evidence of below average KAP of health 
professionals in leprosy [16]. 
 
The WHO “leprosy elimination by 2000” goal has also had an impact on the leprosy control 
programs, leading to less commitment in dealing with the true burden of leprosy. Indeed, it 
brought budget limitations in most leprosy activities due to the pulling out of donors [129]. 
However, the WHO leprosy strategy for the years 2011 to 2015 has put renewed emphasis on 
major issues: early detection of leprosy through active case detection, contact tracing 
especially in hotspots, and reducing disability [6] which is a step forward towards controlling 
leprosy.  
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1.2. Leprosy manifestations  
 
1.2.1. Signs and symptoms of leprosy 
Leprosy is caused by Mycobacterium leprae (M. leprae). It is a unique and challenging 
pathogen that primarily affects peripheral nerves and the skin through invading and residing 
in Schwann cells (SC) and macrophages. It also affects the eyes, the testis, the extremities, 
the hands and feet, and the upper respiratory tract [181;205]. Being primarily a nerve and 
skin disease, the clinical examination of leprosy is mainly based on the assessment of skin 
lesions and nerve involvements. There are three basic signs and symptoms to identify leprosy. 
These are: loss of sensation, presence of skin lesions and nerve thickenings [181]. The degree 
of sensation loss, the number and features of lesions and the number and level of nerve 
involvement vary widely in patients depending on the bacillary load and the host 
immunological capability, which strongly correlate with the different clinical forms of 
leprosy. In most patients, all three signs of leprosy are present. However, there are also cases 
with only skin lesions and no or undetectable nerve involvement, while on the other hand 
there are some cases with only nerve involvement and no skin manifestations, referred to as 
neuritis. These are the commonly missed cases during diagnosis since they are not fully 
covered by standard WHO classification methods [169].  
 
In addition, a new mycobacterium species, Mycobacterium lepromatosis which can cause a 
fatal diffuse lepromatous form of leprosy was discovered in 2008 [99]. Preliminary 
phylogenetic analysis of few genes including the 16S rRNA gene revealed a significant 
difference of M. lepromatosis and M. leprae [101;213]. This fatal type of leprosy has been 
reported as endemic in Mexico and Costa Rica for a century [101;102;237] and according to 
a recent report it is also found in Singapore [100], Brazil and Myanmar [97].  
 
1.2.2. Clinical forms of leprosy and diagnosis 
i. Clinical forms of leprosy 
The diverse clinical manifestations of leprosy are primarily associated with the 
immunological and genetic variability of the host [181;216].  This renders leprosy an 
immunologically interesting and challenging human disease [146]. There are three main 
aspects that have led to the categorization of leprosy into five clinical forms. These are: 
1. The level and type of the immunological response.  
2. The bacillary load.   
3. The histopathological features.  
The five clinical forms of leprosy established as standard classification especially for research 
purposes by Ridley and Jopling [181] are tuberculoid leprosy (TT), borderline tuberculoid 
leprosy (BT), borderline borderline leprosy (BB), borderline lepromatous leprosy (BL) and 
lepromatous leprosy (LL). The TT and LL are the two stable forms of leprosy at the opposite 
extremes or poles. The BT, BB and BL forms are immunologically unstable groups which 
could possibly downgrade or upgrade, depending on e.g. initiation and efficiency of treatment.  
The TT and BT forms (Fig 1A) are characterized mainly by few skin lesions and high levels 
of cell mediated immunity (CMI). This involves the activation and proliferation of T helper 1 
(Th1) cells; subsets of effector CD4
+
 T cells important in activating macrophages via 
production of pro-inflammatory cytokines like IFN-γ. Along with this, a well characterized 
granuloma with undetectable or few bacilli are important features characterizing this group 
[153;181;205]. The “indeterminate” leprosy type is very similar to the TT group except that 
the lesions can be at an early stage and need to be confirmed histopathologically. Both the TT 
and indeterminate forms of the disease may spontaneously heal.  
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On the other side of the spectrum, the BL and LL forms (Fig 1B) are characterized by 
multiple skin lesions, poor CMI and strong humoral responses. Their granulomas are 
disorganized and filled with foamy macrophages and numerous bacilli which is a typical 
histopathological feature for these clinical forms. The BB group which is in the middle of all 
forms is difficult to clearly define with clinical or histopathological features as it shares 
characteristics from both BT and BL groups.  
 
                                       
Figure 1. A patient with borderline tuberculoid leprosy (BT) (1A) and patients with lepromatous leprosy (LL) 
(1B). Patients were enrolled in one of the studies in this thesis.  
Photo by S/r Genet Amare; AHRI (Posted with permission) 
1.3. Diagnostic tools 
 
Leprosy diagnosis requires significant expertise because of the multi-facetted leprosy 
manifestations and its complications. In most leprosy burdened countries, diagnosis mainly 
relies on clinical examination, supplemented to some extent by the acid fast bacilli (AFB) 
staining of the skin slit smear (SSS) reported as BI (Bacterial Index). However, clinical 
diagnosis can only detect an already manifested and visible stage of leprosy, at which stage 
often irreversible tissue damage has already occurred.  This illustrates the key importance of 
developing diagnostic tools that can detect leprosy earlier. 
 
 Clinical 
As mentioned in the previous section, clinical examination includes 1) lesion characterization: 
number, demarcation, pigmentation, formation (raised, nodular), symmetry and loss of 
sensation; 2) voluntary muscle testing (VMT) and 3) examining of possible nerve 
enlargement. It is challenging to clearly diagnose leprosy and classify it into one of the 5 
forms based on the clinical signs and symptoms unless it is supported with Acid Fast Bacilli 
staining (AFB) from skin slit smear (SSS) and with Hematoxylin and Eosin (H&E) staining 
of biopsy samples. The AFB staining and bacterial index (BI) reporting (Table 1) is within 
the capacity of many poor resource settings but the histopathological examination needs 
advanced lab facilities and a pathologist. Hence, classifying leprosy into the five classical 
forms remains important mainly for research purposes but not for routine diagnosis and 
treatment. Instead, World Health Organization (WHO) has recommended a more pragmatic, 
two arm classification of leprosy patients; paucibacillary (PB) patients with less than 5 
lesions; and multibacillary (MB) with more than 5 lesions (WHO 1982) which simplifies 
leprosy management in resource poor settings. 
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Table 1 
BI grading in leprosy diagnosis 
BI grading Definition 
1+ At least 1 bacillus in every 100 fields 
2+ At least 1 bacillus in every 10 fields 
3+ At least 1 bacillus in every field 
4+ At least 10 bacilli in every field 
5+ At least 100 bacilli in every field 
6+ At least 1000 bacilli in every field 
Source: WHO (www.who.int/lep/microbiology/en.) 
 
Other than clinical signs and symptoms, there are some serological tests which have been 
developed but none of these has been used for routine diagnosis; they are of limited value 
since they mainly detect MB but not PB patients. These tests include the following: 
 
Anti PGL-I IgM antibody ELISA 
Phenolic glycolipid I (PGL-I) is the dominant lipid component of the cell wall of M. leprae 
and is “specific” for M. leprae although there are some reports of its presence in Leishmania 
parasites [95]. The IgM antibodies level produced against PGL-I in patients is measured 
using ELISA and is usually high in MB (BL/LL) which have poor CMI and high humoral 
responses [181].  M. leprae has never been grown on artificial media and can only be cultured 
in armadillos or in the mouse foot-pad, which severely limits its availability and research into 
disease mechanisms. Therefore, synthetic PGL-I made of natural disaccharide octyl human 
serum albumin (ND-O-HSA) is used in these ELISAs. This technique clearly detects BL/LL 
patients and can also be used to monitor their treatment outcome as it is reduced during 
treatment [168]. TT/BT patients are usually seronegative and do not reproducibly produce 
detectable circulating antibodies to PGL-I [205]. Clinically, identifying BL/LL patients is not 
difficult for dermatologists and in that case the anti-PGL-I ELISA may not contribute 
substantially to the diagnosis as the main challenges are detecting TT/BT patients and sub-
clinically infected individuals. Nevertheless, there is some evidence showing its utility in 
identifying HHC with higher risk of developing the disease [18;60].  
 
Anti PGL-I IgM antibody ML-Flow test  
This is an immunochromatographic test which is also based on PGL-I but detects IgM faster 
[27;28]. It does not require special skills to perform the test and does not need a reader as it 
can be graded by visual inspection [133] unlike the ELISA. However, it has the same 
limitations as the anti-PGL-I ELISAs in that it mainly detects MB patients and is not 
quantitative. 
 
NDO-LID® rapid test 
This is a recently developed rapid serological diagnostic test which measures IgM antibodies 
against PGL-I through the use of NDO-BSA and measures IgG antibodies against LID-1, a 
fusion protein made of ML0405 and ML2331 [62;65;191]. It is an immunochromatographic 
test which requires small amounts of serum or whole blood. Like the other serological tests, it 
detects most MB patients and relatively improved numbers of PB patients (32.3%) compared 
with NDO-BSA (6.5%) [62]. However, a large scale evaluation of this test in different 
endemic sites is necessary to evaluate its precise utility in leprosy.  
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Lepromin Skin Test 
This is a skin test using a suspension of whole, killed M. leprae, called lepromin, injected 
intradermally. The reaction to this test is measured as mm induration 4 weeks after injection. 
Lepromin is not used for diagnosis of leprosy; rather it measures or provides information 
about the individual’s immune response:  a positive lepromin reaction indicates the ability of 
the individual to develop a granulomatous response to M. leprae while a negative reaction is 
commonly seen in lepromatous patients who are incapable to contain or clear the bacilli 
[103;205].  
 
PCR based M. leprae viability assay 
Several attempts have been made since the last 3 decades to establish clinically applicable 
PCR based leprosy diagnostic tools [192;193;245]. However, the major challenges had been 
identifying potential target genes for specific detection of M. leprae and determination of 
bacilli viability. In recent years, real time PCR based amplification of the repetitive element 
of M. leprae (RLEP) DNA had shown strong correlation with AFB count and was found 
reliable for specific quantification of M. leprae from mouse and armadillo tissues but with 
limitations of providing absolute data on viability [48]. In recent development, expressions of 
number of genes were assessed [135;232] among which hsp18 (encoding 18kd heat shock 
protein) and esxA (encoding the ESAT 6 protein) were found reliable in detecting viable M. 
leprae [48]. This newly established hsp18 and esxA based viability assay can be used as an 
assessment tool for early detection of M. leprae infection in close household contacts of 
leprosy patients, in monitoring treatment outcome and in detection of drug resistance by 
eliminating the tiresome bacterial isolation process. However, the cost and the demand for 
trained personnel remain limiting factors to implement the assay as point of care (POC) in 
resource poor settings. 
 
1.4. Treatment and drug resistance 
 
Despite being an ancient disease, treatment for leprosy was not available until the 1940s. The 
first modern treatment was dapson (diaminodimethyl sulfone) and was given for long-term to 
life time in case of MB cases. Poor compliance to the long term treatment contributed to the 
occurrence of dapsone-resistant M. leprae isolates in most countries and was a challenge for 
the leprosy control programs [77;108;167;241]. Several efforts were made to replace dapsone 
with other monotherapies such as clofazimine, ofloxacin or rifampin but resistance against 
these antimicrobial agents developed when given as monotherapy. To resolve this, a 
combined treatment consisting of dapsone, clofazimine and rifampicin which commonly 
referred as multi-drug treatment (MDT) was recommended by WHO in 1981[1]. Currently, 
the WHO recommended treatment period is 6 months for PB patients and one year for MB 
patients (reduced from two years since 1997) [4], however, there are countries which still 
treat MB cases for two or more years especially those countries with high resources and low 
leprosy burden). In both PB and MB 100 mg dapsone daily and 600 mg rifampicin monthly is 
given while for MB cases an additional 50 mg daily and 300 mg monthly dose of clofazimine 
is given. There is also a third regimen which is recommended to single-lesion PB patients; 
this is a single dose rifampicin (600 mg), ofloxacin (400 mg) and minocycline (100 mg), 
commonly referred as ROM. Currently, ROM is being tested for MB patients as 12 month 
regimen [79;126]. For patients who are unable to take medications because of allergy or 
suspected complications, fluoroquinolones, ofloxacin, moxifloxacin, or pefloxacin and 
minocyline, macrolide clarithromycine can be given as second line drugs. MDT is efficient as 
witnessed by the dramatic reduction of leprosy prevalence since its initiation.  
                                                                                         General Introduction 
19 
 
 
Drug resistance to MDT is not considered as a major issue (ILEP report 2013), however, 
there are recent reports which identified either mono or multiple drug resistant M. leprae 
strains [244;246]. A study which evaluated samples from 230 new and 3 relapse cases from 
Venezuela and Brazil using sequencing and real-time PCR Taqman technologies showed 
drug (rifampicin and dapson) resistance-associated mutations in folP1 and rpoB genes in the 
3 relapse cases [214]. Similarly, SNPs in biopsy samples of 4 among a total of 92 (4.3%) 
relapse cases in Brazil were found where in 2 relapse cases multi drug resistance (SNPs in 
folP1, rpoB and gyrA) was observed [46]. Although cases with SNPs were small in number, 
the reports in general indicate the importance of regular drug resistance monitoring especially 
in relapse cases. 
 
1.5. Vaccines against leprosy 
 
Mycobacterium bovis BCG (Bacillus Calmette–Guérin) is the only vaccine currently 
available for TB. It protects young infants from severe forms of TB, mainly the miliary and 
meningeal forms, but its protection wanes over time and varies across age, different countries 
and the type of vaccine strain used. The BCG vaccine was initially developed for both TB 
and leprosy but its protective role in leprosy became neglected because of MDT campaigns. 
There is evidence for higher BCG induced protection in young individuals that wanes 
overtime and for increased protection through several doses of BCG [41;141;182;208;248].  
 
There were long (up to 8 years) follow up studies that assessed the protection of killed M. 
leprae combined with BCG in comparison with BCG alone. In a Venezuelan study, no better 
protection was observed after five years follow up [40].  In contrast, in an Indian study, the 
combined M. leprae killed/BCG vaccine showed 64% protection compared to BCG alone 
which was 34.1% [96].  
 
Further assessment and use of killed M. leprae vaccines need large production of M. leprae 
which is very challenging. Therefore, other easily cultivable mycobacteria such as M. w, M. 
vaccae and M. habanna used in vaccine preparations were tested in household contacts of 
leprosy patients and showed more than 50% protection for at least 3 to 6 years [209;229;238]. 
Crude M. leprae antigens were also assessed in mice [80;152]. rBCG vaccines that express 
Ag85 and MMP- II also inhibited M. leprae multiplication [134;160]. From recent antigen 
screenings, those antigens recognized by PB patients were also further assessed for their 
potential as a vaccine in mice work [63]. So far no successful vaccine has been developed for 
use except BCG implicating the need for continuous effort to develop potential leprosy 
vaccines. 
 
1.6. Mycobacterium leprae and its unique characteristics 
 
Leprosy has been with humans since ancient times as evidenced by some records in India and 
China and by more reliable archaeological discoveries of the 2
nd
 Century BC in Egypt [224]. 
However, M. leprae, the etiologic agent of leprosy was discovered only a century ago as the 
first human pathogen, notably by the Norwegian scientist Gerhard Henrik Armauer Hansen 
[104;105]. Other human pathogens discovered later have been more intensely investigated 
than M. leprae due to its challenging unique characteristics and the inability to culture M. 
leprae [38;69]. 
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1.6.1. M. leprae classification and its cell wall composition 
M. leprae is an intracellular obligate, acid-fast, capsulated, rod shaped bacillus which belongs 
to the order Actinomycetales, family Mycobacteriaceae and genus Mycobacterium. As any 
other mycobacteria it replicates by binary fission but unlike any other species which belong 
to either fast or slow growers in this genus, M. leprae divides in 12-14 days and it has never 
been grown in artificial media/in vitro [179].  
 
The M.leprae capsule is an electron transparent zone composed of phthioceroldimycoserosate 
and phenolic glycolipid (PGL) composed of three sugar molecule linked to phthiocerol (fat) 
with a phenol component. The outer layer of the cell wall is similar to other mycobacteria 
containing lipopolysaccharides composed of branched chains of arabinogalactan and long 
chains of mycolic acids. The inner part of the cell wall is composed of a peptidoglycan layer 
which is formed from chains of alternating N-glucosamine and N-glycolyl muramyl linked by 
peptides cross bridges [61;205]. 
 
1.6.2. Genome and metabolism  
The genome of M. leprae was first sequenced in 2001 [38]. The genome size, 3.3Mb, is 
smaller than that of M. tuberculosis (Mtb) and contains 1133 pseudogenes, leaving a total of 
1614 genes encoding for functional proteins, and displaying a major reduction of G+C 
content. The reduced genome size with nearly 50% inactivated genes is the reason for the 
absence of several metabolic pathways, a feature which distinguishes M. leprae from other 
mycobacteria [38]. As a result of this, M. leprae utilizes glucose but no other carbon sources 
as an energy source, which makes it highly dependent on the host. The M. leprae genome 
project also revealed that the genes encoding enzymes degrading other carbon sources such 
as acetate and galactose are in fact pseudogenes while in Mtb these genes encode functional 
enzymes capable of degrading these carbon sources [38;69;243]. Being intracellular 
mycobacteria, M. leprae and Mtb are also known to utilize host-derived lipids as energy 
sources through lipolysis. However, M. leprae has very few lipase genes as compared to Mtb. 
M. leprae has also lost the anaerobic pathways and has less efficient aerobic pathways left 
due to its incapability to generate ATP by oxidizing NADH which is one possible reason why 
it is unable to grow in artificial media as it will be difficult to provide appropriate levels of 
oxygen in the media [243]. It also lost the mbt operon, leading to deficiency in iron 
acquisition from its environment as it is not able to produce mycobactin [113]. However, 
there are many other genes related to iron storage still active, indicating M. leprae is able to 
use host iron.  
 
1.6.3. Host preference 
Besides humans, the wild nine-banded armadillo (Dasypus novemcinctus) is a highly 
susceptible natural host of M. leprae. Primates such as Chimpanzee and Mangabey Monkey 
were reported as hosts as well but not to a major extent [2]. The wild nine-banded armadillos 
are common in the south central USA [226] and recently, a study in Texas showed genotype 
similarities of the isolates from US leprosy patients and infected armadillos, indicating the 
possible existence of zoonotic leprosy in that specific area [228]. Nine banded armadillos and 
nude mice are very important for leprosy related experiments. The mouse foot pads are 
convenient to grow M. leprae and the nine-banded armadillos also show fully disseminated, 
MB infection when inoculated with M. leprae [205]. These experimental animals are 
important for drug resistance monitoring, to assess bacilli viability and to culture bacilli for in 
vitro or in vivo immunological studies.  
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1.6.4. M. leprae in the environment 
M. leprae is known for being an obligate pathogen. However, there are recent reports 
indicating the presence of viable M. leprae in soil mainly in areas with high prevalence of 
leprosy [121;231]. The genotypes of those isolated from soil were found similar with those 
isolated from patients in that specific area [231]. MB patients carry very high number of 
bacilli in their upper respiratory tract and the bacilli can easily be excreted from the nasal area 
through washing or sneezing [210]. Hence, finding live M. leprae in the surrounding soil and 
water might not be surprising. Previous studies also showed its survival outside the host for 9 
days [53] and in an extended study it was found to survive 46 days in wet soil and 60 days in 
saline at room temperature [54]. M. leprae was also found viable and intact after being 
ingested by a free living pathogenic amoeba for at least 72 hours [119] and a recent study 
revealed a long term (up to 8 months ) survival of M. leprae in free living amoebae cyst while 
retaining its virulence [242]. However, further investigations are required to further 
understand the capability of the M. leprae bacilli found in the surrounding environment 
including free living amoebae to infect the host and if so these environmental sources can be 
considered as potential reservoirs for M. leprae. 
  
1.7. Host-pathogen Interactions in leprosy 
 
The manifestation of the disease in its different forms, closely correlating with host genetic 
and immunological factors, has made leprosy an immunological disease model [144;146;147]. 
Besides its great potential to provide a research model for human immune mediated diseases, 
extensive knowledge about host-pathogen interactions in leprosy will also help to improve 
and innovate leprosy control activities. 
 
1.7.1. The route of infection/ entrance of M. leprae/ transmission 
Untreated lepromatous patients carrying high bacillary load reaching 10
11
 per gram of tissue, 
are the main sources of infection where the aerosol spreading of nasal droplets from these 
patients infects healthy individuals through nasal/respiratory routes [107]. Due to lack of 
active case detection strategy in high burden countries, there is high possibility for untreated 
MB patients to transmit the infection to their close contacts [175]. Sub-clinically infected 
individuals as source of infection cannot be ruled out although no clear evidence is available 
as yet. Transmission through skin contact [55], via nine-banded Armadillos [120;227] and via 
free living amoebae that contained M. leprae [242] also need due attention and further 
investigation. 
 
1.7.2. Innate Immunity; uptake of M. leprae by host cells 
M. leprae and Schwann cells 
The presence of considerable number of bacilli in the endothelial cells lining the blood 
vessels and lymphatics revealed that endothelial cells could be sites for M. leprae replication 
and establishment of infection [42;137].  Moreover, they might further assist M. leprae  to 
reach peripheral nerve tissues through the blood stream [17] and act as reservoirs to further 
infect Schwann cells [199;200;207]. A layer of basal lamina which covers the Schwann cell-
axon complex is the area where M. leprae can interact with laminin-2 as an entrance to infect 
Schwann cells. In addition, the expression of C-type lectin (CD209) on the surface of 
Schwann cells also enhances the binding and uptake of M. leprae which is regulated by Th2 
cytokines like IL-4 [223]. There are also evidences that infected Schwann cells are capable of 
processing and presenting M. leprae antigens to inflammatory type 1 T cells which results 
demyelination, lyse of infected Schwann cells and nerve function impairment especially in 
tuberculoid patients with high CMI [161;220;221]. 
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M. leprae and Macrophages 
The various pattern recognition receptors (PRR) such as toll like receptors (TLR), C-type 
lectins, nucleotide-binding oligomerization domain (NOD2) and others recognize pathogen 
associated molecular patterns (PAMPs) and play a role in determining the function of 
macrophages during M. leprae infection [144]. In mycobacterial infections like TB and 
leprosy, microbial lipoproteins trigger TLR2, TLR2/1 or TLR2/6 heterodimers and this 
activation is enhanced by Th1 type cytokines and inhibited by Th2 cytokines.  
 
Macrophages (M), being mediators of both  the innate and adaptive immune systems, show 
distinct features in different forms of leprosy and determine the outcome of the pathogenesis. 
In tuberculoid leprosy, Ms are activated and their vitamin D dependent antimicrobial 
function (VDR) is dominant leading to killing of the bacteria. In lepromatous patients, the 
phagocyte function is more dominant and the Ms appear to be foamy, filled with lipid 
droplets derived from M. leprae and the host itself [9;44;146;147;222]. These features are 
visible in the types of granulomas formed in skin lesions of TT/BT and BL/LL patients (Fig 3 
Granulomas). There is also evidence in vitro and in tissues that TLR2 and TLR1 are more 
expressed in TT/BT patients than BL/LL [114]. The mannose receptor (CD206) is mainly 
expressed on mature macrophages and facilitates phagocytosis through binding to the 
mannose capped liproarabinomanan. 
 
The dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin (DC-SIGN); 
CD209 is also a major receptor on DCs, having similar ligand properties with CD206 for 
mannose capped liproarabinomanan and mycobacteria target DC-SIGN to suppress DC 
maturation through induction of IL-10 and inhibition of IL-12 [78;155]. There is also 
evidence for the expression of CD209 on macrophages of both TT and LL patients, and this 
is important in recognition of mannose-rich glycoconjugates like mycobacterial lipoglycan 
mannosylated lipoarabinomanan (ManLam), facilitating the binding and phagocytic process.  
 
Along with this, innate cytokines in the lesions regulate the functions of macrophages in 
leprosy where IL-10 induces the phagocytic pathway and IL-15 induces the vitamin D 
dependent antimicrobial pathway [144;146;147]. The complement receptors (CR1, CR3 and 
CR4) also play a role in facilitating the phagocytosis process; CR3 especially facilitates the 
uptake of PGL-I by macrophages [197;198]. However, the activated phagocytic pathway in 
BL/LL patients will not culminate in the fusion of phagosome and lysosome because of the 
foamy nature of the Ms: this impairs lysosomal function and proper antigen presentation due 
to disrupted HLA-DR rafts [118;144;147]. Similarly, the higher frequency of regulatory T 
cells with higher production of anti-inflammatory cytokines in lepromatous compared with 
tuberculoid patients can also be considered as a potential factor modulating the formation of 
foamy macrophages which eventually form a diffused, unorganized granuloma in BL/LL 
patients unlike in TT/BT [165;188]. 
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A. BT            B.   LL 
 
Figure 3. H&E staining of tissues taken from a BT patient skin lesion (A) and LL patient skin lesion (B) showing the 
differences in granuloma formation. 
Image A is taken from www.dermpedia.org and image B is photographed by Dr. Munir Hussien (Dermatovenorologist and 
Pathologist, AHRI)  
 
Dendritic cells and Langerhans cells in leprosy 
Dendritic cells (DCs) are professional APCs and are very efficient in priming and activating 
naïve T cells. In lesions of lepromatous patients, a deficit in DCs both in the dermis and 
epidermis was observed [211]. In addition, peripheral monocytes do not differentiate into 
CD1
+ 
DC following TLR activation in lepromatous patients [115]. These CD1
+ 
DCs (CD83
+
) 
are capable of presenting non-peptide components; lipids and glycolipids to CD1
+
 restricted 
T cells which in turn produce enormous levels of IFN-γ.  Expression of the co-stimulatory 
molecule B7.1 is also decreased in LL patients [194].  This shows how M. leprae is capable 
of impairing the antigen presenting role of DCs. However, a recent study has indicated that 
activation of monocytes via NOD2 (Nucleotide-binding oligomerization domain containing 
protein 2) with its ligand muramyl dipeptide induces their differentiation into DC a process 
which was dependent on IL-32. Indeed, the expression of NOD2, IL-32 and CD1b
+
 DC in 
leprosy lesion was found to correlate with bacterial control, being higher in TT/BT patients 
[196].  
 
Langerhans cells are known to block dissemination of M. leprae at the infection sites and 
there is evidence showing reduced number of Langerhans cells in lepromatous patients 
compared to tuberculoid ones, which does not change after treatment [136;143].  
 
1.7.3. Adaptive immunity in leprosy 
Leprosy manifests itself in a wide-ranged spectrum where differences among the various 
forms are characterized by the type and level of immune responses. Cell mediated immunity 
(CMI) is important in controlling intracellular pathogens like M. leprae and Mtb. In 
tuberculoid leprosy patients, M. leprae infected macrophages eliminate the bacilli and present 
antigens in the context of MHC Class II molecules which induces IL-12 and stimulate CD4
+ 
Th1 cells [9]. These dominant Th1 cells, CD4
+
 T helper and memory T cells in lesions of TT 
patients produce pro-inflammatory cytokines mainly IFN-, IL-2, TNF and other Th1 
associated factors [117] and play an important role in activating macrophages to initiate their 
microbicidal activity and control bacillary multiplication [171].  Simultaneously, the 
numerous cytotoxic T cells, CD4
+
 and CD8
+
 T cells, which are restricted to MHC-Class II 
and I respectively produce effector molecules such as perforin, granzyme B and granulysin 
and lyse the infected macrophages. 
 
In lepromatous leprosy patients (LL), suppressor type CD8
+
 T cells are present, which are 
distributed in the lesions together with CD4
+
 T cells. The suppressor CD8
+
 T cells are 
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important in down regulating the macrophage activation and suppressing CMI. On the other 
hand, there is high production of antibodies which leads to accumulation of immune 
complexes   activating the complement system[93]. The IgM level in the circulation 
facilitates the M. leprae evasion through activated C3 which are capable of co-stimulating 
naive T cells via complement regulation protein CD46, which leads to differentiation of IL-
10 secreting regulatory T cells [29]. The Th2 type responses in the lepromatous patients are 
mainly characterized by the production of cytokines like IL-4, IL-5 and IL-13 and lack of 
IFN- and IL-2 to the extent of M. leprae specific anergy in LL patients. In these patients,  a 
higher number of regulatory CD4
+
 T cells characterized either by their expression of CD25, 
FoxP3, or production of cytokines such as IL-10 and TGF-β and also higher numbers of anti-
inflammatory macrophages (Mϕ2) in the circulation and in skin lesions have been reported in 
several studies [24;116;165;188]. Along with this, Kumar et al., pointed out the importance 
of the molecular cross-talk of TGF-β, CTLA-4 and Cb1-b and the disruption of HLA-DR 
rafts leading to M. leprae persistence and T-cell hypo-responsiveness in lepromatous patients 
which they claim is a Th3 type response [117;118]. Other than the classical Th1 and Th2 type 
responses, a role for Th17 has been uncovered recently in a study in which higher level of IL-
17 associated cytokines IL-1, IL-22 and RORC (Th17 transcription factor) were reported in 
the tuberculoid form of leprosy [187].  
 
1.7.4. Host genetics and susceptibility to leprosy  
It has been a century since leprosy was described as not inherited but rather caused by an 
infectious pathogenic bacterium. Nevertheless, the very different manifestations of leprosy 
with its distinct clinical presentations and immunological responses has led to investigations 
which collectively revealed the involvement of various human host genes involved in 
susceptibility to leprosy [11] and in developing specific forms of leprosy and leprosy 
reactions [8;11;75;91;236].  
 
Human leukocyte antigens (HLA) are known for their association with several diseases. The 
association with leprosy was demonstrated three decades ago [49;50] although the presence 
of genetic susceptibility or predisposition was speculated since 1841 [74]. Later, the major 
role of the HLA Class II linked genes in determining the type/form of disease to be developed 
was demonstrated [51;162;236] as for instance shown in previous studies that HLA-DR3 and 
-DR2 are more associated with tuberculoid leprosy [49] where as HLA-DQ1 is associated 
with lepromatous leprosy [164]. The polymorphic nature of the peptide binding groove in 
HLA molecules is the main factor for HLA-peptide binding differences and this basic 
understanding has led to the development of in silico tools that predict immunogenic epitopes 
relevant in biomarker search for leprosy diagnosis [85]. 
 
Two genes highly associated to leprosy susceptibility more recently are PARK2 and PACRG 
[122;142]. The PARK2 gene is known for its association with Parkinson’s disease. The 
PARK2 and LRRK2 genes have a role in cell apoptosis regulation. Another gene associated 
with susceptibility or resistance to leprosy and also linked with development of different 
forms of leprosy is NRAMP1 [8;30;94;139;215]. TLRs, NOD2 and MRC1 are also among 
the genes which are important in the early phase of host pathogen interaction with roles of 
bacterial recognition and uptake. The LTA4H gene regulates Lipoxin A4, one of the factors 
in the formation of macrophages filled with lipid droplets in LL patients. Genes such as TNF, 
LTA and IFN- and other related genes are involved in the formation of granulomas and in 
the maintenance of adaptive immunity  [31]. Since TLR and VDR are important in 
recognition and killing of the bacilli respectively, polymorphisms in these genes are also 
important factors in determining the outcome of the leprosy infection. Other than the 
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previously reported susceptible loci, a recent genome-wide association study of leprosy in a 
Chinese population revealed six new susceptible loci where BATF3, CCDC88B and CIITA-
SOCS1 were reported as new susceptible genes [123].  
 
Genetic studies are powerful tools to decipher host pathogen interactions. Obtaining more 
detailed insights into the genetic control of infection and disease susceptibility of leprosy 
affected people, their household contacts and endemic controls may further help in designing 
strategies for early detection of individuals who are at risk of developing leprosy and 
contribute towards reducing leprosy transmission.  
 
1.8. Reactions in Leprosy 
 
Leprosy reactions are acute immunologic hypersensitivity episodes which can occur before, 
during or after MDT in about 30% to 50% of the leprosy patients. These complications are 
the main reasons of nerve impairment and disabilities in leprosy which increase leprosy 
related morbidity [26;111;130;131;240].   
 
There are two commonly known leprosy reactions referred to as reversal reaction (RR) or 
type 1 reaction (T1R) and erythema nodosum leprosum (ENL) or type 2 reaction (T2R) 
[190;239]. There is also a third category of reactions, called the Lucio phenomenon, but this 
is less common and is reported mainly  in central and south America  in non-nodular 
lepromatous patients[145] as well as  in patients with lepromatosis [98].  
 
1.8.1. Reversal Reaction (T1R) 
T1R mainly occurs in borderline patients (BT, BB and BL). It is characterized by 
inflammations in the skin and/or nerves with edema of the hands, feet and face [34;234] (Fig 
4A). The diagnosis is mainly clinical and sometimes typical T1R histologic features can help 
the diagnosis. As T1R are frequently recurrent, close follow up of patients is necessary to 
avoid additional nerve damage [234]. Although not yet exhaustive, various host and pathogen 
factors are associated with T1R such as enhanced CMI with expression of IFN-, IL-6, IL-8, 
IL-13, TNF-α and other pro-inflammatory cytokines and chemokines like IP-10 which are 
typical characteristics of T1R [14;154;166;206]. Recent analysis of T1R has also revealed an 
increased production of CXCL9, IL-17A and VEGF in addition to IFN- and IP-10, and a 
reduction in IL-10. G-CSF and cytotoxicity associated genes such as granulysins, granzymes, 
perforins were shown to be up regulated during T1R compared with their levels before T1R 
[90]. An increased serum level of IL-17F during T1R was also reported which might indicate 
a role in inflammation [33]. Infiltration of CD4
+
 T cells and presence of pro-inflammatory 
cytokines observed in the periphery were reported in skin lesions in patients with T1R. 
Upregulation of human beta-defensin 3 was also reported during T1R, which later subsided 
during corticosteroid treatment [37]. The association of certain genes or proteins either being 
upregulated or downregulated during T1R or after treatment with corticosteroids is an 
important clue towards a better understanding and management of reactions through 
developing tools that can possibly predict those at risk of developing reactions. 
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Figure 4 A. Type 1 reaction (T1R) or Reversal reaction (RR) 
Photo by Dr. Elizabeth Bizuneh, ALERT (posted with permission) 
1.8.2. Erythema nodosum leprosum (ENL) 
ENL or T2R is an immune complex mediated episode which is more common in LL patients 
and some BL because of high level of M. leprae antigens and anti-M. leprae antibodies in the 
circulation of these patients [12;111]. Unlike T1R, ENL is characterized by infiltration of 
neutrophils into the lesions [45]. ENL is commonly diagnosed clinically as patients have 
tender red papules and nodules associated with fever (Fig 4B). As this type of reaction is a 
systemic disorder, it may affect organ systems and confer systemic complications. ENL starts 
as acute but can progress to a chronic phase and can also be recurrent [239]. High levels of 
serum C-reactive protein, amyloid A protein and alpha-1-antitrypsin are ENL markers [110] 
but are not commonly tested for.  
 
 
 
Figure 4B. Type 2 Reaction (T2R) or Erythema Nodosum Leprosum (ENL) 
Photo by S/r Genet Amare; AHRI (Posted with permission) 
 
1.8.3. Risk factors for developing leprosy reactions 
Leprosy reactions can occur at any time before, during or after MDT. However, the 
proportions of patients that develop reactions during and after treatment are higher compared 
to those before treatment. This is mainly because of the bactericidal effect of rifampicin 
which kills high numbers of bacilli leading to the release of M. leprae antigens in the 
circulation that trigger inflammatory reactions. Clinically, high BI (or being an MB patient), 
anti-PGL-I antibody level and being on MDT are among the potential risk factors. A genetic 
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study  revealed that polymorphisms in genes such as TLR1 and TLR2, VDR, NRAMP-1, 
C4B and IL-6 have associations with developing leprosy reactions [73]. 
In addition, co-infections, especially oral infections, hepatitis C and hepatitis B are among 
reported possible risk factors for developing leprosy reactions [149-151]. The majority of 
leprosy patients co-infected with HIV show T1R [52] but further investigation is required to 
conclude this with more certainty.  
 
1.8.4. Treatment of T1R and ENL 
For both reaction types, corticosteroids (commonly prednisolone) are given to control the 
inflammation and reverse the nerve impairment. The regimen starts with high dose according 
to the severity of the reaction and is tailored based on clinical assessments made every 2 
weeks. To avoid the long term side effects of corticosteroids, cyclosporine, methotrexate and 
tacrolimus are also considered as options to manage T1R.  
 
Unavailability of treatment options is a big challenge in management of leprosy reactions but 
lack of knowledge present among health professionals in identifying reactions properly and 
prescribing the right dose of corticosteroids and tailoring down or up as to the degree of 
severity of the reaction is a major knowledge gap as well.  
 
Thus, in addition to the currently available diagnostics tools and treatment, there is a demand 
to investigate leprosy-specific host or pathogen biomarkers for early detection of leprosy and 
prediction of leprosy reactions. 
  
1.9. Search for leprosy-specific Biomarkers    
1.9.1. Major challenges in leprosy and current opportunities 
There have been major achievements in the control of leprosy, especially after the 
introduction of MDT since the 1980s [205]. However, the presence of pocket areas in 
different endemic countries contributes to the consistent number of new cases every year, the 
percentage of patients reporting with grade 2 disabilities and considerable numbers of new 
pediatrics cases [125;131;202]. This indicates how much effort is needed to “eliminate” 
leprosy and prevent leprosy associated disabilities. MB patients with high bacillary load and 
visible deformities stay in the population from months to years due to lack of awareness or 
being threatened by   stigma. Hence, these patients serve as potential sources of infection. On 
the other hand, preclinical patients without any visible signs and symptoms of leprosy but 
harboring M. leprae in their body also live in the population until the disease is manifest   
because M. leprae has a long incubation period. Although it needs solid evidence, these “sub-
clinically” infected individuals might be other sources of infection and there are no clinical or 
laboratory diagnostic tools to detect them [83].    
  
Leprosy research has provided several key findings in the pre-genomics era. However, the 
area has benefitted and developed more in the postgenomic era mainly from the whole 
genome sequencing and bioinformatics which avails all necessary information about M. 
leprae, related Mycobacterial species and other species including the human genome. This 
has shortened the search for unique M. leprae antigens and the production of recombinant 
proteins and synthetic peptides enabling the evaluation of these antigens in a larger endemic 
population [20;23;83;86] to further use the promising ones in the biomarker search and 
development of novel tools for early detection of leprosy and prediction of leprosy reactions.  
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1.9.2. The search for unique and immunogenic M. leprae antigens in post genomic era 
 In the search for potential and promising antigens, both T and B cell based approaches have 
been used. As recently reviewed, about 200 M. leprae proteins and more than 10 fusion 
proteins have been tested for CMI and HMI in endemic countries in several studies in Brazil, 
Bangladesh, Ethiopia, India, Nepal, Pakistan, Philippines, Venezuela, China and in countries 
with relatively low number of leprosy cases like Japan and South Korea [81] . 
 
T cell-based approaches 
Previously, several M. leprae antigens like 18kDa, 35kDa, 45kDa or undefined mixtures of M. 
leprae components were tested for their immunogenicity in endemic and non-endemic 
populations [25;58;59;106;225]. Later our group at LUMC and others, using bio-informatics 
tools and whole genome sequences of M. leprae and other related species, identified M. 
leprae unique regions, with either known or unknown functions in infection biology. Genes 
with unique sequences were selected and their recombinant proteins were produced by 
cloning [76]. The recombinant M. leprae proteins and/or their synthetic peptides with 9-15 
unique sequential amino acids fitting into MHC-I and II binding grooves were first tested for 
their specificity in non-infected and non-exposed individuals living in non-endemic countries, 
and next tested in endemic countries for their immunogenicity in whole blood assays (WBA) 
or in lymphocyte stimulation tests (LST) through analysis  of IFN- by CD4+ or CD8+ T cells 
stimulated with these specific antigens in different groups: leprosy patients (TT/BT, BL/LL, 
patients with reactions), household contacts (HHC), healthy endemic controls (EC) and TB 
patients. 
 
The main purpose of this evaluation process was to select potential T cell epitopes for 
diagnostics that could enable to differentiate M. leprae-infected from non-infected or exposed 
individuals, or detecting those who are at risk of developing the disease [84;88;218] or to 
accelerate leprosy vaccine development [66;67;87;176;191]. For instance, M. leprae proteins; 
ML0049 and ML0050, homologues of Mtb ESAT-6 and CFP-10 respectively were tested 
with the intention to develop similar diagnostic test for leprosy. However, cells of TB patients 
in endemic countries also recognized these M. leprae proteins as measured by IFN- response 
although their sequences are not similar (only 36% and 40% similarity) probably indicating 
cross-reactivity by the highly similar peptides, although co-infection of the TB patients with 
M. leprae could not be excluded [89]. Other M. leprae specific proteins which were initially 
tested in Brazil [84;218] were further tested in different populations in Africa and Asia 
[23;86]. Proteins ML1989 and ML1990 were almost fully recognized by all groups which 
included leprosy patients, household contacts and endemic controls questioning their 
potential as diagnostic tools. On the other hand, proteins such as ML0126 and ML1601 were 
found to be immunogenic and showed specific responses in leprosy patients although also 
nearly half of the healthy endemic controls responded to these antigens [23;86]. Further 
analysis of these proteins and their peptides including ML1601 and ML2478 in healthy 
endemic controls with different levels of exposure confirmed the diagnostic potential of these 
antigens, since endemic controls with relatively higher levels of exposure to M. leprae 
showed increased level of IFN-, IP-10, IL-1β, IL-6, TNF- and CCL2 [22]. Similarly based 
on the cellular responses to these antigens, biomarkers other than IFN-, MCP-1, MIP-1β and 
IL-1β were shown to differentiate TT/BT patients from HHC [83].  
 
Serological approaches 
Antibody responses against M. leprae-unique proteins and other components of M. leprae 
have been analysed in several studies for potential use as diagnostic tools to monitor 
treatment, or disease progression [64;172;191;219]. Assessment of antibody responses 
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against 12 M. leprae specific antigens in leprosy patients and household contacts showed that 
antibodies to ML2028, ML0286, ML2038, LID-1, ML0405 and ML2055 proteins were 
detectable in MB patients and antibodies to ML2028, ML0286, ML2038 proteins were 
detectable in PB patients. The antibody titers against LID-1 and ML2028 were found 
increasing in two household contacts of MB index for about 15 months and one of these HHC 
showed progressively higher antibody titers to MLSA (M. leprae soluble antigen), LAM and 
PGL-I and developed borderline leprosy after two years of enrollment [219]. One of these 
proteins, the fusion protein LID-1 that induces strong IgG responses mainly in MB cases 
[170;172;180] is also used in the development of NDO-LID rapid test [62] (see page 17).  
The fundamental reason for identifying and evaluating M. leprae specific antigens based on T 
cell or humoral approaches is to use these antigens in the development of rapid and field-
friendly diagnostic tools to detect M. leprae infection earlier and for rapidly monitoring 
treatment outcome.  
 
1.9.3. Cytokines/chemokines as potential biomarkers in leprosy 
The search for biomarkers induced by these antigens, however, has many challenges in itself 
[82;163]. Several immunological biomarkers for T-cell based assays have now been 
identified and are discussed below: 
 
Interferon-gamma 
IFN- is a stable cytokine which has been and will remain a good indicator of pro-
inflammatory/Th1 host responses against M. leprae and other mycobacteria. If the M. leprae 
protein used to activate its production is specific enough, unexposed individuals will not 
produce IFN- in in vitro assays.  This would confirm the absence of cross reactivity with 
other mycobacteria which is important in selecting specific and immunogenic proteins 
[13;84;86]. As shown in TB diagnostics, two commercially available IFN- release assays 
(IGRAs), QuantiFERON
©
-TB Gold assay and T-SPOT TB, are developed based on the IFN- 
response to Mtb specific peptides of ESAT-6, CFP-10 and TB7.7, and has been successful in 
detecting latent Mtb infection in non-endemic areas and BCG vaccination does not interfere 
as these peptides are from the RD1 region unique to Mtb [35;36]. There is a continuing effort 
to develop relatively similar diagnostic tests for leprosy and it was shown that IFN- can be 
used to differentiate levels of M. leprae exposure as a response to M. leprae specific antigens 
[22;83]. However, prospective longitudinal studies are required to clearly define the different 
levels of exposure as risk or protective signals [82]. 
 
IFN- induced protein 10 (IP-10) 
IP-10 is a small chemokine produced by many cell types but mainly by antigen presenting 
cells (APCs). There are several signals that induce IP-10 secretion such as T-cell derived 
IFN-, IL-2, IL-17, IL-23 and others. This makes IP-10 a reliable downstream marker as 
readout of cytokines like IL-2 and IFN- in CMI assays. Its expression is much higher which 
makes it more preferable for application in diagnostic tests [184]. In TB diagnostics, IP-10 
has become a potential alternative to IFN- as it was found comparable to QuantiFERON© In-
Tube test (QFT-IT) with higher level of expression [186] and also in combination with IFN- 
for detection of Mtb infection [185]. In leprosy, it has been decades since Kaplan et al. 
showed the potential of IP-10 in differentiating the different forms of leprosy by measuring 
its expression in skin lesions of TT/BT and LL patients where more IP-10 level was observed 
in TT/BT lesions [112]. Recent reports also revealed the potential of IP-10 in leprosy 
diagnosis by correlating with the level of exposure [22] and its potential in predicting T1R 
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[90;206]. It has now also been optimized for use in the field friendly UCP-LF assay [21] see 
chapter 5. 
 
Monocyte chemo attractant protein 1 (MCP-1) (CCL2) 
MCP-1 is a CC chemokine which is produced by various types of cells but mainly by 
monocytes/macrophages. It promotes macrophage infiltration in various inflammatory 
diseases and there is evidence for its importance in granuloma formation [47] which is an 
important phenomenon in containment of mycobacterial infections like leprosy and TB. 
There is evidence in TB studies that plasma levels of MCP-1 associate with TB disease and 
treatment responses [109]. Its potential to differentiate TT/BT patients from endemic controls 
was reported [83]. Its association with the PARK2 gene where level of MCP-1 increases 
along with increased expression PARK2 gene further confirms its involvement in the host 
defense against M. leprae infection [142].  
 
Interleukin 1 beta (IL-1β) 
IL-1β is a prominent member of the IL-1 family and is mainly produced by activated DCs 
and macrophages. Its expression regulates the Th1/Th2 balance such that higher expression 
of IL-1β leads to Th1 dominated response like in TT/BT patients while lower expression 
levels of  IL-1β were found in LL lesions [124]. It was recently reported by our own group as 
a potential biomarker in detecting M. leprae exposure [22] as well as infection [83] 
 
Interleukin-6 (IL-6) 
IL-6 is a pro-inflammatory cytokine associated with inflammation. In leprosy, from previous 
assessments of plasma cytokines and chemokines in plasma of leprosy patients with type 1 
and 2 reactions, IL-6 was reported as being elevated in both episodes as compared with non-
reactional patients [19;148;159]. It was also significantly higher in endemic controls living in 
high leprosy endemic area than in those living in low endemic areas [22]. Recent studies also 
showed associations of single nucleotide polymorphism (SNP) in the IL-6 encoding gene 
with susceptibility to T2R [217], indicating the potential of IL-6 as genetic predictive risk 
marker. Similarly, increased IL6 expression in lesions of leprosy patients with reactions was 
reported [148] which decreased after prednisolone treatment[14]. 
 
1.10. Leprosy and co-infections 
 
Being a mycobacterial infection, leprosy like TB, was predicted to manifest immune 
reconstitution disease (IRD) in HIV co-infected patients initiating treatment with anti 
retroviral therapy (ART). IRD or immune reconstitution inflammatory syndrome (IRIS) is an 
immune restoration disease in immunocompromised individuals such as HIV infected 
patients usually after the initiation of ART or a change to more active ART. As HIV mainly 
affects the host Th1 immune arm by affecting CD4
+
 T cells, failure in containment of the 
disease in tuberculoid patients, an increase in lepromatous leprosy cases and increased 
transmission of leprosy was expected [128;233]. However, this has not been the case thus far: 
lepromatous forms have not increased although some patients on ART are being diagnosed as 
new leprosy cases, which requires attention [127;233]. Previous and recent reports on cellular 
and immunological parameters in leprosy and HIV co-infected patients demonstrated low 
numbers of CD4
+
 T cells in the periphery but extensive CD4
+
 T cells infiltration in the 
lesions of BT [189] with higher CD8
+
 T cells [32]. In addition, no differences in 
histopathological features of leprosy were observed in HIV co-infected versus non-HIV 
patients [52].  
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In some studies, an association of type 1 leprosy reactions with ART was reported [140;195], 
suggesting ART and immune reconstitution could be risk factors for the development of 
leprosy reactions; however this requires further investigation.   
 
In addition, intestinal parasites, mainly helminthic infections (non-protozoan intestinal 
parasites) are known to immune modulate the host by upregulating Th2 responses [10]. In 
mycobacterial infections like TB, studies have shown the importance of helminth infestation 
in weakening the Th1 immunity. For instance, poor immunogenicity of BCG in a helminth 
infested group compared to a de-wormed group was observed in an Ethiopian cohort [70;71]. 
The presence of intestinal helminthes may also facilitate the establishment of M. leprae 
infection or the progression to more severe forms of leprosy. A direct correlation between 
mycobacterial index and the frequency of intestinal helminthes in leprosy patients was also 
previously observed [56;57]. Therefore, further information needs to be collected in the area 
of helminth-leprosy co-infections, since this may have impact on clinical diagnosis and 
management. 
 
Aims and outline of the Thesis 
 
This thesis describes advances in the search for biomarkers relevant to leprosy diagnosis 
focusing in particular on early detection of the disease. It includes the screening of 
immunogenic and specific M. leprae antigens in endemic countries, identification of potential 
host biomarkers and development of field applicable diagnostic tools.  It discusses the 
achievements and the unresolved challenges.   
 
The approach for searching potential pathogen-derived biomarkers has changed dramatically 
after the year 2000 with the availability of the M. leprae whole genome sequence. The studies 
in this thesis selected antigens based on in silico algorithms, tested in leprosy patients, 
household contacts and endemic controls and endemic TB patients for their immunogenicity 
and specificity. Those unique and immunogenic proteins and peptides were investigated 
further as potential biomarkers in patients and healthy control groups, and eventually taken 
further to develop a field friendly diagnostic test based on both T cell and antibody responses. 
Chapter 1 provides a detailed introduction into all areas studied in this thesis. 
 
In Chapter 2, the screening of recombinant M. leprae proteins and synthetic peptides for 
immunogenicity and specificity in populations with different genetic background is described. 
T cell responses of stimulated PBMC from MB and PB patients, household contacts of MB 
patients, healthy endemic controls and TB patients were analysed using IFN- as a read-out 
for antigen-specific T cell activation. The positive responses found in 50% of healthy 
endemic controls for most of the antigens raised the issue of what level of M. leprae exposure 
was present in that subgroup.   
 
In Chapter 3 detailed analysis of host biomarker profiles in responses to the selected M. 
leprae-specific and immunogenic recombinant proteins and synthetic peptides is reported. 
The discriminating potential of these biomarkers among groups based on level of M. leprae 
exposure is an important result, clarifying why 50% of the healthy endemic controls 
responded to specific antigens. Other than the commonly known pro-inflammatory cytokine 
IFN-, several cytokines, chemokines and growth factors induced by adaptive and innate 
immunity were studied as well among which several were identified with discriminating 
potential. Chapter 4 describes potential biomarker profiles in patients, in a longitudinal 
assessment, in an effort to predict leprosy reactions. Increased IFN-, IP-10, IL-17 and VEGF 
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were demonstrated whereas IL-10 was decreased in PBMCs simulated with M. leprae 
antigens during the onset of a reaction. This implicates the importance of combined 
assessments of Th1/Th2 responses in development of potential diagnostic assays. In Chapter 
5, detection of identified biomarkers using lateral flow tests utilizing Up-converting Phosphor 
Technology (UPT) is demonstrated. The highly correlating results of the Up-converting 
Phosphor-lateral flow assay (UCP-LF) and ELISA demonstrated reliability of the assay.  The 
potential of the UCP-LF assay to measure more than one biomarker (cellular and humoral 
responses) at a time has also revealed its appropriateness for field applicability.   
Chapter 6 deals with assessment of the role of Tregs in view of the M. leprae-specific T cell 
non responsiveness in lepromatous patients. Using depletion assays, we demonstrated the 
recovery of T cell responses in one third of lepromatous patients after depletion of CD25
+
 T 
cells. The increased presence of FoxP3 expressing T cells in the vicinity of Mϕ2 in LL 
lesions further revealed Tregs as one of the key factors responsible for poor CMI in 
lepromatous patients. 
 
Chapter 7 describes co-infections in leprosy patients. Although the number of leprosy-HIV 
co-infected patients is small, understanding the influence of one disease on the other is 
important for proper patient management and for implementing proper control mechanisms. 
In recent studies including ours, most of the leprosy HIV co-infected patients on ART 
developed T1R, which requires further investigation to detect the underlying risk factors. In 
addition, we have also analysed and compared IFN-γ responses in helminth free and 
helminth-leprosy co-infected patients. 
 
Finally, in Chapter 8, the main themes of the thesis are discussed in the broad context of 
leprosy diagnosis.  
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Abstract 
 
Ongoing transmission of leprosy is evident from the stable disease incidence in high burden 
areas. Tools for early detection of Mycobacterium leprae (M. leprae) infection, particularly in 
sub-clinically infected individuals, are urgently required to reduce transmission. Following 
the sequencing of the M. leprae genome, many M. leprae-unique candidate proteins have 
been identified, several of which have been tested for induction of M. leprae specific T cell 
responses in different leprosy endemic areas.  
In this study, 21 M. leprae-unique proteins and 10 peptide pools covering the complete 
sequence of five M. leprae-unique proteins (ML0576, ML1989, ML1990, ML2283, and 
ML2567) were evaluated in 160 individuals in Nepal and Ethiopia. These included: 
tuberculoid and borderline tuberculoid (TT/BT), borderline borderline and borderline 
lepromatous (BB/BL) leprosy patients; healthy household contacts (HHC); tuberculosis (TB) 
patients and endemic controls (EC).  Immunogenicity of the proteins was determined by IFN-
 secretion via stimulation of PBMC in 6 days lymphocyte stimulation tests (LST) or in 
whole blood assays (WBA).    
In LST, BB/BL patients (40%) responded to ML0573 and ML1601 whereas ML1604 was 
most immunogenic in TT/BT (35%) and HHC (36%).  Additionally, significant numbers of 
EC displayed IFN- production in response to ML0573 (54%), ML1601 (50%) and ML1604 
(54%). TB patients on the other hand, hardly responded to any of the proteins except for 
ML1989. Comparison of IFN- responses to ML0121, ML0141 and ML0188 for TT/BT 
patients showed specific increase in diluted 6 days WBA compared to the undiluted 24 hours 
WBA, whereas EC showed a reduced response in the diluted WBA, which may indicate 
detection of disease-specific responses in the 6 days WBA.  
In summary, identification of multiple M. leprae proteins inducing M. leprae-specific T cell 
responses in groups at high risk of developing leprosy may contribute to improve early 
detection for M. leprae infection. 
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Introduction 
 
The introduction of multidrug treatment (MDT) recommended by WHO in 1981 aimed at 
eradication of leprosy by 2000 [17]. The shortened treatment period, 6 months and 1 year for 
paucibacillary (PB) (which includes TT/BT) and multibacillary (MB) (which includes 
BB/BL/LL) patients respectively, was one of the major steps forward by WHO which 
improved adherence and contributed to the dramatic reduction of leprosy prevalence globally. 
According to the WHO, eradication of leprosy as a public health problem (defined by less 
than one case per 10,000 people) has been achieved globally. High endemic zones, however, 
still subsist. The percentages of children among new cases of leprosy, which reflect a 
country's endemic level, ranged from 0.6 % in Argentina to 30.3 % in Papua New Guinea 
Moreover, the annual new case detection remains stable in many endemic countries [1]. This 
steady new case detection and the significant number of patients reporting with grade 2 
disabilities, visible and irreversible, urge the need for strong efforts in discovering tools for 
early detection of M. leprae infection [1;5;14;19]. 
 
The disabilities and deformities in leprosy affected people along with wrong perception of the 
disease itself in most societies are the main reasons for stigma and discrimination. Despite the 
fact that the patients are cured from the disease with MDT, most people left out to live with 
unbearable social and psychological damage [3;12;13;16;21]. Hence, WHO has developed a 
new strategy for the next 5 years to mainly work on reducing disabilities, stigma and 
discrimination through provision of high quality patient care and early detection of new cases 
is obviously critical for the success of this effort [1].  However, do the available diagnostic 
tools sufficiently help in detecting leprosy infections at early (pre-clinical) stages? 
 
Multibacillary leprosy patients (MB) are generally known to be main sources of M. leprae 
transmission. Close contacts of these patients who themselves are at high risk of developing 
the disease are believed to be asymptomatic sources of infection. However, the available 
diagnostic tools are not fully capable of detecting infections in these groups [5;8-9;11;20]. 
The clinical signs and symptoms, skin lesions consistent with leprosy having definite sensory 
loss, with or without thickened nerves and positive skin smears [18] are generally helpful to 
diagnose already advanced leprosy cases only. The anti-PGL-I (phenolglycolipid) IgM 
antibody measurement which mainly detects MB cases and which can also be positive for 
asymptomatic HHC, has been used for epidemiological and other related studies but is not 
applicable for routine laboratory diagnosis [15]. The lepromin test, on the other hand, 
measures the potential of an individual in building up granulomatous response to the mixture 
of M. leprae antigens of which lepromin is composed. An individual can develop a positive 
response to the test without ever having had any exposure to M. leprae [19]. This non-
specific cellular response is caused by the fact that lepromin shares many proteins with other 
bacteria thereby inducing cross reactivity.  
 
As in the development of TB diagnostics, the current high-tech era in genetics and bio-
informatics has also contributed to the recent progress in the area of searching for potential 
proteins and peptides specific to M. leprae infection as the whole genome of the bacterium is 
sequenced [6;8-9;11;20]. Recent immunological studies in individuals from endemic 
countries revealed potential M. leprae proteins and peptides that induce T-cell responses. In 
Brazilian patients, ML1989, ML1990, ML2283 and ML2567 induced IFN- responses 
specific to M. leprae exposure [8]. However, further evaluation of these proteins combined 
with another potential specific protein ML2346 [6] and several M. leprae peptides [20] in 
five leprosy endemic countries (Brazil, Pakistan, Bangladesh, Ethiopia and Nepal) showed 
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significant responses in patients, but also in endemic controls (EC) as well as in healthy 
household controls [9]. This significant response in endemic controls raised the question 
whether reactivity to these proteins depicts exposure to or infection with M. leprae and 
whether the prevalence of leprosy in a region influences the responses induced in EC by M. 
leprae antigens. Thus this indicates the demand for continuous search of new M. leprae 
proteins and peptides that can induce T cell responses specific for M. leprae [10;11].      
 
T-cell responses induced by mycobacterial peptides are more specific than those in response 
to mycobacterial proteins although the level of response in some assays is low [9;20]. The 
diversity of HLA in the human population will however require screening of large sets of M. 
leprae peptides in different leprosy endemic countries for possible wider application. 
 
In this study, 21 recombinant M. leprae proteins, identified previously using a post genomic 
approach [8], were evaluated in leprosy patients, healthy household contacts, endemic 
controls and TB patients (completed intensive phase) from two leprosy endemic countries, 
Nepal and Ethiopia. In addition, pools of peptides covering five specific M. leprae proteins 
(ML0576, ML1989, ML2283, ML2346 and ML2567) previously tested in a Brazilian 
population [9;11] were further evaluated in the context of these Asian and African 
populations. 
 
Materials and Methods 
 
General procedure of the study. In this study, Armauer Hansen Research Institute, Addis 
Ababa, Ethiopia and the Mycobacterial Research Laboratory, Anandaban Hospital, 
Anandaban, Nepal, both located in leprosy endemic areas were involved in recruitment of 
patients, endemic controls and healthy household contacts. In both sites, identical standard 
operating procedures (SOPs) were applied and identical reagents were used to ensure 
reproducibility of data. 
M. leprae recombinant proteins.  M. leprae genes encoding candidate proteins derived from 
group VI (unknown function; ref  Sanger database) were selected as described in detail 
previously [2]. The selected genes encoding the candidate proteins were amplified with PCR 
and cloned in pDEST17 expression vector containing an N-terminal histidine tag using the 
Gateway technology platform (Invitrogen, Carlsbad, CA). The recombinant proteins were 
overexpressed in E. coli BL21 (DE3)   and purified from endotoxins. The endotoxin level in 
each recombinant protein was measured using a Limulus Amebocyte Lysate (LAL) assay and 
was below 50IU/mg (Cambrex, East Rutherford, NJ) [7]. All recombinant proteins were 
tested to exclude antigen non-specific T cell stimulation and cellular toxicity by measuring the 
IFN- level induced during 6 days incubation. Responses to medium and PHA were used as the 
negative and positive references in the assay.  PBMC from in vitro PPD unresponsive, Mantoux 
skin test negative healthy Dutch donors recruited at the Leiden University Medical Center 
(LUMC) (with no prior contact with leprosy or TB patients) were used in the test.  
The M. leprae proteins ML0126, ML0840, ML1601, ML1602, ML1603, ML1604, ML0573, 
ML0574, ML0575, and ML0576 were tested in Nepal and Ethiopia. Other M. leprae proteins: 
ML0121, ML0141, ML0188, ML1788, ML0369 and ML0927 only in Ethiopia. ML0121, 
ML0141, ML0188 were kindly provided by Dr. JS Spencer  through the NIH/NIAID 
“Leprosy Research Support” Contract N01 AI-25469 from Colorado State University (these 
reagents are now available through the Biodefense and Emerging Infections Research 
Resources Repository listed at 
(http://www.beiresources.org/TBVTRMResearchMaterials/tabid/1431/Default.aspx).  
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M. leprae whole cell sonicate. Irradiated armadillo-derived M. leprae whole cells were probe 
sonicated with a Sanyo sonicator to >95% breakage (Colorado State University, Fort Collins, 
USA through the NIH/NIAID Leprosy Contract N01-AI-25469). 
Synthetic peptides. Synthetic peptides overlapping the complete sequence of protein ML0576, 
ML1989, ML2283, ML2346 and ML2567, produced as 20-mers overlapping 10 amino acids, 
were purchased from Peptide 2.0 Inc. (Chantilly, VA, USA).   
Study subjects. The study was approved by the local ethics committees in Nepal (Approval nr. 
93 24-08-2006) and Ethiopia (RDHE/163-71/2006). Written informed consent was obtained 
from each participant before sample collection. A total of 160 HIV-negative individuals were 
recruited: 50 BB/BL, 35 TT/BT leprosy patients, 22 healthy household contacts of BL/LL 
patients (HHC), 30 healthy individuals from the same endemic area (EC) and 23 smear 
positive, pulmonary tuberculosis patients (TB). Leprosy patients recruited were new cases or 
patients on treatment for less than 3 months with or without leprosy reactions. Clinical, 
bacteriological and histological examinations were performed to classify the leprosy patients 
according to Ridley and Jopling [18]. HHC were defined as adults living in the same house as 
a BL/LL index case for at least the preceding six months. Both HHC and EC were assessed 
for the absence of signs and symptoms of tuberculosis and leprosy. Staff members working in 
both leprosy centers were excluded as EC. TB patients had been on chemotherapy for at least 
2 months to enable some recovery of T cell function.  
Lymphocyte stimulation tests (LST). Venous blood was obtained from study participants in 
heparinized tubes and PBMC isolated by Ficoll density centrifugation. PBMC (2 x 10
6
 cells/ 
ml) were plated in triplicate cultures in 96-well round bottom plates (Costar Corporation, 
Cambridge, MA) in 200 l/ well of Adoptive Immunotherapy medium (AIM-V, Invitrogen, 
Carlsbad, CA). Synthetic peptides, recombinant protein, M. leprae whole cell sonicate or 
PPD (purified protein derivative of M. tuberculosis, SSI, Copenhagen, Denmark) were added 
at final concentrations of 10 g/ ml. As a positive control stimulus a final concentration of 1 
g/ ml phytoheamagglutinin (PHA; Sigma, St. Louis, MO) was used. After 6 days of culture 
at 37C at 5% CO2, 90% relative humidity, 75 l supernatants were removed from each well 
and triplicates were pooled and frozen in aliquots at –20C until further analysis. 
Whole blood assays (WBA).  Venous blood samples from 9 leprosy patients (BT and BL) and 
8 EC were collected in heparinized tubes and used for 24 hours undiluted and for 6 days 
diluted WBA.  For the 24 hours WBA, 450l of blood per well was added in 48 well plate 
and 50l of stimuli; M. leprae whole sonicate, ML0121, ML0141, ML0188 diluted in AIM-V 
medium with final concentration of 10g/ml and PHA; 1g/ml was added. Plates were 
incubated at 37°C at 5% CO2, 90% relative humidity for 24 hours. For the 6 days WBA, 
blood samples were diluted 1:10 with AIM-V medium (serum free) and 900l was added per 
well. The same stimuli with final concentration of 10g/ml other than PHA (1g/ml) were 
added in 100ul volume per well. Plates were incubated at 37°C in 5% CO2 and 90% relative 
humidity for 6 days. IFN- ELISA was simultaneously done on supernatants of both assays.  
IFN- ELISA. IFN- levels were determined by ELISA (U-CyTech, Utrecht, The 
Netherlands). The cut-off value to define positive responses was set beforehand at 100 pg/ ml. 
The assay sensitivity level was 40 pg/ml. Values for unstimulated cell cultures were typically 
< 20 pg/ ml. Lyophilized supernatant of PHA cultures of PBMC from an anonymous Buffy 
coat (LUMC, The Netherlands) was provided to both sites as a reference positive control 
supernatant. 
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TABLE 1 
Study population at the two participating sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
prevalence per 10,000 individuals 
2 
male/ female ratio 
3 
not applicable 
 
TABLE II 
M. leprae specific candidate proteins 
 
Functional Classification VI: unknown; ** blast reports were run December 2004; blastp = protein vs. protein; 
tblastn = protein vs. translated DNA. # unfinished genomes. Ref: (13) 
 
Results 
 
Testing M. leprae proteins and peptides in different leprosy endemic sites harbouring 
variable genetic backgrounds is essential to develop diagnostic tools that can be widely 
applied. In this study, a total of 160 individuals (50 BB/BL, 35 TT/BT, 22 HHC, 30 EC and 
Site  P
1
 Category BI  
(mean) 
Sex 
ratio
2
 
Mean 
age (yr)      
Anandaban 
(Nepal) 
1.56 BB/BL 3.88 35/2 37.0 
BT/TT 0 18/7 36.9 
HHC  -
3
 14/6 32.7 
EC -
3
 11/7 22.2 
TB -
3
 9/5 29 
Addis 
Ababa 
(Ethiopia)
  
0.60 BB/BL 1.64 9/4  29.2 
BT/TT 0.56  6/4 30.8 
HHC  -
3
 0/2 22 
EC -
3
 4/8 27 
TB -
3
 4/5 23 
Accessi
on  gene 
number* 
Functional  
Classificati
on 
Protein 
product 
Mr 
(kD) 
Percentage identity** with Mycobacterium: 
 
murine 
and 
human 
RT-PCR 
bovis 
AF2122/
97 
blastp** 
(28) 
tuberculosis  
H37Rv  
 Blastp**  
 (28) 
 
paratuberculosis 
K10  blastp** 
(30) 
microti#                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
tblastn** 
(28) 
marinum# 
tblastn** 
(28) 
avium#
tblastn 
** (29 
ulcerans
# tblastn 
** (31 
smegmati
s MC2# 
tblastn 
** (29) 
ML0126 
 
VI Hypothetical 31 + <30% <30% <30% <30% <30% <30% <67% <30% 
ML0369 
 
VI Hypothetical 13 + <30% <30% MAP4250c 38% <30% <33% <39% <37% <33% 
ML0573 
 
VI Hypothetical 10 + <30% <30% <30% <30% <30% <30% <30% <30% 
ML0574 
 
VI Hypothetical 11 + <30% <30% <30% <30% <30% <30% <30% <30% 
ML0575 
 
VI Hypothetical 7 + <30% <30% <30% <30% <30% <30% <30% <30% 
ML0576 
 
VI Hypothetical 8 + <30% <30% <30% <30% <30% <30% <30% <30% 
ML0840 
 
VI Hypothetical 48 + <30% <30% MAP2122 59% <30% <30% <64% <30% <47% 
ML0927 
 
VI Hypothetical 11 + <30% <30% MAP1963c 36% <30% <36% <35% <33% <30% 
ML1601 
 
VI Hypothetical 13 + <30% <30% MAP3249 33% <30% <30% <33% <30% <30% 
ML1602 
 
VI Hypothetical 11 + <30% <30% <30% <30% <30% <30% <30% <30% 
ML1603 
 
VI Hypothetical 9 + <30% <30% <30% <30% <30% <30% <30% <30% 
ML1604 
 
VI Hypothetical 14 + <30% <30% <30% <30% <30% <30% <30% <30% 
ML1788 
 
VI Hypothetical 17 + <30% <30% <30% <30% <30% <30% <30% <30% 
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23 TB) from two endemic sites Anandaban in Nepal and Addis Ababa in Ethiopia were 
enrolled (Table 1). 
 
PBMC or whole blood samples from all individuals were stimulated for 6 days in LST or in 
24 hours WBA with 21 M. leprae proteins and 10 peptide pools each consisting of 
overlapping 20-mer peptides covering the sequence of five M. leprae proteins (ML0576, 
ML1989, ML1990, ML2283 and ML2567) previously shown to be specific for M. leprae 
exposure in a Brazilian population [8;11]. The peptide pools were composed of a total of 50 
peptides [ML0576 (n = 7), ML1989 (n = 11), ML1990 (n = 7), ML2283 (n = 10), ML2567 (n 
= 15). Each pool consisted of five peptides (Table 3). Samples with high IFN- values (> 200 
pg/ml) in the unstimulated negative control wells and with low IFN- values (< 100 pg/ml) in 
response to PHA (positive control for the assay) were excluded from the analysis.  
 
Differential recognition of antigens by individuals within test groups 
M. leprae unique proteins ML0573, ML1601 and ML1604 induced IFN- responses in EC. 
These responses clearly showed two distinct subgroups where 50% of the group showed high 
response and 50% very low (Figure 1).The difference in IFN- response against the unique 
proteins among the endemic controls could be due to the difference in the level of exposure 
to M. leprae (Geluk et al., manuscript in preparation). 
Patients with Type 1 leprosy reactions (RR) recognised ML0573 (48%) more frequently than 
ML1601 (26%) and ML1604 (30%). Although the median response was not above the cut-
off  for positive responses (i.e. 100 pg/ml), 40% of BB/BL patients also showed positive 
responses to ML0573 and ML1601 and 33% HHC and 35% TT/BT to ML1604 (Figure 1). 
 
TABLE III 
M. leprae peptide pool composition 
 
Peptide 
pools 
pool 1 
ML0576 
pool 2 
ML0576 & 
ML1989 
pool 3 
ML1989 
pool 4 
ML1989 &  
ML1990 
pool 5 
ML1990 
5 6 7 8 9 10 45 12 13 
14 
15 16 17 18 
19 
20 21 53 22 
23 
24 25 26 27 
28 
Pool 6         5 10 15 20 24 
Pool 7 6 45 16 21 25 
Pool 8 7 12 17 53 26 
Pool 9 8 13 18 22 27 
Pool 10   9 14 19 23 28 
 pool 11 
ML2283 
pool 12 
ML2283 
pool 13 
ML2567 
pool 14 
ML2567 
pool 15 
ML2567 
29 30 31 32 
33 
34 35 36 37 
54 
38 39 40 41 
42 
43 44 45 46 
47 
48 49 50 51 
52 
Pool 16 29 34 38 43 48 
Pool 17 30 35 39 44 49 
Pool 18 31 36 40 45 50 
Pool 19 32 37 41 46 51 
Pool 20 33 54 42 47 52 
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Figure 1: IFN- production corrected for medium values induced in response to 14 M. leprae proteins in 6 days 
incubation of PBMC from multibacillary leprosy patients (MB; n = 45; 20 with leprosy reaction), paucibacillary 
leprosy patients (PB; n = 30; 7 with leprosy reaction), healthy household contacts (HHC; n = 22), healthy 
endemic controls (EC; n = 22) and TB patients (TB; n = 23).   
 
Similarly, ML0126 and ML0574 were more frequently recognised by EC (41%) than by 
leprosy patients but the median value was slightly below the cut-off. The responses in other 
groups were low for both proteins except the positive responses in 32% of BB/BL patients 
for ML0126 (Figure 1). Responses to ML1602 and ML1603 were low in all groups. However, 
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some individuals from BB/BL and EC group responded well to ML1603 but ML0840 and 
ML0575 were hardly detected in any of the groups (Figure 1).  
 
Peptide pools induce only low IFN- responses in all test groups 
The M. leprae proteins ML0576, ML1989, ML1990, ML2283 and ML2567 were analysed in 
five endemic countries previously and IFN- production was observed in response to these M. 
leprae-unique proteins in all test groups [9]. The current study analysed T cell reactivity in 
response to overlapping peptides of these proteins in LST. Peptide pools 1-5 and 11-15 
(Table 3) were tested in the cohort from Nepal and peptide pools 6-10 and 16-20 were tested 
in Ethiopia (data not shown). The median IFN- levels in response to each peptide pool in all 
groups were found to be very low (Figure 2).  
 
However, pool 1, 3, 5, 11, 14 and 15 containing peptides derived from ML0576, ML1989, 
ML1990, ML2283 and ML2567 respectively, showed some detectable responses in HHC and 
EC. Pool 2, composed of different peptides derived from ML0576 and ML1989 was 
recognised by few individuals from all groups except TB patients. Pool 12 and pool 13 
contained peptides derived from ML2283 and ML2567 respectively, were recognised by 
some individuals from BB/BL, TT/BT, HHC and EC. Peptides from these antigens were 
reported previously also to be specifically recognised by M. leprae exposed (patients and 
HHC) in Brazil [11]. In general, responses induced by peptide pools were found to be low or 
absent. However, the low but detectable IFN- levels indicated the potential of these peptides 
for inducing specific T cell responses which may be enhanced by using different 
immunological boosting techniques such as addition of low concentration of cytokines or 
performing the test at temperatures above 37 C related to fever [2;10]. 
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Figure 2: IFN- production corrected for medium values induced in response to 10 peptide pools in 6 days 
incubation of PBMC from BB/BL and TT/BT leprosy patients, healthy household contacts, healthy endemic 
controls and TB patients from Nepal. 
 
Diluted WBA induced IFN- response in patients but not in EC 
Finally, in order to compare what type of incubation would be preferable for M. leprae-
specific IFN- detection in WBA, M. leprae proteins ML0121, ML0141 and ML0188 were 
simultaneously tested for their immunogenicity in an undiluted 24 hours WBA and a 1 in 10 
diluted 6 days WBA (Figure 3).  
 
The IFN-  responses induced in whole blood samples derived from EC were significantly 
reduced (P=0.007 for ML0121 and P=0.049 for ML0141) in 6 days diluted WBA compared 
to the 24 hours undiluted WBA, whereas an increased IFN- response was seen in TT/BT 
patients in the 6 days diluted WBA. 
 
Discussion 
 
Since transmission of M. leprae infection is still ongoing as evidenced by the number of new 
cases in many endemic countries and the considerable number of patients presenting with 
Grade 2 disabilities, development of tools for early detection of M. leprae infection remains a 
key priority in combating leprosy [14;19].
 
 
The study described here represents the continuation of efforts to identify new M. leprae 
proteins and peptides that induce specific cellular immune responses and may be used in tools 
for early detection of infection in individuals living in leprosy endemic countries. The 
availability of whole genome sequences for M. tuberculosis, M. leprae and other 
mycobacterial species has tremendously supported this search effort through providing 
information on potential functions of proteins from unique genes. By selecting sequences that 
are uniquely found in M. leprae, we aimed to exclude T cell cross reactivity caused by 
homologous sequences. The M. leprae proteins tested in this study are hypothetical 
(categorised in group VI ref Sanger database) and their function is yet unknown except for 
ML1990, which was classified as a putative integral membrane protein. All proteins tested 
are unique to M. leprae except for ML1601, ML0369, ML0840 which have orthologues in M. 
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avium and ML0126 which has a homologue sequence (67 %) in M. ulcerans. Absence of 
responses in TB patients against the proteins confirmed absence of T cell cross reactivity with 
M. tuberculosis, also observed in Brazilian TB patients. 
 
The IFN- responses against ML0573, ML1601 and ML1604 clearly divided the EC in two 
sub-groups: high and low responders. However, in the previous study, the responses from all 
Brazilian study groups were low for ML0573 and the responses to ML1604 were not specific 
as they were also recognised by individuals who did not respond to M. leprae whole sonicate 
in vitro [8] The aim of testing proteins in different endemic countries is to eventually design a 
widely applicable diagnostic tool. Therefore, using combinations of M. leprae proteins could 
be a method to overcome low and high responses in different leprosy endemic areas.  
 
The high responses of EC described above could be due to exposure to M. leprae infection. 
However it is difficult to predict whether it is a sign of protection or infection leading to 
disease. Similar high responses were observed in EC in a previous study in response to other 
M. leprae proteins [9]. Further evaluation of these M. leprae proteins and screening of 
peptides from ML0573, ML1601 and ML1604 in healthy controls living in high, low and in 
non endemic areas and in close HHC in a longitudinal study will provide more insight on 
whether such responses are signs of protection against or susceptibility to disease. In addition, 
ML0573 may also be used in studies which aim to look for potential reaction predicting 
markers in leprosy patients as number of patients on reaction responded against this protein. 
In general, further evaluation of these potential proteins, their peptides and peptide pools in 
defined high risk groups could contribute in the development of early detection tools of 
leprosy infection. 
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Figure 3: IFN- production in response to M. leprae recombinant proteins for EC (squares; n = 8) and BT/TT 
(circles; n = 9) in undiluted 24 hours WBA (undiluted; black symbols) or in 1:10 dilution 6 days WBA (1 in 10; 
open symbols). ** indicates P value = 0.007; * indicates P value = 0.05. 
                                                                                        Detection of M.leprae specific T cell responses                                                                   
    
59 
 
The IFN- levels produced in response to the peptide pools tested in this study in Nepal and 
Ethiopia were in general very low except for a few individuals with detectable responses (> 
50 pg/ ml). Similarly, low responses against peptides were observed in previous studies [8;9]. 
However, considering those detectable responses against the peptide pools 2, 12 and 13, it 
could be useful to further screen single peptides from ML0576, ML2283 and ML2567 and 
also other potential proteins mentioned above especially in EC and HHC as was done 
previously in a Brazilian cohort [11]. As peptides are important in inducing specific 
responses, further boosting techniques should also be examined in order to enhance low but 
detectable IFN-  responses [2;10]. Furthermore, identification of cytokines other than IFN- 
will also be necessary.  
 
In determining what type of WBA would be beneficial to detect M. leprae-specific responses, 
we also compared diluted 6 days WBA to the undiluted 24 hour format.  Interestingly, IFN- 
responses to M. leprae proteins in diluted 6 days WBA were significantly decreased for EC 
but not for leprosy patients, indicating reduction of some non-specific ex vivo responses 
observed in 24 hours WBA. Since the original aim of testing M. leprae proteins in WBA is to 
develop field-friendly diagnostic tools, 24 hours WBA would be preferred. However, diluted 
6 days WBA is still very useful for selecting immunogenic M. leprae proteins which may 
induce specific memory T cell responses in M. leprae infected individuals. Therefore, 
working with diluted blood in 6 days WBA can be used in primary screening of proteins and 
peptides giving lower load and requiring small amount of blood [4].   
 
The challenges in leprosy, prevention of deformities, disabilities, stigma, and interruption of 
transmission in leprosy endemic countries, require tools for early detection of M. leprae 
infection. Hence, identifying and screening candidate M. leprae proteins and peptides which 
could potentially induce cellular responses specific for M. leprae in individuals at high risk of 
developing leprosy should remain a continuous effort.   
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3.1 Peptides Derived from Mycobacterium leprae ML1601c Discriminate 
Between Leprosy Patients and Healthy Endemic Controls 
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Abstract 
 
The stable incidence of new leprosy cases suggests that transmission of infection continues 
despite worldwide implementation of MDT. Thus, specific tools are needed to diagnose early 
stage Mycobacterium leprae infection, the likely sources of transmission. M. leprae antigens 
that induce T-cell responses in M. leprae exposed and/ or infected individuals thus are major 
targets for new diagnostic tools. 
Previously, we showed that ML1601c was immunogenic in patients and healthy household 
contacts (HHC). However, some endemic controls (EC) also recognized this protein. To 
improve the diagnostic potential, IFN- responses to ML1601c peptides were assessed using 
PBMC from Brazilian leprosy patients and EC. Five ML1601c peptides only induced IFN- 
in patients and HHC. Moreover, in 24-hour whole blood assays (WBA), two ML1601c 
peptides could assess the level of M. leprae exposure in Ethiopian EC. Besides IFN-, also 
IP-10, IL-6, IL-1, TNF- and MCP-1 were increased in EC from areas with high leprosy 
prevalence in response to these ML1601c peptides.  
Thus, ML1601c peptides may be useful for differentiating M. leprae exposed or infected 
individuals and can be used to indicate the magnitude of M. leprae transmission even in the 
context of various HLA alleles as present in different genetic backgrounds.  
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Introduction 
 
Leprosy is a treatable infection caused by Mycobacterium leprae (M. leprae) involving skin 
and peripheral nerves and is influenced by genetic and environmental factors [1-3]. The 
infection can result in skin lesions, nerve degeneration and deformities. Despite a spectacular 
decrease in global prevalence since 1982, transmission of leprosy is sustained as evidenced 
by the hundreds of thousands new cases of leprosy that keep being detected globally every 
year: 244,796 new cases of leprosy were detected during 2009 amongst whom 22,485 were 
children and the registered prevalence at the beginning of 2010 was 211,903 cases [4].  
 
In Brazil, for example, the number of new cases detected during 2009 was 37,610 resulting in 
a registered prevalence of 38,179 at the end of first quarter of 2010 [4]. These figures 
demonstrate that M. leprae infected contacts and persons with subclinical, undiagnosed 
leprosy, likely the major sources of unidentified transmission, are an incessant source of 
active transmission. Despite many efforts, prediction of disease development in affected 
individuals is still not possible nor can we detect asymptomatic M. leprae infection. 
Diagnosis of leprosy is usually based on clinical features and skin smear results including the 
number of skin lesions. M. leprae is not cultivable and bacterial enumeration by microscopic 
examination is required for leprosy classification, choice in choosing and monitoring 
chemotherapy regimens, and diagnosis of relapse. However, detection and quantification 
using standard microscopy yields data of limited specificity and sensitivity. Thus, in order to 
complement current clinical methods, especially for PB patients, and to allow informed 
decision making on who needs treatment at a preclinical stage, several groups are 
investigating design of improved diagnostic tools. These tools will reduce transmission, 
prevent functional disabilities and stigmatizing deformities and facilitate leprosy eradication, 
especially in individuals at risk for developing leprosy such as close contacts of leprosy 
patients. 
 
Assays have been developed that detect M. leprae specific IgM antibodies against PGL-I 
[5;6], which are able to identify multibacillary (MB) leprosy patients (with strong humoral 
immunity to M. leprae), but these fail to detect most paucibacillary (PB) leprosy patients and 
leprosy patients' contacts as these typically develop strong cellular but not humoral immunity.  
One of the hurdles hampering T-cells based diagnostic tests is that M. leprae antigens can 
cross-react at the T-cells level with antigens present in other mycobacteria, like M. 
tuberculosis or BCG even if the homology is relatively low as is the case for ESAT-6 and 
CFP-10 [7;8]. Using comparative genomics, we previously identified candidate proteins 
highly restricted to M. leprae which showed promising features with respect to application in 
leprosy diagnostics [9;10].  
 
For specific detection of M. tuberculosis infection, commercially available IFN- release 
assays (IGRAs) like QuantiFERON-TB Gold have been developed [11]: these tests are 
based on cellular immune responses induced by a cocktail of peptides derived from ESAT-6 
(Rv3875), CFP-10 (Rv3874) and TB7.7 (Rv2654) that are selectively expressed by M. 
tuberculosis and deleted from all (non-virulent) BCG strains and most other NTM [11]. This 
has inspired research into the feasibility of developing similar peptide-based assays for the 
identification of asymptomatic leprosy: encouraging results have been generated indicating 
that some synthetic peptides induce specific responses in individuals exposed to M. leprae 
and could potentially be developed into a rapid test for the detection of M. leprae infection 
[10;12;13]. In contrast to TB, however, ESAT-6 or CFP-10-derived peptides will not be 
useful due to the crossreactive T-cells responses they induce in TB patients [7;8].  
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Since T-cell reactivity to peptides are HLA-restricted [14-16], the use of a pool composed of 
several different M. leprae peptides, in analogy to the pool of peptides applied in the 
QuantiFERON-TB Gold tests, will increase sensitivity [17;18], while avoiding T-cells 
cross-reactivity. In order to improve sensitivity of a specific diagnostic peptide mixture, we 
have in this study extended the number of peptides with potential to distinguish exposure to 
M. leprae from BCG vaccination and exposure to other mycobacteria in a future diagnostic 
tool. 
 
The protein ML1601c was previously identified by us as highly immunogenic in M. leprae 
exposed Brazilian individuals [9], and aalthough it does not contain a homologous sequence 
in M. tuberculosis, it does have an orthologue in M. avium paratuberculosis, MAP3249 
which is 33 % identical to ML1601c.  
 
Table I 
ML1601c synthetic peptides 
           
  
Peptide#  Amino acid sequence*   Amino acid identity**           
           
 
11  AHHNAHAAPAFLWSGLVSA  42 % (8/19)  
12  FLWSGLVSAAVLIADGRGE  52 % (10/19)   
13  AVLIADGRGEDTYLPIISIY  40 % (8/20)  
14  DTYLPIISIYLARGNELKPN  10 % (2/20)  
15   LARGNELKPNPLLSVIYVEH  25 % (5 /20)  
16  PLLSVIYVEHLLVLFYQSVG  35 % (7/20)  
17  LLVLFYQSVGDHCGFGRYDF  45 % (9/20)  
18  DHCGFGRYDFGKTMVLACYG  50 % (10/20)  
19  GKTMVLACYGCVGTRSLLSG  30 % (6/20)           
20  CVGTRSLLSGRDDDLVTSVP  15 % (3/20)           
3         RDDDLVTSVPPCGRASVVHRS   0 % (0/21)           
           
 
* Synthetic peptides overlapping ML1601c are shown in single letter amino acid code.   
**Amino acids sequences of ML1601c (M. leprae TN and BR4923) peptides were analyzed using BLAST 
(http://blast.ncbi.nlm.nih.gov); amino acids that are identical to the MAP3249 are depicted in bold.  
 
To identify single peptides that are only recognized by M. leprae exposed and/or infected 
individuals, we here analyzed IFN- production in Brazilian leprosy patients and controls in 
response to overlapping ML1601c peptides covering the whole protein.   
 
Materials and Methods 
 
Synthetic peptides. ML1601c overlapping peptides (Table I: two 19-mers with 9 amino acid 
overlap; eight 20-mers with 10 amino acid overlap; one 21-mer with 10 amino acids overlap) 
were purchased from Peptide 2.0 Inc. (Chantilly, VA, USA). Homogeneity and purity were 
confirmed by analytical HPLC and by mass spectrometry. Purity of all peptides was ≥ 80%. 
All impurities consist of shorter versions of the peptides caused by < 100% coupling 
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efficiency in each round of synthesis. Aliquots of identical batches of the synthetic peptides 
were tested in Brazil, Ethiopia and The Netherlands. 
Recombinant ML1601c protein. The ML1601c gene was amplified by PCR from genomic 
DNA of M. leprae and cloned using the Gateway technology platform (Invitrogen, Carlsbad, 
CA) with pDEST17 expression vector containing an N-terminal histidine tag (Invitrogen) 
[19]. Sequencing was performed on selected clones to confirm identity of all cloned DNA 
fragments. Recombinant proteins were overexpressed in E. coli BL21 (DE3) and purified as 
described to remove any traces of endotoxin. Each purified recombinant protein was analyzed 
by 12% SDS-PAGE followed by Coomassie Brilliant Blue staining and Western-blotting 
with an anti-His antibody (Invitrogen) to confirm size and purity. Endotoxin contents were 
below 50 IU per mg recombinant protein as tested using a Limulus Amebocyte Lysate (LAL) 
assay (Cambrex, East Rutherford, NJ). Recombinant ML1601c protein was tested to exclude 
protein non-specific T-cells stimulation and cellular toxicity in IFN- release assays using 
PBMC of in vitro PPD-negative; healthy Dutch donors recruited at the Blood bank Sanquin, 
Leiden, The Netherlands. None of these controls had experienced any known prior contact 
with leprosy or TB patients.  
M. leprae whole cell sonicate. Irradiated armadillo-derived M. leprae whole cells were probe 
sonicated with a Sanyo sonicator to >95% breakage. This material was provided through the 
NIH/NIAID “Leprosy Research Support” Contract N01 AI-25469 from Colorado State 
University (these reagents are now available through the Biodefense and Emerging Infections 
Research Resources Repository listed at  
http://www.beiresources.org /TBVTRMResearchMaterials/tabid/1431/Default.aspx). 
Study subjects. Twenty two Brazilian leprosy patients (11 paucibacillary (PB) leprosy 
patients and 11 multibacillary (MB)) were recruited from the Leprosy Out-Patient Unit, 
Leprosy Laboratory (Oswaldo Cruz Institute, city of Rio de Janeiro) and from the Duque de 
Caxias Outpatient Units (Health Department, city of Duque de Caxias, Rio de Janeiro State). 
Leprosy patients were diagnosed and classified based on clinical, bacteriological, and if 
possible histopathological findings. MB patients were treated with rifampicin, dapsone and 
clofazimine. PB patients were treated with rifampicin and dapsone. All MB patients were 
skin slit smear-positive whereas PB patients were all skin slit smear negative. All patients 
were tested before MDT was initiated. As controls, 19 healthy household contacts of MB 
leprosy patients (HHC), 8 tuberculosis patients (TB) and 17 healthy endemic controls (EC) 
were recruited from Duque de Caxias (n = 7) and the city of  Rio de  Janeiro (n = 10). 
Leprosy detection rates at the time of recruitment were 1.26 per 10,000 in Rio de Janeiro and 
3.40 per 10,000 in Duque de Caxias (Ministry of Health of Brazil; www.datasus.gov.br). 
From Ethiopia 34 healthy controls were tested: 18 EChigh who were derived from a subcity of 
Addis Ababa (Kolfe Keranio Clinic) with a prevalence rate of 1.5 per 10,000 (72 in 465,811), 
whereas16 EClow were derived from areas with a prevalence rate of 0.36 per 10,000 (10 in 
273,310). Prevalence rates in Ethiopia were calculated based on the number of patients in the 
health centers provided by the personnel of each health center. TB patients were recruited 
from the Ambulatory Service, District Hospital Raphael de Paula e Souza, Rio de Janeiro. As 
non-endemic controls, 21 Dutch healthy individuals (NEC) were recruited at the Blood bank 
Sanquin, Leiden, The Netherlands. None of the NEC had experienced any known prior 
contact with leprosy patients. Informed consent was obtained from all individuals before 
venepuncture. Ethical approval of the study protocol was obtained through the appropriate 
local ethics committees.  
Lymphocyte stimulation tests (LST). Venous blood was obtained from study participants in 
heparinized tubes and PBMC isolated by Ficoll density centrifugation. PBMC (1.5 x 10
6
 
cells/ ml) were plated in triplicate cultures in 96-well round bottom plates (Costar 
Corporation, Cambridge, Mass.) in 200 l/well of Adoptive Immunotherapy medium     
Chapter 3 
 
68 
 
(AIM-V, Invitrogen, Carlsbad, CA). Synthetic peptides, recombinant protein, M. leprae 
whole cell sonicate or PPD (purified protein derivative of M. tuberculosis, Mycos, Loveland, 
Colorado) were added at final concentrations of 10 g/ ml. As positive control stimuli SEB 
(staphylococcus enterotoxin B; 1 g/ ml; Toxin Technology, Inc., Sarasota, FL, USA) or 
PHA (phytoheamagglutinin; 2 g/ ml; Sigma, St. Louis, MO) were used. After 6 days of 
culture at 37C at 5% CO2, 90% relative humidity, 110 μl supernatants were removed from 
each well, triplicates were pooled and frozen in aliquots at –20C until further analysis. 
Whole blood assays (WBAs). Venous undiluted heparinized blood (450 μl per well) was 
incubated in 48-well plates at 37°C at 5% CO2, 70% relative humidity with 50 μl of 
ML1601c peptides (p11 and p16) solution (10 g/ ml final concentration). Blood was added 
to each well within 2 hours of collection. After 24 h of culture 180 l of supernatants were 
removed from each well and frozen in aliquots at –20C until further analysis. 
IFN-γ ELISA. Detection of IFN-γ in culture supernatants of in vitro cultured cells was 
performed by ELISA (BD Bioscience) according to the manufacturer's instructions. OD values 
were converted into concentrations using Microplate Manager Software, version 5.2.1 (Bio-
Rad Laboratories, Veenendaal, The Netherlands). The cut-off value to define positive 
responses was set beforehand at100 pg/ml. The assay sensitivity level was 20 pg/ml. Values 
for unstimulated whole blood cultures were typically < 30 pg/ml. 
Multiplex determination of cytokines and chemokines. According to the manufacturer’s 
guidelines, 18 inflammatory and immunomodulatory cytokines or chemokines (IL-1β, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, G-CSF, GM-CSF, IFN-, IP-10 
(CXCL10), MCP-1 (CCL2), MIP-1β (CCL4) and TNF) were measured in unstimulated, 
antigen-stimulated or mitogen-stimulated samples by Bio-Plex Suspension Array System 
powered by Luminex xMAP multiplex technology (Bio-Rad Laboratories, Veenendaal, The 
Netherlands) and analyzed with the Bio-Plex Manager
TM
 Software 4.0 (Bio-Rad Laboratories, 
Veenendaal, The Netherlands). After pre-wetting the filter with assay-solution, the beads 
were washed twice with washing-solution using 96-well multiscreen filter plates (Millipore), 
an Aurum
TM 
vacuum manifold and a vacuum pump (Bio-Rad Laboratories, Veenendaal, The 
Netherlands). Supernatant samples (50 μl) were added to the plates and the plates were 
incubated 45 minutes at room temperature in the dark at 300 rpm on a plate shaker. After 
three washes, 12.5 μl detection antibody cocktail was added per well and plates were 
incubated at room temperature in the dark for 30 minutes on a plate shaker. After three 
washes, 25 μl strepavidin-PE solution was added per well and incubated for 10 minutes. After 
three washes, 100 μl of assay buffer was added to each well and the plates were placed in the 
Bio-Plex System. From each well, a minimum of 100 analyte-specific beads were analyzed 
for fluorescence. A curve fit was applied to each standard curve according to the 
manufacturer's manual. Sample concentrations were interpolated from these standard curves. 
Analyte concentrations outside the upper- or lower limits of quantification were assigned the 
values of the limits of quantification of the cytokine or chemokine. 
Statistical analysis. Differences in cytokine levels between groups were analyzed with the 
two-tailed Mann-Whitney U test for non-parametric distribution using GraphPad Prism 
version 5.00 for Windows (GraphPad Software, San Diego California USA; 
www.graphpad.com). P-values were corrected for multiple comparisons. The statistical 
significance level used was p<0.05.  
Factor Analysis. The factor analysis technique was applied to evaluate the IFN- production 
levels induced by ML1601c and the ML1601c-derived peptides in order to identify the 
different patterns of response associated with these stimuli, and to group together peptides 
inducing similar patterns of IFN- production. Three independent factors representing 
combinations of the original variables were determined. The factor loadings are the 
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correlation coefficients between the original variables or IFN- responses to a given peptide 
and the factors (StatSoft, Inc. 2010. STATISTICA, data analysis software system, version 9 
www.statsoft.com). 
Results 
3.1. Identification of M. leprae specific T-cells epitopes of ML1601c in Brazilian 
population highly endemic for leprosy. 
In view of its high immunogenicity in M. leprae exposed individuals [9], the recombinant 
protein ML1601c was tested for induction of IFN- in PBMC derived from multibacillary 
(MB) and paucibacillary (PB) leprosy patients, healthy house contacts (HHC), tuberculosis 
(TB) patients, healthy controls (EC) from Brazil and from 21 Dutch (non endemic) control 
(NEC) individuals (Figure 1). As controls, stimulation by M. leprae whole cell sonicate, 
purified protein derivative (PPD) of M. tuberculosis and staphylococcus enterotoxin B (SEB) 
were also analyzed. As can be seen from Figure 1 all groups responded well to the SEB 
control with median production > 2400 pg/ml. For the Dutch NEC the positive control PHA 
was used instead of SEB, inducing overall higher IFN- responses in this group (Figure 1A). 
PPD was highly immunogenic in all groups as well, be it that IFN- responses to M. leprae 
showed more variability as only three individuals responded well in the NEC group, two 
intermediately and 16 were non-responders for M. leprae. Additionally, the MB patients did 
not or only barely respond to M. leprae, which is a general phenomenon for this type of 
leprosy patients. Similar to PPD, ML1601c protein did not induce significantly different IFN-
 production in EC compared to NEC, nor compared to the HHC group, whereas MB patients 
again responded less well than the five other test groups. In summary, these data indicate that 
IFN- responses induced by ML1601c protein cannot be used to discriminate between M. 
leprae exposed and non-exposed individuals. 
Table II 
Use of factor analysis for grouping together peptides and protein  
inducing similar patterns of IFN-responses*  
         _____   
     Factor 1                         Factor 2            Factor 3 
            ___ 
p11   0.9630     0.0767   0.1875  
p12   0.9401     0.0452   0.1643  
p13   0.9219   0.0913     0.2498 
p14   0.7010   0.0961     0.3563  
p15   0.1877                -0.0058   0.9473  
p16   0.9243   0.0214     0.1205  
p17   0.1487   0.9606     0.0324  
p18   0.5554                -0.0218   0.3223 
p19   0.7157                -0.0095   0.3751 
p20   0.3068   0.0327     0.8787 
p3   0.9524   0.0701     0.1830 
    ML1601c                     -0.0081            0.9788                 -0.0103 
           
* Values indicative of high correlation of a peptide IFN- response with one factor are depicted in bold. Factor analysis of 
the IFN- responses induced by the ML1601c protein and ML1601c peptides was performed with IFN- values observed in 
MB, PB, HHC, TB and EC (STATISTICA, data analysis software system, version 9). The 3 factors are new and independent 
variables that capture the characteristics of the original variables    (IFN- responses to the peptides and ML1601c protein 
in the different groups). The factor loadings indicative of the correlation of the IFN- responses induced by a peptide with 
each factor are shown. The 0.80000 value was arbitrarily selected for indicating a high correlation of one peptide with a 
given factor. 
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In view of this nondiscriminatory nature of the IFN- responses induced by the ML1601c 
protein in Brazilian individuals and due to the fact that ML1601c contains sequences similar 
or identical to M. avium paratuberculosis (MAP3249), peptides overlapping the entire 
sequence of ML1601c (Table I) were synthesized. Analysis of IFN- responses induced by 
these ML1601c synthetic peptides in PBMC is shown in Figure 2: again, similar to 
stimulation with ML1601c protein, MB patients responded less well than PB patients and 
HHC. In these latter two groups each ML1601c peptide was recognized by  1 (HHC) or   3 
(PB) individuals with a maximum of 11 HHC recognizing p17. In contrast to the responses to 
the whole ML1601c protein, the synthetic peptides induced lower IFN- responses especially 
in NEC and TB, as none of the peptides was recognized by NEC and only p17 induced 
significant responses in three TB patients. Importantly, for the Brazilian EC only some 
peptides (p15, p17, p20 and to a lesser extent p18) induced significant responses in multiple 
donors. Thus, these data clearly indicate that peptide-induced IFN- production in response to 
ML1601c are more specific for and correspond with M. leprae exposure and/or infection.   
 
3.2. Identification of ML1601c peptides with discriminatory capacity. 
Since peptide responses are HLA-restricted, a combination of multiple M. leprae peptides 
will be required to render a diagnostic test for leprosy broadly applicable. Thus, for the 
selection of peptides with the best performance in discriminating individuals with M. leprae 
infection and/ or -exposure based on their capacity to induce IFN- production in PBMC, a 
factor analysis was performed using the IFN- data (Figure 2) induced by all ML1601c 
peptides and the ML1601c protein (Table II).  
 
 
Figure 1 IFN- production by PBMC induced by SEB (A.), PPD (B.), M.leprae (C.) and ML1601c recombinant protein (D.) in MB (n = 11), PB (n = 11), HHC 
(n=19), TB (n = 8) and EC (n = 17) from Brazil as well as in Dutch NEC (n = 21). For NEC PHA was used instead of SEB. Values were corrected for 
background values. All background values were typically < 20 pg/ml. Horizontal bars indicate median responses. 
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This type of analysis has the potential to group together peptides inducing comparable 
patterns of IFN responses, and as a consequence presenting high correlations (factor 
loadings) with the same factor. The 3 factors obtained from the IFN- responses to the 
ML1601c protein and the ML1601c peptides can in fact be linked to features relevant in the 
selection of peptides for use in diagnostic tests. Peptides presenting high correlations with 
factor 1 (factor loading > 0.8; p3, p11, p12, p13 and p16) induce high-level responses only in 
a subset of the  exposed and/ or infected individuals (MB, PB, HHC) but not on those for 
which exposure is less likely (EC), absent (NEC) or TB patients. Therefore, IFN- production 
induced by these peptides was depicted for each peptide separately as well as for the sum of 
the IFN- values for all five of these ML1601c peptides combined (Figure 3). This figure 
shows that IFN- levels in response to p13 were most frequent but were also observed in 
three EC and in one NEC, whereas p3, p11 and p16 showed very specific responses only in 
leprosy patients and in M. leprae exposed HHC. This analysis clearly shows that M. leprae-
specific IFN- responses can be induced selectively in PBMC derived from M. leprae 
exposed and/ or infected individuals by peptides derived from a protein that is not uniquely 
present in the M. leprae genome. The ML1601c protein and p17 were highly correlated with 
factor 2. Responsiveness to these two stimuli was present in the exposed and/ or infected 
groups, in the EC and in TB patients. So, the ML1601c protein and p17 (correlated to factor 2) 
are not useful antigens in terms of potentially discriminating M. leprae infection or disease. 
ML1601c p15 and p20 (correlated to factor 3) share with the factor 1 subset specificity for 
exposed and/ or infected individuals. However, p15 and p20 also stimulate EC rendering 
these peptides not useful for leprosy diagnostics either. 
 
3.3.Whole blood assays using ML1601c peptides in Ethiopian healthy controls. 
ML1601c p11 and p16 induced significant IFN- responses (> 200 pg/ml; Figure 3) in 10 and 
11 M. leprae exposed or infected Brazilians, respectively, indicating recognition of these 
peptides in the context of various HLA-alleles. Since one of the aims of this study was to 
develop field-friendly test that is world-wide applicable, IFN- production in response to a 
mix of these peptides was analyzed in a 24-hour WBA [20] using 34 healthy controls from 
areas in Ethiopia with different leprosy prevalence (Figure 4; EClow: n=16; EChigh: n=18). 
Although both groups responded equally well to the positive control stimulus PHA (Figure 
4A), there was a significant difference (p = 0.0067) between IFN- responses induced by the 
ML1601c peptide mix in individuals from an area with low endemicity (EClow) compared to 
those from an area with high endemicity (EChigh).  
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Figure 2 IFN- production by PBMC induced by ML1601c peptides (see Table I) in MB (n = 11), PB (n = 11), 
HHC (n=19), TB (n = 8) and EC (n = 17) from Brazil as well as Dutch NEC (n = 21). Values were corrected for 
background values. All background values were typically < 20 pg/ml. Horizontal bars indicate median responses. 
 
Thus, WBA show that IFN- levels induced by ML1601c peptides selected on the basis of 
IFN- responses induced in M. leprae exposed or infected individuals in Brazil, can be 
detected as well in Ethiopian individuals exposed to M. leprae. IFN- responses to these 
peptides in a field-friendly 24-hour WBA can therefore be used as indication of the 
magnitude of the M. leprae transmission level in a given population.  
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3.4. Sequence homology of ML1601c peptides. 
Since M. avium paratuberculosis contains a homologue of ML1601c (MAP3249), the 
sequence of ML1601c was aligned with that of MAP3249 and the amino acid identity was 
determined for ML1601 peptides (Table I). This alignment showed that the percentage 
identity in general was not very high, with 42 % and 35 % identical to MAP3249 for p11 and 
p16 respectively. Immunogenicity of the peptides did not correlate with the percentage 
identity, as p17 and p12 both had high percentage identical sequence (52 % and 45 %, 
respectively) but only p17 was recognized by many individuals. Thus, although a homologue 
of ML1601c protein is present in M. avium paratuberculosis, exact sequence identity is 
relatively low and allows induction of specific T-cells responses in M. leprae exposed 
individuals by ML1601c peptides. 
 
3.5.Multiplex determination of cytokines and chemokines in response to ML1601c peptides. 
Immunological correlates of protection in leprosy are still lacking: although antigen-specific 
IFN- production is often used as a biomarker for M. leprae infection [9], it is possible that 
additional cytokines might allow more specific or qualitatively different detection of immune 
responses against M. leprae peptides.  
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Figure 3: IFN- production by PBMC induced in all test groups by ML1601c peptides p3, p11, p12, p13, and 
p16 and the sum of the IFN- values for p3, p11, p12, p13, and p16 combined. The proportions of responders in 
each test group are indicated below the x-axis. 
 
In order to further characterize the cellular immune response directed against ML1601c 
peptides, 15 additional cytokines and chemokines were tested in multiplex assays on identical 
supernatants as those used for IFN- (described above, Figure 4) obtained from the 24-hour 
WBA stimulated with a mix of ML1601c p11 and p16 using 34 healthy Ethiopian individuals. 
Although hardly any responses were detected for IL-17, G-CSF, VEGF, IL-1, IL-10 and 
GM-CSF, nor any significant differences observed between EClow and EChigh for the levels of 
IL-12, MIP-1, MIG and IL-8 (data not shown), significantly different levels were observed 
between these two groups when IL-1 (p = 0.0042), IL-6 (p = 0.0006), IP-10 (p = 0.0001), 
TNF- (p < 0.0001) or MCP-1 (p = 0.0347) were measured (Figure 5). Thus, in addition to 
IFN-, detection of these cytokines can also be used to indicate the magnitude of the M. 
leprae transmission level in a given population. Whether or not such cytokine responses also 
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indicate disease development or, alternatively, protection from disease will as yet have to be 
determined in longitudinal follow-up studies in HHC. Such studies are currently underway in 
highly leprosy endemic areas. 
 
Figure 4: IFN- production in response to the positive control PHA (a) or a mix of ML1601c peptides no. 11 and 
no. 16 (b) measured after 24h culture of undiluted whole blood derived from 34 Ethiopian healthy controls (ECs) 
derived from areas with low endemicity for leprosy (EClow; n=16) or from areas highly endemic for leprosy 
(EChigh; n=18). 
 
Discussion 
 
It is quite clear that elimination of leprosy requires, in addition to multidrug therapy (MDT), 
novel diagnostic tools that allow early detection of preclinical M. leprae infection, likely the 
major source of unidentified transmission. Also, the fact that children are still developing 
leprosy suggests that MDT has not substantially reduced transmission [2;3]. Therefore, 
identifying antigens that can be used as tools in diagnostic tests has been an important topic 
in leprosy research the last two decades. 
 
In classical, PBMC-based IFN- release assays, M. leprae peptides have been shown to 
discriminate in a more specific fashion than proteins between M. leprae exposed contacts and 
patients as opposed to healthy controls from the same endemic area [10;12]. Our previous 
studies identified M. leprae peptides derived from proteins such as ML1989, ML1990, and 
ML2567 that induced IFN- in a 6 day proliferation assay using PBMC. The slight 
disadvantage of peptides though is that they usually induce significantly lower levels of IFN-
 than proteins, particularly when whole blood is used [13;20]. This could, however, be 
inherent to the selected peptides as for TB diagnosis; the combination of > 20 peptides is used 
successfully in WBA-based IGRA such as QuantiFERON-TB Gold assay. Therefore, more 
peptides, shared in different M. leprae strains that can be applied in diagnostic tools for 
leprosy should be identified and tested in the context of various genetic backgrounds in 
South-America, Asia and Africa to enable development of a peptide-based WBA. 
 
The Brazilian population can roughly be divided in three ethnic groups, namely from 
Caucasian, indigenous and African descent. Given this genetical diversity and the 
extraordinarily high leprosy endemicity compounded by poverty in several of its areas, Brazil 
is a suitable region for developing globally applicable T-cells based diagnostic tools. Indeed, 
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this study shows that even HLA-restricted, M. leprae peptides can be identified in a Brazilian 
population and applied to measure M. leprae exposure in an African population in Ethiopia. 
Two ML1601c peptides, p11 and p16, only induced IFN- production in PBMC from leprosy 
patients and HHC in Brazil and not, unlike ML1601c protein, in TB patients, EC or NEC. 
The combination of these peptides could be applied in a field-friendly, 24-h WBA in Ethiopia 
to estimate exposure to M. leprae. This is consistent with the findings of other M. leprae 
peptides (Martins et al., submitted) thereby indicating that combinations of peptides can be 
designed and used efficiently to indicate substantial exposure to M. leprae. 
 
The observation in this study that ML1601c protein induced significant IFN- responses in 
EC, TB as well as some NEC, is in agreement with the finding that the use of recombinant 
proteins coincides with an increased risk of detecting cross-reactive T-cells responses 
irrespective of overall sequence homology. In addition, purification and quality control 
assays for recombinant proteins are more labor-intensive than is the case for synthetic 
peptides. Therefore, despite the fact that T-cells responses to peptides are HLA-restricted, 
which may limit the applicability of single peptides with respect to diagnostic T-cells-based 
assays in genetically diverse populations [21], a cocktail of M. leprae peptides can be used to 
identify M. leprae exposure in genetically different populations. 
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Figure 5: Production of IL-1β (a), IL-6 (b), IP-10 (c), TNF- (d), and MCP-1 (e) in response to selected 
ML1601c peptides measured after 24h culture of undiluted whole blood derived from 34 Ethiopian healthy 
controls (ECs) derived from areas with low endemicity for leprosy (EClow: n=16) or from areas highly endemic 
for leprosy (EChigh: n=18). 
 
An alternative approach that we addressed here is that alternate cytokines or chemokines may 
be able to provide a distinction between progression to disease and containment of M. leprae 
infection. Therefore, we also tested supernatants of whole blood cultures stimulated with 
ML1601c p11 & p16 for 15 additional cytokines: significantly different levels were observed 
between EClow and EChigh when IL-1 (p = 0.0042), IL-6 (p = 0.0006), IP-10 (p = 0.0001), 
TNF- (p < 0.0001) or MCP-1 (p = 0.0347) were used as read-outs. Thus, in addition to IFN-
, detection of these cytokines can also be used to estimate the magnitude of the M. leprae 
transmission level in a given population. The significant differences observed for both IL-1 
and IL-6 suggest differences in the innate responses between the test groups [22]. For TB 
susceptibility it has been described that the polymorphism at the IL-1 locus influences the 
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cytokine response and may be a determinant of delayed-type hypersensitivity and disease 
expression in human tuberculosis [23]. For leprosy, however, no association with IL-1 
polymorphism has been described [24]. 
 
In combination with classical detection of anti-PGL-I IgM antibodies, M. leprae peptide-
based WBA measuring cytokines will not only allow detection of most forms of leprosy (PB 
and MB) but may also identify those at risk of developing disease by detecting preclinical 
forms of leprosy, thereby enabling installment of MDT at an early stage. Additional M. 
leprae peptides will presumably be identified in the future, but to ensure the success of 
developing an affordable, field-friendly test for the early diagnosis of leprosy, continued 
funding for these efforts will be critical.       
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Abstract 
 
Silent transmission of Mycobacterium leprae, as witnessed by the stable leprosy incidence in 
various countries, remains challenging despite worldwide implementation of multidrug 
therapy (MDT). The development of tools for early diagnosis of M. leprae infection should 
therefore be emphasized in leprosy research. As part of the continuous effort to identify 
antigens with diagnostic potential, M. leprae unique peptides derived from predicted 
virulence-associated proteins (groupIV.A; 
http://www.sanger.ac.uk/Projects/M_leprae/Ml_gene_list_hierarchical.shtml) were identified 
using advanced genome pattern programs and bioinformatics. Based on the presence of HLA-
binding motifs, we selected 21 predicted promiscuous HLA-class I and 8 HLA-class II 
restricted T-cell epitopes as 9mers for further field-testing in Brazil, Ethiopia and Nepal. 
High levels of IFN-  were induced by peptide ML2055 p35 in PBMC of TT/BT leprosy 
patients from Brazil and Ethiopia as well as controls from areas with high leprosy prevalence 
(EChigh) in Ethiopia, whereas Brazilian EChigh recognized ML1358 p20 and ML1358 p24. 
None of the peptides was recognized by non endemic controls. In addition, in Nepal peptide 
pools composed of these peptides induced IFN- by PBMC of leprosy patients as well as 
EChigh. Thus, these M. leprae virulence-associated peptides may be useful to differentiate M. 
leprae exposure in the context of different HLA polymorphisms.  
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Introduction 
 
Despite the extensive decrease of the annual prevalence of leprosy since the introduction of 
multidrug therapy (MDT) over 30 years ago, a consistent number of new cases, including 
children, is still reported annually in a number of countries. This indicates continued and 
significant transmission at the population level, which challenges disease control efforts 
(WHO, 2011). The incubation period of Mycobacterium leprae (M. leprae) and the time 
elapsed before manifestation of symptoms in an infected individual ranges between 4 and 10 
years but can even reach 30 years [7]. It is hypothesized that, most patients have been 
infected subclinically for a considerable amount of time before leprosy becomes apparent, 
thereby presumably representing a major source of M. leprae transmission. 
 
Early detection of leprosy and prompt treatment with MDT will help to reduce transmission 
and infection, and thus have a major impact on preventing nerve damage, disabilities and 
deformities. However, there are currently no diagnostic tests available that can detect 
asymptomatic M. leprae infection. Development of a specific immunodiagnostic tool for 
leprosy requires adequate information about the specific antigens of the pathogen. The failure 
to grow M. leprae on artificial media [31] has greatly hampered leprosy research for many 
decades, including the development of specific diagnostic tools for leprosy. The recent 
availability of improved bioinformatics tools as well as the M. leprae genome sequence has 
opened up new possibilities in leprosy research, enabling the prediction of relevant proteins 
and potential HLA class I and class II epitopes that can activate T-cells [12]. The use in 
multiple studies of M. leprae unique antigens defined through such post-genomic approaches 
have led to the detection of M. leprae-protein or peptide specific T-cell responses that may 
help identify M. leprae exposed or -infected subjects [13;29;3;15;6;5]. 
 
Antigenic proteins usually contain multiple peptide epitopes and thus may be preferred as 
diagnostic tools in various populations containing different genetic backgrounds. However, 
an advantage of using peptides as diagnostic tools is the observed reduction in or lack of T-
cell cross-reactivity compared to proteins [16;15]. Hence, analysing single M. leprae unique 
peptides, or pools thereof, in different leprosy endemic settings can be useful to identify 
promiscuous peptides with diagnostic potential across different genetic backgrounds. The 
immunogenic and diagnostic significance of Mycobacterium tuberculosis (Mtb) proteins 
ESAT-6 and CFP-10 and their peptides from the RD-1 region (involved in enhancing 
virulence) [4] have led us to search for similar possibilities in leprosy by using M. leprae-
unique virulence-associated peptides. Hence, in the current study, the M. leprae whole 
proteome was in silico dissected into 20-mer amino acid peptides. Next, M. leprae unique 
peptides derived from group IV.A (virulence; 
http://www.sanger.ac.uk/Projects/M_leprae/Ml_gene_list_hierarchical. shtml) and predicted 
to bind promiscuously to HLA class I or II alleles were selected and synthesized. In vitro 
analysis of these synthetic peptides was performed using PBMC or whole blood derived from 
TT/BT and BL/LL leprosy patients and healthy endemic controls (EC) from areas with high 
or low leprosy prevalence in Brazil, Ethiopia and Nepal.  
 
Materials and Methods 
 
Peptide search strategy. The peptide identification procedure is depicted in Figure 1: all 20-
mers in the M. leprae genome [9] were identified. A length of 20 amino acids was chosen 
since this may accommodate for both HLA class I and class II T-cell epitopes. 20-mers with 
an overlap of eight or more amino acids in a continuous stretch with sequences from other 
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mycobacteria, from completed or nearly complete genomes and from sequences available in 
the entire database of GenBank (www.ncbi.nlm.nih.gov/GenBank) were excluded from this 
study. This selection procedure is described in more detail below. 
Bacterial genomes. All genomes used in this study were retrieved from GenBank and consist 
of a total of six completely sequenced mycobacterial genomes: M. leprae (GenBank Protein 
accession number: NC_002677), M. tuberculosis strains H37Rv (AL123456 and NC_000962) 
and CDC1551 (NC_002755), M. bovis (NC_002945) and M. avium paratuberculosis 
(NC_002944). Other (nearly) completely sequenced mycobacterial genomes (unpublished at 
the time of peptide selection) such as M. avium, M. smegmatis, M. tuberculosis strain 210 
(www.tigr.org), M. marinum, M. microti (www.sanger.org), M. paratuberculosis and M. 
ulcerans (http://www.pasteur.fr/) were further included indirectly by using BLAST 
(described below) to give a broader picture of the conservation of  20-mers. 
Bioinformatics tools.  The complete M. leprae genome was divided into 20-mers with 19 
amino acids overlap by using the GenomePatterns program resulting in the M. leprae-list. In 
order to check homology of M. leprae with closely related mycobacterial genomes that were 
completely sequenced, the GenomePatterns program was also used to generate a list of 20-
mers with 19 amino acids overlap for M. tuberculosis strains H37Rv and CDC1551, M. bovis 
and M. paratuberculosis (the MTB-list). The M. leprae-list was then compared to the MTB-
list and all 20-mers within the M. leprae-list which had a continuous stretch of eight or more 
identical amino acids to the MTB-list were excluded from further analysis. This resulted in 
141,300 20-mers which are unique to the M. leprae genome. The 20-mers coded by any of 
the 1,116 pseudogenes of M. leprae were excluded, reducing the M. leprae-list to 138,938 
20-mers derived from 1,546 different M. leprae candidate proteins. To narrow down the 
number of peptide candidates that needed to be blasted, we selected peptides derived from 
genes in functional classification group IV.A (virulence; including the following 13 genes: 
ML0360, ML0361, ML0362, ML0885, ML1214, ML1358, ML1811, ML1812, ML2055, 
ML2208, ML2466, ML2589, ML2711;  
http://www.sanger.ac.uk/Projects/M_leprae/Ml_gene_list_hierarchical.shtml, currently 
designated as genes involved in virulence, detoxification and adaptation or genes involved in 
cell wall and cell processes on http://mycobrowser.epfl.ch/leprosy.html, resulting in 886 
candidate 20-mers. Next, we used a perl script “genediff.pl” that compares genomes using 
BLAST (CBS, script used internally) and excluded proteins homologous with the human 
genome and three homologs with M. tuberculosis. The overlapping M. leprae-derived 20-
mers were assembled (if they occurred in sequential order) resulting in 40 protein fragments. 
BLAST was used to exclude fragments that were found in unfinished mycobacterial genome 
sequences of M. smegmatis, M. tuberculosis strain 210 and M. microti OV254 
(www.sanger.org and www.tigr.org). In addition, the assembled M. leprae fragments were 
BLASTed against all sequences (not only mycobacterial) available in GenBank 
(http://www.ncbi.nlm.nih.gov/blast/). All hits that had an identity of more than eight amino 
acids with M. leprae peptides were again excluded. Out of the 40 fragments, 14 from 6 
proteins remained unique for M. leprae. 
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Figure 1: M. leprae peptide selection procedure. Identification and selection of predicted M. leprae 
promiscuous HLA class I epitopes (n = 21) and predicted M. leprae promiscuous HLA class II epitopes; n = 8) 
derived from M. leprae proteins from functional classification group IV.A (virulence; 
http://www.sanger.ac.uk/Projects/M_leprae/Ml_gene_list_hierarchical.shtml). 
 
Prediction of CD4 and CD8-restricted T-cell epitopes. NetCTL version 1.2 
(www.cbs.dtu.dk/services/NetCTL) was used to predict 9-mer epitopes for CD8
+
 T-cells from 
the 14 M. leprae unique fragments as described previously for 12 supertypes (HLA-A1, A2, 
A3, A24, A26 and HLA-B7, B8, B27, B39, B44, B58, B62) [19]. All peptides with a 
combined score above 1.25 were selected as potential MHC class I ligands. An adapted 
version of the program TEPITOPE [28] was used in this study to predict CD4-restricted T-
cell epitopes from the 14 M. leprae unique fragments that were found in a total of 6 M. leprae 
proteins. These 6 protein sequences were submitted to the SubCell 1.0 server 
(www.cbs.dtu.dk/services/) in order to predict the subcellular localization of these proteins for 
gram-negative and gram-positive bacteria. From the resulting sequences peptides were 
selected in such a manner that predicted binding sequences were included for most HLA 
alleles. In this selection, priority was given to peptides predicted to bind promiscuously to 
multiple HLA alleles (Table I). This selection resulted in 21 potential CD8-restricted T-cell 
epitopes and 8 potential CD4-restricted T-cell epitopes (Tables I and II). In case of induction 
of a positive CD4 response by 9mers (possibly suboptimal length), only the strongest 
inducers will be identified using this approach. 
Synthetic peptides. The identified virulence-associated M. leprae-derived peptides were 
purchased from Peptide 2.0 Inc. (Chantilly, VA, USA). Homogeneity and purity were 
confirmed by analytical HPLC and by mass spectrometry. Purity of all peptides was ≥ 80%. 
All impurities consist of shorter versions of the peptides caused by < 100% coupling 
efficiency in each round of synthesis. All peptides were divided in aliquots to allow field 
testing of identical batches in Brazil, Ethiopia, Nepal and The Netherlands. 
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Table I 
Selected M. leprae virulence-associated peptides (HLA class I; n=21) 
# 
 
Peptide (9 mer) 
 
Starting-
position 
ML 
accession 
number 
Accession number 
 
HLA 
 
HLA 
 
HLA 
 
p15 RAAVVQAAL 262  ML0885 NP_301670.1_245_270 B7 B8 B58 
p16 SMDAAVAAL 193  ML1812 NP_302233.1_181_201 A2 B39   
p17 GIAGSASYY 202  ML2055 NP_302372.1_189_211 A1 B62   
p18 HRKGLWAIL 10  ML2055 NP_302372.1_1_78 B27 B39   
p19 QMLEASSSV 210  ML1811 NP_302232.1_209_232 A2     
p20 ALDTFGIPV 73  ML1358 NP_301968.1_64_92 A2     
p21 NGIAGSASY 201  ML2055 NP_302372.1_189_211 A26     
p22 KVTVSSVRK 220  ML1811 NP_302232.1_209_232 A3     
p23 TEAVHSAQL 58  ML0885 NP_301670.1_54_76 B44     
p24 KLMGALDTF 69  ML1358 NP_301968.1_64_92 B58     
p25 VASASAFTM 23  ML2055 NP_302372.1_1_78 B58     
p26 AVVASASAF 21  ML2055 NP_302372.1_1_78 B62     
p27 APLPPSTAT 42  ML2055 NP_302372.1_1_78 B7     
p28 GPVPAVATL 220  ML0885 NP_301670.1_220_250 B7     
p29 IPVAGRCCL 79  ML1358 NP_301968.1_64_92 B7     
p30 RPRRGSVSR 3  ML1812 NP_302233.1_1_20 B7     
p31 LPSADIVPM 172  ML1358 NP_301968.1_158_181 B7     
p32 SASAFTMPL 25  ML2055 NP_302372.1_1_78 B7     
p33 APIPASVSA 274  ML2055 NP_302372.1_257_287 B7     
p34 RPVPVSTAR 204  ML1214 NP_301879.1_173_212 B7     
p35 IPASVSAPA 276  ML2055 NP_302372.1_257_287 B7     
 
M. leprae recombinant proteins. M. leprae genes encoding proteins from which the 
virulence-associated peptides derived were amplified by PCR from genomic DNA of M. 
leprae and cloned using the Gateway technology platform (Invitrogen, Carlsbad, CA) with 
pDEST17 expression vector containing an N-terminal histidine tag (Invitrogen) [11] 
Sequencing was performed on selected clones to confirm identity of all cloned DNA fragments. 
Recombinant proteins were overexpressed in E. coli BL21 (DE3) and purified as described to 
remove any traces of endotoxin [11]. Each purified recombinant protein was analyzed by 12% 
SDS-PAGE followed by Coomassie Brilliant Blue staining and Western-blotting with an 
anti-His antibody (Invitrogen) to confirm size and purity. Endotoxin contents were below 50 
EU (endotoxin unit) per mg recombinant protein as tested using a Limulus Amebocyte Lysate 
(LAL) QCL-1000 assay (Lonza Inc., Basel, Switzerland). Recombinant proteins were tested to 
exclude protein non-specific T cell stimulation and cellular toxicity in IFN- release assays 
using PBMC of in vitro PPD-negative, healthy Dutch donors recruited at the Blood Bank 
Sanquin, Leiden, The Netherlands. None of these controls had experienced any known prior 
contact with leprosy or TB patients.  
M. leprae whole cell sonicate (WCS). Irradiated armadillo-derived M. leprae whole cells 
were probe sonicated with a Sanyo sonicator to >95% breakage. This material was provided 
through the NIH/NIAID “Leprosy Research Support” Contract N01 AI-25469 from Colorado 
State University (available through the Biodefense and Emerging Infections Research 
      M.leprae virulence peptides
   
       
87 
 
Resources Repository listed at http://www.beiresources.org/TBVTRMResearch 
Materials/tabid/1431/ Default.aspx). 
Study participants. The following HIV-negative individuals were recruited between August 
2008 and February 2011: in Brazil: 10 TT/BT leprosy patients, 10 healthy controls living in 
an area of Fortaleza with low prevalence (Mereiles; prevalence < 0.2/10,000; EClow) and 10 
healthy controls living in an area of Fortaleza with high prevalence (Bom Jardin; prevalence > 
4/ 10,000; EChigh); in Ethiopia 23 leprosy patients (tuberculoid /borderline tuberculoid (10 
TT/BT) and borderline lepromatous/lepromatous leprosy (13 BB/BL), 12 HHC of BL/LL 
patients and 52 healthy controls were tested: 25 EChigh who were derived from a subcity of 
Addis Ababa (Kolfe Keranio) with a prevalence rate of 1.5 per 10,000 (72 in 465,811), 
whereas 27 EClow were derived from areas with a prevalence rate of 0.36 per 10,000 (10 in 
273,310). Leprosy endemicity for each Ethiopian EC was based on the number of new cases 
and leprosy prevalence in nearby health centers per area. From Nepal, 7 TT/BT and 5 BL/LL 
patients and 20 EChigh were enrolled in this study. The national leprosy prevalence in Nepal 
was 1.1 per 10,000 in 2008/ 2009 (Annual report 2008/ 2009, Leprosy control division, 
Nepal).  
In all settings, leprosy was diagnosed based on clinical, bacteriological and histological 
observations and classified by a skin biopsy evaluated according to the Ridley and Jopling 
classification [22] by qualified microbiologists and pathologists. All patients were recruited 
when newly diagnosed and were untreated and did not develop leprosy reactions within 3 
months of MDT initiation. EC were assessed for the absence of clinical signs and symptoms 
of tuberculosis and leprosy. Staff members working in the leprosy centers or TB clinics were 
excluded as EC.  
Whole blood assays (24 h WBA). Within 3 hours of collection, venous heparinized blood 
(450 μl per well) was incubated in 48-well plates at 37°C at 5% CO2, 90% relative humidity 
with 50 μl of antigen solution (100 g/ ml). After 24 h, 150 l of supernatants were removed 
from each well and frozen in aliquots at –20C until further analysis. 
 
Table II 
Selected M. leprae virulence-associated peptides (HLA class II; n=8) 
# 
 
Peptide (9-mer) 
 
Starting-
position 
ML 
number 
Accession number 
 
HLA 
 
HLA 
 
HLA 
 
p36 VVRDLRLRA  197 ML1358 NP_301968.1_192_213 1_0301 1_1101 1_1501 
p37 WAILAIAVV  15  ML2055 NP_302372.1_1_78 1_0101 1_0801 1_1101 
p38 ILAIAVVAS  17 ML2055 NP_302372.1_1_78 1_0301 1_0401 1_1101 
p39 VRPVPVSTA  203 ML1214 NP_301879.1_173_212 1_0301 1_1101   
p40 LRADSVLAV  203 ML1358 NP_301968.1_192_213 1_0301 1_0401   
p41 LQQVPTLPA  199 ML1214 NP_301879.1_173_212 1_1101     
p42 LAIAVVASA  18 ML2055 NP_302372.1_1_78 1_1101     
p43 ISLATVLSA  158 ML1358 NP_301968.1_158_181 1_1101     
 
Lymphocyte stimulation tests (LST). PBMC were isolated by Ficoll density centrifugation 
from venous, heparinized blood and plated in triplicate cultures (2 x 10
5
 cells/ well) in 96-
well round bottom plates (Costar Corporation, Cambridge, Mass.) in 200 l/well of serum 
free Adoptive Immunotherapy medium (AIM-V, Invitrogen, Carlsbad, CA). Synthetic 
peptides, recombinant protein, M. leprae WCS or PPD (purified protein derivative of M. 
tuberculosis, Statens Serum Institut, Copenhagen, Denmark) were added at final 
concentrations of 10 g/ ml. As a positive control 1 g/ ml PHA (phytoheamagglutinin; 
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Remel, Oxoid, Haarlem, The Netherlands) was used. After 6 days of culture at 37C at 5% 
CO2, 90% relative humidity, 75 μl of supernatant were removed from each well, triplicates 
were pooled and frozen in aliquots at –20C until further analysis. 
IFN- ELISA. IFN- concentrations were determined by ELISA (U-CyTech, Utrecht, The 
Netherlands) [13]. The cut-off value to define positive responses was set beforehand at 100 
pg/ ml. The assay sensitivity level was 40 pg/ml. Values for unstimulated cell cultures were 
typically < 20 pg/ ml. Lyophilized supernatant of PHA cultures of PBMC from an 
anonymous buffycoat (Sanquin, Leiden, The Netherlands) was provided to both laboratories 
as a reference positive control supernatant. 
Multi-cytokine and -chemokine assay. The concentrations of 19 analytes (IL-1, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IFN-, IP-10 (CXCL10), G-CSF, 
GM-CSF, MCP-1 (CCL2), MIG (CXCL9), MIP-1 (CCL4) and TNF) in supernatants from 
24 h WBA were measured using the Bio-Plex suspension array system powered by Luminex 
xMap multiplex technology (Bio-Rad Laboratories, Veenendaal, The Netherlands) and 
analyzed using the Bio-Plex Manager
TM
 software 6.0 (Bio-Rad laboratories, Veenendaal, The 
Netherlands). After pre-wetting the filter with assay-solution, the magnetic beads were 
washed twice with washing-solution using 96-well multiscreen filter plates (Millipore), an 
Aurum
TM 
vacuum manifold and a vacuum pump (Bio-Rad Laboratories, Veenendaal, The 
Netherlands). Supernatant samples (50 μl) were added to the plates and the plates were 
incubated for 45 minutes at room temperature in the dark at 300 rpm on a plate shaker. After 
three washing steps, 12.5 μl detection antibody cocktail was added per well and plates were 
incubated at room temperature in the dark for 30 minutes on a plate shaker. After three 
washes, 25 μl strepavidin-PE solution was added per well and incubated for 10 minutes. After 
three washes, 80 μl of assay buffer was added to each well and the plates were placed in the 
Bio-Plex System. From each well, a minimum of 50 analyte-specific beads were analyzed for 
fluorescence. A curve fit was applied to each standard curve according to the manufacturer's 
manual. Sample concentrations were interpolated from these standard curves. Analyte 
concentrations outside the upper- or lower limits of quantification were assigned the values of 
the limits of quantification of the cytokine or chemokine. 
Statistical analysis. Differences in cytokine concentrations between test groups were 
analysed with the two-tailed Mann-Whitney U test for non-parametric distribution using 
GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego California USA; 
www.graphpad.com). P-values were corrected for multiple comparisons. The statistical 
significance level used was p<0.05.  
Ethics. This study was performed according to ethical standards in the Helsinki Declaration 
of 1975, as revised in 1983. Ethical approval of the study protocol was obtained through the 
appropriate national or institutional ethics committees, namely: Brazilian National Council of 
Ethics in Research (CONEP), National Health Research Ethical Review committee (NERC) 
and the Nepal Health Research Council (NHRC). Informed consent was obtained from all 
individuals before venepuncture.  
 
Results 
 
Post-genomic approach for improved, M. leprae-specific CMI test antigens 
Owing to the shorter length of CD8-restricted epitopes, reliable bio-informatic methods for 
their prediction were developed at an early stage (e.g. SYFPEITHI 
(http://www.SYFPEITHI.de). More recently, prediction methods for the longer CD4-
restricted T-cell epitopes were designed by way of better training sets and algorithms. 
Notably, the PROPRED program (http://www.imtech.res.in) has been shown to accurately 
predict human T-cell epitopes and many of these have been confirmed experimentally [30;28]. 
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Using the available genomic sequences and these bio-informatic tools, we identified M. 
leprae-unique candidate antigens that were subsequently screened in silico for potential T-
cell epitopes (Figure 1 and Materials and Methods section). Using this post-genomic 
approach, M. leprae-unique sequences representing epitopes of M. leprae proteins derived 
from functional group IV.A (virulence) were identified. Synthetic peptides encoded by these 
sequences, designated in this study as M. leprae virulence-associated peptides (Table I) 
were used to evaluate cellular responses in leprosy patients and controls from Brazil, Ethiopia 
and Nepal. 
 
T-cell recognition of M. leprae peptides in non endemic controls (NEC)  
To exclude the induction of nonspecific T-cell responses by the selected M. leprae virulence-
associated peptides, they were first tested in 6 days lymphocyte stimulation assays (LST) 
using PBMC as well as in 24 h whole blood assays (WBA) using undiluted venous blood 
from Dutch healthy controls (NEC). Most individuals showed high responses to PPD (7/8) 
and M. leprae WCS (5/8). None of the NEC showed detectable IFN- responses against any 
of the peptides tested separately or in pools using PBMC (Figure 2A) or in 24 h WBA 
(Figure 2B), thereby ensuring the absence of M. leprae-non specific T-cell responses.  
 
 
Figure 2: IFN- responses to M. leprae peptides in PBMC from NEC. IFN- production (corrected for 
background values) induced using M. leprae virulence-associated peptides or pools thereof (A) in 6 day PBMC 
cultures of Dutch healthy controls (n = 8) or as pools in a 24 h WBA (B). Pool V1: 15-20; V2: 21-26; V3: 27-32; 
V4: 33-35, 37-39; V5: 36, 40- 43 (numbers indicate peptide sequences depicted in Table I and II). 
Chapter 3  
 
90 
 
T-cell recognition of M. leprae peptides in PBMC from Brazilian test groups  
The overall aim of our study was to identify new antigens that specifically indicate M. leprae 
exposure and/ or infection. Thus, M. leprae virulence-associated peptides (Table I) were first 
tested in a Brazilian population using PBMC in 6 days LST. For this study we enrolled 
tuberculoid or borderline tuberculoid leprosy patients (TT/BT), healthy endemic controls 
living in an urban area with high leprosy prevalence (P>4/10000; EChigh) and endemic 
controls living in the same city in an area with low prevalence (P<0.2/10000; EClow). In the 
Brazilian EChigh group 50% and 70% specifically recognized ML1358 p20 and ML1358 p24 
(Figure 3A), respectively, whereas none of the EClow group nor the TT/BT group produced 
IFN- in response to these two peptides (Figure 3B). In contrast, ML2055 p35 induced 
considerable levels of IFN- (> 1000 pg/ml) in 40% of the TT/BT patients, whereas ML1214 
p41, ML1812 p30, ML2055 p31, ML2055 p37, ML2055 p39 and ML2055 p42, induced IFN-
 responses in 30 - 40% of this group, although median values were lower (200 pg/ml; Figure 
3C). 
 
T-cell recognition of M. leprae peptides in PBMC from Ethiopian individuals  
In order to accommodate differences in genetic backgrounds, test groups from different 
leprosy endemic settings need to be included, thereby allowing analysis of T-cell responses 
induced by peptides in the context of HLA polymorphism. Thus, the M. leprae virulence-
associated peptides were also tested using PBMC derived from 12 Ethiopian TT/BT leprosy 
patients (Figure 3D) and 7 EC (2 EChigh and 5 EClow; Figure 3E). The overall IFN- 
concentrations measured in response to the M. leprae virulence-associated peptides in both 
groups were lower compared to those in Brazil, with the exception of ML2055 p35 which, as 
was the case for Brazilian TT/BT, induced IFN- in 50% of the Ethiopian TT/BT patients 
(Figure 3D). In addition, one of the EChigh individuals responded to 8 of the 28 peptides (>100 
pg/ml; Figure 3E). Thus, ML2055 p35 is recognized most frequently in TT/BT patients both 
in Brazil and in Ethiopia.  
 
IFN- responses in Ethiopian EChigh and EClow in WBA 
In order to identify peptides with the ability to indicate exposure levels of M. leprae in a rapid 
field-assay, peptides ML2055 p35, ML2055 p42, ML2055 p37 and ML1358 p24 were 
selected for subsequent comparative analysis of Ethiopian EClow (n = 17) and EChigh (n = 18) 
in a 24 h WBA. Two of these peptides, ML2055 p35 and ML2055 p42, which were 
recognized by Brazilian TT/BT patients also induced significant levels of IFN- in Ethiopian 
EChigh (p= 0.023 and p= 0.020, respectively) compared to EClow (Figure 4). The IFN- levels 
in response to the other M. leprae peptides were low and no differences were observed 
between EChigh and EClow.  
 
IP-10 as potential biomarker for diagnosis of M. leprae exposure 
Although IFN-γ is the hallmark effector molecule of Th1 cells and a critical component of the 
pro-inflammatory immune response, host immunity and immuno-pathogenicity in response to 
M. leprae involves complex interactions between a variety of cells expressing different 
effector and regulatory molecules. Thus, assessment of multiple rather than single biomarkers 
may be more representative of the immune status of the host and may identify patterns 
predisposing to M. leprae infection. Therefore, aliquots of the 24 h WBA samples of 
Ethiopian EChigh and EClow were also used for multiplex analysis of 19 additional cytokines/ 
chemokines. IFN- induced protein 10 (IP-10 or CXCL10) has been shown to be a useful 
biomarker for diagnosis of M. tuberculosis infection [28;24]. Interestingly, ML2055 p35 
induced significant levels of IP-10 in EChigh but not in EClow (p = 0.005; Figure 4E). ML2055 
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p42 also induced increased levels of IP-10 in EChigh compared to EClow although the 
difference was not significant (p=0.06; Figure 4F). None of the other analytes showed 
significantly different levels between EChigh and EClow (data not shown). Thus, the high IP-10 
levels induced by M. leprae specific antigens in WBA of EChigh shows that  this chemokine 
may have potential as a biomarker for differentiating levels of M. leprae exposure in new 
diagnostic tools in analogy to what has been reported for TB immunodiagnostic assays [23,2].  
 
IFN- production in response to M. leprae recombinant proteins  
Strikingly, the M. leprae virulence-associated peptides that induced IFN- responses in 
several individuals in this study were derived from only a few proteins, since p35, p37 and 
p42 were derived from ML2055, p20 and p24 from ML1358 and p41 from ML1214. To 
investigate the immunogenicity of the whole antigens, recombinant proteins ML2055, 
ML1358 and ML1214 were tested in 24 h WBA in Ethiopian BB/BL patients, HHC and EC 
(EChigh: n = 7 and EClow: n = 3; Figure 5). ML2055 protein induced IFN- response (> 100 
pg/ml) in 60% (7 out of 13) BB/BL and 42% (3 out of 7 EChigh), but only one HHC 
responded to this protein. IFN- responses against ML1358 were very low in EC and HHC, 
but significantly present in 60% of BB/BL patients responded to this protein. ML1214 
induced IFN- response in 69% BB/BL, 66% HHC and 60% EC.  
 
 
 
 
 
 
Chapter 3  
 
92 
 
 
 
 
 
 
 
 
 
      M.leprae virulence peptides
   
       
93 
 
 
 
 
 
 
Figure 3: IFN- responses to M. leprae peptides in PBMC from Brazilian and Ethiopian individuals. IFN- 
production (corrected for background values) induced using M. leprae virulence-associated peptides in 6 day 
PBMC cultures of endemic controls from areas of Fortaleza with low (EClow; prevalence <0.2/10,000; A; n = 10) 
and high (EChigh; prevalence > 4/ 10,000; B; n = 10) leprosy endemicity,  Brazilian TT/BT patients (C; n = 10),  
Ethiopian TT/BT patients (D; n = 10) and Ethiopian EC (E; n=7). Median values per test group are indicated by 
horizontal lines. Background values were < 20 pg/ml.  
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T-cell responses to pools of M. leprae virulence-associated peptides in Nepal 
To include data from an Asian endemic population, individuals from Nepal were also 
enrolled in this study. Here, M. leprae virulence-associated peptides were tested in 5 peptide 
pools (V1: p15-p20; V2: p21-p26; V3: p27-p32; V4: p33-p35, p37-p39; V5: p36, p40- p43) 
using PBMC of Nepali leprosy patients and EC. When peptide pools (V3, V4 and V5) 
containing ML2055 p35, p37 and p42, were similarly screened in Nepal, IFN- production 
was observed by PBMC of EC, but hardly by PBMC of leprosy patients before treatment 
(Figure 6).  Interestingly, after completion of MDT, 3 out of 7 of the same BT patients 
showed increased concentrations of IFN- in response to the peptide pools (Figure 6C and 
6F). Although, these findings will need confirmation in much larger numbers of subjects, 
they indicated that these peptides may have relevance for monitoring therapeutic intervention. 
 
 
Figure 4: IFN- and IP-10 responses to M. leprae virulence-associated peptides in 24 h WBA of Ethiopian 
EChigh and EClow. IFN- (A-D) and IP-10 (E, F) production in response to M. leprae peptides ML2055 p35 (A, 
E), ML2055 p42 (B, F), ML2055 p37 (C) and ML1358 p24 (D) in 24 h WBA of healthy individuals from areas 
in Ethiopia with low leprosy endemicity (EClow; prevalence = 0.36/ 10,000; n=17) and high leprosy endemicity 
(EChigh; prevalence =1.5/ 10,000; n=18). Responses are corrected for background values. Median values per test 
group are indicated by horizontal lines. 
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Discussion 
 
Globally, every year more than 200,000 people are newly diagnosed with leprosy at health 
facilities. The majority of these cases are multibacillary leprosy patients (MB) amongst 
including a considerable percentage of grade 2 cases as well as children [1]. The lack of tools 
for early detection of leprosy together with the complications that accompany leprosy 
reactions, represent the most important challenges still to combat in leprosy research [26;27].  
 
 
Figure 5: IFN-  responses to newly identified M. leprae virulence-associated proteins. 
IFN- production (corrected for background values) induced using M. leprae recombinant proteins ML1214, 
ML1358 and ML2055 in 24 h WBA from BB/BL (n=13), HHC (n=12) and EC (n=10) in Ethiopia  
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The availability of genome sequences of several organisms and the advanced application of 
bioinformatics has facilitated the search for potential unique antigens in leprosy research 
[10;29;16;15;6;12]. The current study builds upon our previous studies [13;29;15;17] 
although instead of aiming at hypothetical peptides derived from group VI (M. leprae 
proteins with unknown functions), this study focuses on peptides derived from virulence-
associated M. leprae proteins (group IV.A). Twenty-nine M. leprae virulence-associated 
synthetic peptides were selected through bioinformatics-supported prediction of M. leprae 
unique sequences as potential targets of HLA class I and II and subsequently tested in 
different leprosy endemic areas in three continents for their potential to detect M. leprae 
exposure/ infection. 
 
The peptides that induced T-cell reactivity in leprosy patients or healthy individuals living in 
areas hyperendemic for leprosy (EChigh) but not in NEC were mainly derived from three M. 
leprae-unique proteins: ML2055, ML1358 and ML1214. Consistent with the IFN- 
production observed in response to its single peptides, 7 out of 13 leprosy patients and 3 out 
of 7 Ethiopian EChigh indeed recognized ML2055 recombinant protein as well.  
 
The differences in M. leprae peptide recognition patterns observed in this study between 
PBMC of leprosy patients and EChigh on one hand and EClow on the other hand, imply their 
potential use to estimate the level of M. leprae exposure in individuals as described recently 
for ML1601-derived peptides as well [5]. Interestingly, ML2055 p35 and ML2055 p42 were 
recognized by Brazilian as well as Ethiopian leprosy patients. Moreover, these two peptides 
induced significant levels of IFN- as well as IP-10 in Ethiopian EChigh, suggesting that 
ML2055 p35 and ML2055 p42 can likely detect M. leprae exposure in the context of various 
HLA-alleles. Also, ML2055 has been described to induce strong serological responses in 
lepromatous patients [25]. The low responses to ML2055 in Ethiopian HHC compared to EC 
could have been due to overexposure to mycobacteria, as possible in HHC of MB, may result 
in T cell downregulation as hypothesized recently [20]. 
 
Despite similarities we also observed differences in peptide recognition patterns between 
Brazilian EChigh (ML1358 p20 and ML1358 p24) and Ethiopian EChigh (ML2055 p35 and 
ML2055 p42), reflecting the HLA-polymorphisms in these different areas. Both groups of 
peptides may be useful to indicate M. leprae exposure since neither Brazilian nor Ethiopian 
EClow responded to these peptides. However, longitudinal analysis of T-cell responses 
induced by these peptides in a cohort of EChigh and household contacts of MB patients at 
multiple leprosy endemic sites may resolve whether these peptides can be used to predict 
progression to disease or merely indicate the level of M. leprae exposure. 
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Figure 6: IFN- responses to M. leprae virulence-associated peptide pools in PBMC from Nepali 
individuals. IFN- production (corrected for background values) induced by pools of M. leprae virulence-
associated peptides (10 g/ml each) in 6 day PBMC cultures of newly diagnosed BT (A; n = 7) and BL/LL (B; n 
= 5) patients before MDT and after MDT (C and D) and EC (E; n = 20) from Nepal. IFN- responses of all 
leprosy patients before and after treatment in response to pool V4 (F); Pool V1: p15-p20; V2: p21-p26; V3: 
p27-p32; V4: p33-p35, p37-p39; V5: p36, p40- p43. 
 
The benefits of testing peptide pools in detecting potential epitopes among several candidate 
peptides has been reported previously [16] and combination of peptides, as applied in the 
QuantiFERON
®
-TB test for TB diagnostics [8] can cover a wider number of HLA alleles 
than single peptides [21;18;29;14;15].  
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Therefore, the M. leprae virulence-associated peptides were additionally tested in pools 
containing 4 - 6 peptides in Nepali EC and patient (TT/BT/BL/LL) groups before and after 
treatment. Three peptide pools (V3, V4 and V5), which included the immunogenic peptides 
(ML2055 p35, ML2055 p37 and ML2055 p42) that induced IFN- responses in the Brazilian 
and/ or Ethiopian individuals showed a significant induction of Th1 response in the Nepali 
EC as well (Figure 6E). In contrast, in leprosy patients before MDT hardly any responses 
could be detected (Figure 6A and 6B). However, after MDT some BT patients displayed 
significantly increased IFN- responses against the peptide pools as well as M. leprae (Figure 
6D) thereby reflecting improved cellular immunity against M. leprae. The low or absent IFN-
 responses detected for BL/LL patients were in line with their lepromatous phenotype, 
lacking Th1 cell responses. 
 
Immune responses against M. leprae are a collective/ synergistic effect of various cascades 
involving both innate and adaptive immune cells inducing cytokines and chemokines. IFN- 
has been known to be a potential marker of Th1 response and will remain useful depending 
on the specificity of the stimulus used. Besides IFN-, other cytokines and chemokines such 
as IP-10 may also have potential to distinguish between different level of exposure and /or 
infection for leprosy [5] as well as TB [8].  
 
 
 
 
Figure 7: Individuals with IFN- responses to M. leprae virulence-associated peptides. The total number of 
individuals that induced IFN- production in response to 5 promising M. leprae virulence-associated peptides is 
indicated for each test group: Dutch NEC, combined Brazilian and Ethiopian EChigh, EClow and TT/BT. 
 
In the current study, the induction of IP-10 in Ethiopian EChigh in response to ML2055 p35 
and p42 further confirms the potential of this chemokine as a biomarker to specifically 
indicate M. leprae exposure. Additionally IP-10 can also be used in HIV infected patients 
since, unlike IFN-, IP-10 was not affected by low CD4 counts in TB patients with HIV [2]. 
Currently further studies on the use of IP-10 as a biomarker for leprosy diagnostics in HIV
+
 
individuals are ongoing in our Ethiopian test site. 
 
The main advantage of the use of synthetic peptides compared to proteins is the fact that 
peptides, unlike proteins, less frequently induce T-cell cross reactivity [29;15]. However, due 
to HLA-restriction of peptide recognition by T-cells, single peptides will not be able to cover 
a wide population. In this study, we show that ML2055 p35 and ML2055 p42 as well as 
ML1358 p20 and ML1358 p24 were recognized by patients or EChigh individuals in both 
Brazil and Ethiopia. In addition, these peptides also induced IFN- responses in 30% - 40 % 
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Nepali EC when used in pools. Therefore, as in the case of TB diagnostics, analysis of IFN- 
and other cytokines such as IP-10, after stimulation with combinations of M. leprae 
(virulence-associated) peptides will be helpful in developing new tools for detection of M. 
leprae exposure/ infection.  
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Abstract 
 
Leprosy is not eradicable with currently available diagnostics or interventions as evidenced 
by its stable incidence. Early diagnosis of Mycobacterium leprae infection should therefore 
be emphasized in leprosy-research. It remains challenging to develop tests based on 
immunological biomarkers that distinguish individuals controlling bacterial replication from 
those developing disease.  
To identify biomarkers for field-applicable diagnostics, we determined cytokines/chemokines 
induced by M. leprae proteins in blood of leprosy patients and controls (EC) from high 
leprosy-prevalence areas (Bangladesh, Brazil, Ethiopia) and from South Korea where leprosy 
is not endemic anymore.  
M. leprae-sonicate induced IFN- was similar for all groups, excluding M. leprae/IFN- as a 
diagnostic read-out. By contrast, ML2478 and ML0840 induced high IFN- concentrations in 
Bangladeshi EC, which were completely absent for South Korean controls. Importantly, 
ML2478/IFN- could indicate distinct degrees of M. leprae exposure, and thereby the risk of 
infection and transmission, in different parts of Brazilian and Ethiopian cities.  
Notwithstanding these discriminatory responses, M. leprae proteins did not distinguish 
patients from EC in one leprosy endemic area based on IFN-. Analyses of additional 
cytokines/chemokines showed that M. leprae and ML2478 induced significantly higher 
concentrations of MCP-1, MIP-1 and IL-1 in patients compared to EC, whereas IP-10, like 
IFN-, differed between EC from areas with dissimilar leprosy prevalence.  
This study identifies M. leprae-unique antigens, particularly ML2478, as biomarker tools to 
measure M. leprae exposure using IFN- or IP-10, and also shows that MCP-1, MIP-1 and 
IL-1 can potentially distinguish pathogenic immune responses from those induced during 
asymptomatic exposure to M. leprae.  
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Introduction 
 
Leprosy is a treatable immuno-pathogenic infection caused by Mycobacterium leprae (M. 
leprae). It mainly affects skin and peripheral nerves and ranks as the second most pathogenic 
mycobacterial infectious disease after tuberculosis (TB). Despite a spectacular decrease in 
global prevalence since 1982, leprosy is still considered a public health problem in 32 
countries, mostly from the African, Asian and South American continents that cover 92% of 
all registered patients [1]. Transmission of leprosy is sustained as evidenced by the hundreds 
of thousands of new cases of leprosy that keep being detected globally every year: 228,474 
new cases were detected in 2010 amongst whom 20,472 were children [1]. However, our 
understanding of the mode of M. leprae transmission has been complicated due to the long 
incubation time of leprosy and the lack of tests that detect asymptomatic M. leprae infection, 
a presumed major source of transmission, or predict possible progression of infection to 
clinical disease. Tests used in leprosy diagnostics include a serological test detecting IgM 
antibodies against phenolic glycolipid-1 (PGL-I), an M. leprae specific cell-surface antigen. 
Although it is useful for detection of most multibacillary (MB) leprosy patients, it has limited 
value in identifying paucibacillary (PB) leprosy patients, since the latter typically develop 
cellular rather than humoral immunity [2]. The Mitsuda skin test, on the other hand, evaluates 
the in vivo immune response against M. leprae bacilli (lepromin) and is used for classification 
of leprosy. However, this test is not specific for M. leprae as it can also be mediated by 
lymphocytes responsive to M. tuberculosis and thus does not represent an adequate tool to 
measure M. leprae exposure or latent infection [3;4]. 
 
Since the methods and knowledge available to date have obviously not been sufficient to 
eliminate leprosy, the WHO 2011-2015 global strategy highlighted the need for early 
diagnosis and treatment [5] which will block development of nerve damage, disability and 
deformity, the hallmarks of leprosy. To design new diagnostic tests for early diagnosis, 
various studies have focused on identifying genes encoding M. leprae-unique antigens since 
the availability of the M. leprae genome sequence about one decade ago [6]. Subsequently, 
these (hypothetical) antigens were used as recombinant proteins or synthetic peptides in in 
vitro T cell stimulation assays, mostly assessing IFN-γ production [7-12]. Although it is not 
an immunological correlate of protection, the number of IFN--releasing antigen-specific T 
cells and the amount of total IFN- released remain widely used as surrogate markers for the 
pro-inflammatory immune response against M. leprae and M. tuberculosis [13]. A pitfall of 
the use of IFN-  for leprosy diagnosis in a leprosy endemic area, however, is that not only 
infected individuals but also individuals with adequate immunity against M. leprae produce 
substantial concentrations of IFN- in response to M. leprae antigens. 
 
In a previous study we tested recombinant proteins that had been selected based on their 
unique sequence in M. leprae [10]. Notwithstanding this selection, IFN- production by EC-
derived PBMC or whole blood was observed in response to most of these M. leprae proteins. 
Since these EC were living in areas with pockets of high leprosy prevalence (e.g. Dhaka and 
Karachi) and also responded to M. leprae whole cell sonicate (WCS) in vitro, the observed 
cellular responses towards the M. leprae- unique proteins may still have indicated M. leprae-
specificity. The inclusion in the current study of groups of individuals with distinct degrees of 
exposure to M. leprae allowed us to investigate whether and to what extent the level of 
leprosy endemicity in a certain community influences the cellular immunity to M. leprae-
unique antigens. 
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Since host immunity and immuno-pathogenicity in response to M. leprae involves complex 
interactions between a variety of cells expressing different effector and regulatory molecules, 
assessment of multiple rather than single biomarkers may be more representative of the 
immune status of the host and may identify patterns predisposing to leprosy. Therefore, here 
we have analyzed the concentrations of multiple cytokines, besides IFN-, after 24 hour 
whole blood stimulation with 17 M. leprae antigens in various cohorts from leprosy endemic 
areas in Bangladesh, Brazil and Ethiopia. To our knowledge, this study describes the first 
identification of cellular host biomarkers, other than IFN-, that differ between leprosy 
patients and EC in one endemic area and thus could have value for early diagnosing leprosy 
and monitoring the response to MDT. 
 
Materials and Methods 
 
General procedure of the study. Patients and controls were recruited at: International Center 
for Diarrhoeal Disease Research Bangladesh (ICDDR,B), Dhaka, Bangladesh, Yonsei 
University (YU), Seoul, South Korea, Fiocruz Fortaleza, Brazil and the Armauer Hansen 
Research Institute (AHRI) in Addis Ababa, Ethiopia. To ensure reproducibility of data 
throughout the study at each site, all experiments carried out by the laboratories involved 
were performed according to standard operating procedures (SOP) and each site was 
provided with identical reagents. Multiplex analyses were performed in one laboratory. 
Recombinant proteins. M. leprae candidate genes were amplified by PCR from genomic 
DNA of M. leprae and cloned using the Gateway technology platform (Invitrogen, Carlsbad, 
CA) with pDEST17 expression vector containing an N-terminal histidine tag (Invitrogen) 
[14]. Sequencing was performed on selected clones to confirm identity of all cloned DNA 
fragments. Recombinant proteins were overexpressed in E. coli BL21(DE3) and purified as 
described to remove any traces of endotoxin [14]. Each purified recombinant protein was 
analyzed by 12% SDS-PAGE followed by Coomassie Brilliant Blue staining and Western-
blotting with an anti-His antibody (Invitrogen) to confirm size and purity. Endotoxin contents 
were below 50 EU (endotoxin unit) per mg of recombinant protein as tested using a Limulus 
Amebocyte Lysate (LAL) QCL-1000 assay (Lonza Inc., Basel, Switzerland). Recombinant 
proteins tested in this study (n = 17) included: ML0009, ML0091, ML0755, ML0811, 
ML0840, ML0953, ML0957, ML1601, ML1976, ML2044, ML2055, ML2307, ML2313, 
ML2478, ML2531, ML2532 and ML2666. ML0091, ML0811, ML2044 and ML2055 were 
kindly provided by Dr. M.S. Duthie (Seattle, USA).  
Recombinant proteins were tested to exclude protein non-specific T cell stimulation and cellular 
toxicity in IFN- release assays using PBMC of in vitro PPD-negative, healthy Dutch donors 
recruited at the Blood Bank Sanquin, Leiden, The Netherlands. None of these controls had 
experienced any known prior contact with leprosy or TB patients.  
M. leprae whole cell sonicate (WCS). Irradiated armadillo-derived M. leprae whole cells 
were probe sonicated with a Sanyo sonicator to >95% breakage. This material was provided 
through the NIH/NIAID “Leprosy Research Support” Contract N01 AI-25469 from Colorado 
State University (now available through the Biodefense and Emerging Infections Research 
Resources Repository listed at 
http://www.beiresources.org/TBVTRMResearchMaterials/tabid/1431/Default.aspx). 
Study participants. The following HIV-negative individuals were recruited between August 
2008 and February 2011: in Bangladesh (prevalence = 2.45/ 10,000): 10 TT/BT leprosy 
patients (Leprosy Control Institute & Hospital, Dhaka), 10 healthy household contacts of 
BL/LL patients (HHC), 10 healthy individuals from the same endemic area (EC); in South 
Korea (prevalence <1/10,000): 10 smear positive, pulmonary tuberculosis patients (TB) and 
10 healthy controls (EC); in Brazil: 10 TT/BT leprosy patients, 10 HHC, 10 EC living in an 
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area of Fortaleza with low prevalence (Mereiles; prevalence <0.2/10,000; EClow) and 10 
healthy controls living in an area of Fortaleza with high prevalence (Bom Jardin; prevalence > 
4/ 10,000; EChigh); in Ethiopia 35 healthy controls were tested: 18 EChigh who were derived 
from a sub city of Addis Ababa (Kolfe Keranio) with a prevalence rate of 1.5 per 10,000 (72 
in 465,811), whereas17 EClow were derived from areas with a prevalence rate of 0.36 per 
10,000 (10 in 273,310). Leprosy endemicity for each Ethiopian EC was based on the number 
of new cases and leprosy prevalence in nearby health centers per area.  
Leprosy was diagnosed based on clinical, bacteriological and histological observations and 
classified by a skin biopsy evaluated according to the Ridley and Jopling classification [15] 
by qualified personnel. Patients were treated with chemotherapy for less than 3 months with 
no signs of leprosy reactions. HHC were defined as adults living in the same house as a 
BL/LL index case for at least the preceding six months. TB patients were diagnosed based on 
a positive culture of M. tuberculosis in sputum and were recruited at the outpatient clinic of 
the Pulmonary Division, Severans Hospital, Yonsei University Health System (YUHS) and 
had been on chemotherapy for at least 3 months to enable recovery of T cell function. EC 
were assessed for the absence of signs and symptoms of tuberculosis and leprosy. Staff 
members working in the leprosy centers or TB clinics were excluded as EC. Ethical approval 
of the study protocol was obtained through the appropriate local and national or institutional 
ethics committees, namely in Bangladesh: Ethical Review Committee of ICDDR,B; in South 
Korea: Institutional Review Board for the Protection of Human Subjects at YUHS; in Brazil: 
Brazilian National Council of Ethics in Research (CONEP); in Ethiopia: National Health 
Research Ethical Review committee (NERC). Informed consent was obtained from all 
individuals before venepuncture.  
Whole blood assays (WBA). Within 3 hours of collection, venous heparinized blood (450 μl 
per well) was incubated in 48-well plates at 37°C at 5% CO2, 90% relative humidity with 50 
μl of antigen solution (100 g/ ml). After 24 hour 150 l of supernatants were removed from 
each well and frozen in aliquots at –20C until further analysis. 
Lymphocyte stimulation tests (LST). PBMC were isolated by Ficoll density centrifugation 
from venous, heparinized blood. and plated in triplicate cultures (2 x 10
5
 cells/ well) in 96-
well round bottom plates (Costar Corporation, Cambridge, Mass.) in 200 l/well of serum 
free Adoptive Immunotherapy medium (AIM-V, Invitrogen, Carlsbad, CA). Recombinant 
protein, M. leprae WCS or PPD (purified protein derivative of M. tuberculosis, Statens 
Serum Institut, Copenhagen, Denmark) were added at final concentrations of 10 g/ ml. As a 
positive control 1 g/ ml PHA (phytoheamagglutinin; Remel, Oxoid, Haarlem, The 
Netherlands) was used. After 6 days of culture at 37C at 5% CO2, 90% relative humidity, 75 
μl of supernatant were removed from each well, triplicates were pooled and frozen in aliquots 
at –20C until further analysis. 
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IFN- ELISA. IFN- concentrations were determined by ELISA (U-CyTech, Utrecht, The 
Netherlands) as described [16]. The cut-off value to define positive responses was set 
beforehand at 100 pg/ml. The assay sensitivity level was 40 pg/ml. Values for unstimulated 
cell cultures were typically <20 pg/ml. Lyophilized supernatant of PHA cultures of PBMC 
from an anonymous buffycoat (Sanquin, Leiden, The Netherlands) was provided to all 
laboratories as a reference positive control supernatant. 
Serum Antibody ELISA. Recombinant protein ML2028 (M. leprae Ag85B), a synthetic 
analog of the M. leprae-specific phenolic glycolipid I (PGL-I; ND-O-BSA) and M. leprae 
lipoarabinomannan (LepLAM) were coated onto high-affinity polystyrene Immulon IV 96-
well ELISA plates (Dynex Technologies, Chantilly, VA) using 50 ng per well in 100 l of 
0.1M sodium carbonate buffer, pH 9.0 at 4
o
C overnight.  Unbound antigen was washed away 
using PBS, pH 7.4, containing 1% BSA and 0.05% Tween 80 (blocking buffer) six times.  A 
1:200 dilution of serum diluted in 100 l blocking buffer was added to the wells and 
incubated for 2 h at room temperature. After incubating with the primary antibody, the wells 
were washed six times with PBS with 0.05% Tween 80 (wash buffer), followed by the 
addition of 100 l of a 1:5,000 dilution of the secondary anti-human polyvalent antibody 
(Sigma) for 2 h. Following washing the wells with PBS six times, 100 l of p-
nitrophenylphosphate substrate (Kirkegaard and Perry Labs, Gaithersburg, MD) was added. 
The absorbance at 405 nm was read using a VersaMax Pro plate reader (Molecular Devices, 
Sunnyvale, CA) at 15 minutes. The cutoff for positivity was considered to be three times the 
background O.D. average for the non-endemic control sera (n = 23) determined by binding 
BSA with a 1:200 serum dilution (cutoff 0.411).  
Multi-cytokine and -chemokine assay. The concentrations of 19 analytes [IL-1, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IFN-, IP-10 (CXCL10), G-CSF, 
GM-CSF, MCP-1 (CCL2), MIG (CXCL9), MIP-1 (CCL4) and TNF] in supernatants from 
24 hour WBA were measured using the Bio-Plex suspension array system powered by 
Luminex xMap multiplex technology (Bio-Rad Laboratories, Veenendaal, The Netherlands) 
and analyzed using the Bio-Plex Manager
TM
 software 6.0 (Bio-Rad laboratories, Veenendaal, 
The Netherlands) [17]. After pre-wetting the filter with assay-solution, the magnetic beads 
were washed twice with washing-solution using 96-well multiscreen filter plates (Millipore), 
an Aurum
TM 
vacuum manifold and a vacuum pump (Bio-Rad Laboratories, Veenendaal, The 
Netherlands). Supernatant samples (50 μl) were added to the plates and the plates were 
incubated for 45 minutes at room temperature in the dark at 300 rpm on a plate shaker. After 
three washing steps, 12.5 μl detection antibody cocktail was added per well and plates were 
incubated at room temperature in the dark for 30 minutes on a plate shaker. After three 
washes, 25 μl strepavidin-PE solution was added per well and incubated for 10 minutes. After 
three washes, 80 μl of assay buffer was added to each well and the plates were placed in the 
Bio-Plex System. From each well, a minimum of 50 analyte-specific beads were analyzed for 
fluorescence. A curve fit was applied to each standard curve according to the manufacturer's 
manual. Sample concentrations were interpolated from these standard curves. Analyte 
concentrations outside the upper- or lower limits of quantification were assigned the values of 
the limits of quantification of the cytokine or chemokine. 
Statistical analysis. Differences in cytokine concentrations between test groups were 
analysed with the two-tailed Mann-Whitney U test for non-parametric distribution using 
GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego California USA; 
www.graphpad.com). P-values were corrected for multiple comparisons. The statistical 
significance level used was p<0.05.  
 
Results 
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IFN- responses to M. leprae antigens in WBA in Bangladesh and South Korea  
In a previous study IFN- production by T cells from EC was observed in response to M. 
leprae-unique proteins [10]. However, since these EC were derived from areas with high 
leprosy prevalence and also responded to M. leprae WCS in vitro, the observed cellular 
responses towards the M. leprae-unique proteins could still indicate M. leprae-specificity. To 
investigate this, 17 M. leprae antigens were tested in an area highly endemic for leprosy 
(Dhaka, Bangladesh) and an area with low prevalence (South Korea) by analysis of IFN- 
production after 24 hour incubation of whole blood cultures stimulated with recombinant 
proteins in 10 TT/BT leprosy patients, 10 EC and 10 HHC from Bangladesh and the same 
numbers of EC and TB patients from South Korea. To ensure reproducibility, exactly the 
same batches of control antigens, recombinant M. leprae proteins and ELISA kits were 
provided to both sites. ML0755, ML0091, ML0811, ML0953, ML2044, ML2055, ML2307, 
ML2313 and ML2666 were only tested in the Bangladeshi groups, in which they showed low 
responses, in tuberculoid patients and/ or in HHC (Supplemental Figure S1A), and were 
therefore not investigated in other cohorts. 
 
IFN- responses for the negative and positive controls (medium and PHA) were similar in 
individuals from both areas indicating that the blood samples used for all five groups were 
equally able to produce IFN- (Figure 1). M. leprae induced some variability in IFN- 
between the two EC groups. Nevertheless median values were comparable for all groups, 
thereby excluding the use of IFN- responses to M. leprae WCS as a discriminatory read-out. 
Importantly, significant differences in IFN- concentrations between exposed individuals 
versus individuals living in a population where they are less likely to be exposed were 
induced by ML0840 and ML2478 (both p<0.0001): all Bangladeshi EC and none of the EC 
from South Korea recognized these proteins (Figure 1). ML1601 was significantly better 
recognized in the EC group in Bangladesh (p=0.0005), whereas 9 out of 10 TB patients from 
South Korea also recognized this protein which has an orthologue in M. avium 
paratuberculosis [18]. ML0009, ML0957, ML1976 and ML2531 did not show significant 
differences, although ML0009 (p=0.0686) and ML2531 (p=0.0342) showed a tendency 
towards higher responses in EC from Bangladesh (Supplemental Figure S1B).  
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Figure 1: IFN- responses in WBA from individuals in Bangladesh and South Korea. IFN- production in 
responses to control stimuli (medium, PHA and M. leprae WCS) or to recombinant proteins (ML0840, ML1601, 
and ML2478) in 24h WBA of leprosy patients (TT/BT; n=10), HHC (n=10), and EC 9n=10) from Bangladesh 
(prevalence =.45/10,000), or healthy controls (Ec; n=10) and tuberculosis patients (TB; n=10) from Soth Korea 
(prevalence <1/10,000). For each group, the number of IFN- responders (>100pg/ml) versus thetotal number of 
individuals in the group is indicated below the x-axis. Background values were <50pg/ml. Medium values for 
each group are indicated by horizontal lines. Significant differences between test groups are indicated by p 
values. 
 
Thus, IFN- responses in 24 hour WBA using M. leprae-specific recombinant proteins 
ML2478 and ML0840, but not M. leprae WCS, correlate with differences in M. leprae 
exposure likelihood as estimated from EC living in high versus low leprosy prevalence areas.  
 
Next, sera from these individuals were analyzed for the presence of antibodies (Ab) to the M. 
leprae homolog of Ag85B (ML2028), a synthetic analog of the M. leprae-specific PGL-I 
(ND-O-BSA) and M. leprae lipoarabinomannan (LepLAM) [19]. In contrast to the 
discriminatory IFN- patterns induced in 24 hour WBA of EC (South Korea) vs. EC 
(Bangladesh) with ML2478 and ML0840, the Ab concentrations to the three M. leprae 
antigens tested could not differentiate between these two EC groups (Supplemental Figure 
S2). 
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IFN- responses to M. leprae antigens in EChigh and EClow from the same city 
In order to expand these findings using healthy controls from an area with low numbers of 
new leprosy cases and a group from an area with much higher leprosy endemicity (EClow vs. 
EChigh), we investigated reactivity to the above M. leprae antigens in EC in Fortaleza (Brazil), 
where pockets in the city have a prevalence of less than 0.2 per 10,000 (EClow) and another 
area with a leprosy prevalence of more than 4 per 10,000 (EChigh). In addition, HHC and 
TT/BT patients from Fortaleza were included (Figure 2). Since comparison of WBA and 
lymphocyte stimulation tests (LST) showed similar IFN- responses (Supplemental Figure 
S3), 6 day LST with PBMC were used as a test format in this part of the study to allow 
testing of more antigens. 
 
Whereas PBMC of all groups were equally capable of producing IFN- after 6 days as 
indicated by the response to PHA (Figure 2A), ML2478 (p=0.0029) again showed 
significantly higher induction of IFN- responses in PBMC from TT/BT patients, HHC, and 
importantly, from EChigh as compared to PBMC from the EClow group from the same city. 
Thus, ML2478 (p=0.0021), but not M. leprae WCS (p=0.104), is useful to estimate 
differences in M. leprae exposure between EC defined by whether they reside in high versus 
low prevalence areas, even within the same city. 
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Figure 2. IFN- responses to M. leprae Ags in PBMC from EChigh and EClow in Brazil. IFN-g production 
(corrected for background values) induced using PHA(A), M. leprae (B), or ML2478 recombinant protein (C) in 
6-d cultures of PBMC from healthy individuals from an area of Fortaleza, Brazil, with low (EClow; 
prevalence ,0.2/10,000; n = 10) or high (EChigh; prevalence .4/10,000; n = 10) leprosy prevalence, HHC of 
multibacillary leprosy patients, and TT/BT patients. Median values for each group are indicatedby horizontal 
lines. Background values were 20 pg/ml. 
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IFN- responses to M. leprae antigens in WBA in EChigh and EClow in Ethiopia 
Based on the data obtained in Bangladesh, South Korea and Brazil, we next included an 
African setting by studying the response induced by selected M. leprae antigens in EC from 
Ethiopia. Eighteen EChigh were derived from a sub city of Addis Ababa (Kolfe Keranio) with 
a prevalence rate of 1.5 per 10,000, whereas 17 EClow were derived from areas in Addis 
Ababa with a prevalence rate of 0.36 per 10,000. All individuals responded equally well to 
the positive control stimulus PHA (Figure 3A) but responses to M. leprae WCS differed 
between the two EC groups (Figure 3B). Importantly, ML2478 again induced much higher 
concentrations (p=0.0001) of IFN- in the WBA of Ethiopian EChigh
 
compared to Ethiopian 
EClow (Figure 3C; p=0.0001). In contrast to responses observed for EC from Bangladesh, 
ML0840 induced low responses in all Ethiopian EC (data not shown) and was not 
discriminatory with respect to M. leprae exposure. Thus, ML2478 combined with IFN- as a 
read-out, can also be used in 24h WBA to estimate differences in M. leprae exposure 
between EC in areas with different leprosy prevalence even when located in one city. 
 
Multiplex analysis of cytokines and chemokines in response to M. leprae antigens in 
WBA in Bangladesh, South Korea and Ethiopia 
In our previous study [10] only IFN- was determined after stimulation of whole blood or 
PBMC. Recent studies on TB show that other (combinations of) cytokines are likely to be 
suitable for application in diagnostic assays [13;20;21]. Since IFN- production induced by 
recombinant proteins was found in the current study not to be significantly different between 
the three different groups in Bangladesh (TT/BT, HHC and EC), IFN- cannot be used as a 
single biomarker to discriminate between leprosy patients (TT/BT) and those merely exposed 
to M. leprae (EC). Therefore, 18 additional cytokines and chemokines were tested using 
aliquots of WBA-supernatants (described in Figure 1). In striking contrast to IFN-γ, the 
concentrations of IL-1, macrophage inflammatory protein-1 (MIP-1 or CCL4) and 
monocyte chemotactic protein-1 (MCP-1 or CCL2) were significantly enhanced in TT/BT 
patients after stimulation with M. leprae WCS compared to Bangladeshi EC (p= 0.0006, p= 
0.0007 and p= 0.0021 respectively; Figure 4A-C).  
 
When cumulative values were considered (Figure 4D) even higher degrees of significance 
were observed between EC and TT/BT groups in Bangladesh (p<0.0001), as well as between 
EC and TB groups in South Korea (p=0.0032). Thus, in contrast to IFN-, the levels of MCP-
1, MIP-1 and IL-1 induced in leprosy patients as well as TB patients are increased 
compared to EC from the same areas, potentially reflecting immune responses associated 
with mycobacterial infection.To further analyze the potential of MCP-1, MIP-1 and IL-1 
as biomarker tools for leprosy diagnostics, ROC (receiver operating characteristics) were 
analyzed (Table II), showing AUC (areas under the curve) ranging from 0.89 (IL-1) to 0.94 
(MIP-1) thereby indicating good to excellent discrimination between the TT/BT and EC 
groups in Bangladesh. Combining the three biomarkers enhanced this diagnostic ability even 
more as evident from the AUC value (0.99).  
 
It is of interest that IL-1 concentrations in HHC were very heterogeneous, resulting in two 
subgroups. This could indicate that some individuals in this group may induce similar 
immune responses as TT/BT patients. Longitudinal cytokine analysis of these HHC may 
reveal whether such immune responses could correlate with progression to disease. 
Interestingly, TB patients from South Korea produced significantly higher concentrations of 
MCP-1 than EC (p= 0.0001) arguing for a specific role of MCP-1 in mycobacterial diseases.  
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Figure 3. IFN-g responses to M. leprae proteins in WBA from EChigh and EClow in Ethiopia. IFN-g production 
(corrected for medium values) in response to PHA(A), M. leprae WCS(B), or recombinant protein ML2478 (C) 
in 24-h WBA of healthy individuals from areas in Addis Ababa, Ethiopia, with low (EClow; prevalence = 
0.36/10,000; n = 17) and high (EChigh; prevalence = 1.5/10,000; n = 18) leprosy endemicity. Median values per 
test group are indicated by horizontal lines. For each group, the number of IFN-g responders versus the total 
number of individuals in the group is indicated below the x-axis.  
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Despite some interindividual differences, the data revealed that the overall concentrations for 
most cytokines (IL-10, IL-17, IL-2, IL-6, IL-8, G-CSF, GM-CSF, IP-10, MIG and TNF) 
showed no significant differences between TT/BT, HHC and EC from Bangladesh (Figure 4 
and data not shown). In all test groups the remaining cytokines IL-4, IL-5, IL-7, IL-12p70 
and IL-13 were hardly detected (median <50 pg/ml; data not shown). Thus, these multiplex 
analyses demonstrate that cytokines/ chemokines other than IFN-, namely IL-1, MIP-1 
and MCP-1, have the potential to distinguish pathogenic immune responses as present in 
patients of mycobacterial diseases from those induced during asymptomatic exposure to M. 
leprae. 
 
The multiplex cytokine analysis of WBA of Ethiopian EChigh
 
and EClow (Figure 5) implied a 
comparison between two test groups of healthy individuals and thus does not necessarily 
reveal biomarkers related to pathogenic immune responses. IFN- induced protein 10 (IP-10 
or CXCL10) has been shown to be a useful biomarker for diagnosis of M. tuberculosis 
infection [21]. In Figure 5 it is shown that, in line with the differences in IP-10 observed 
between EC from Bangladesh and South Korea (Figure 4), IP-10 responses correlated with 
prevalence-estimated M. leprae exposure density, as EChigh
 
produced substantially higher 
concentrations of IP-10 than EClow (p <0.0001).  
 
Concentrations of MCP-1 were slightly increased in the EChigh group but not as significantly 
as IP-10. In contrast, IL-1 and MIP-1 that were increased in TT/BT patients in Bangladesh 
compared to EC from that area, did not show significant differences between the two 
Ethiopian EC groups. This is similar to the finding that these cytokines did not differ 
significantly between EC from Bangladesh and from South Korea either, whereas IP-10 
concentrations could distinguish between these groups (Figure 4). None of the other 
cytokines tested displayed concentrations that differed sufficiently between patients and EC 
(data not shown).  
 
Stimulation with the M. leprae-unique protein ML2478 instead induced a cytokine pattern 
similar to that of M. leprae WCS stimulated whole blood cultures for IP-10 and to a slightly 
lesser extent for MCP-1 (Figure 5E and 5F) indicating that, in addition to IFN-, IP-10 can 
also be used as a biomarker tool to measure M. leprae exposure. No MCP-1, MIP-1 and IL-
1 was induced by ML2478 in NEC (Supplemental Figure S3B). 
 
Determination of IFN-/ IL-10 ratios in WBA 
Since both pro- and anti-inflammatory cytokines play a role in protection from and 
pathogenesis of mycobacterial diseases, their balance may control or predict an eventual 
clinical outcome. In this respect the IFN-/ IL-10 ratio has been described to significantly 
correlate with TB cure and severity [22-25]. Determination of the IFN-/ IL-10 ratio for 
individuals from Bangladesh showed a higher IFN-/ IL-10 ratio for EC than for HHC and 
TT/BT, a difference that was not observed by separate analysis of these two cytokines 
(Figure 6). Similarly, TB patients in South Korea also had a decreased IFN-/ IL-10 ratio 
compared to EC from that area. This corroborates the value of this ratio as an indicator for 
pathogenic responses to mycobacteria.  
 
Discussion 
The stagnant decline in new leprosy cases demonstrates that transmission of M. leprae is 
persistent and not affected sufficiently by current control measures [1;26;27]. In part this is 
Chapter 3  
 
116 
 
the consequence of the present practice of leprosy diagnosis which is mainly based on 
recognition of clinical symptoms, requiring special, frequently not available, expertise.  
 
 
Figure 4. Multiplex cytokine analyses inWBA from individuals in Bangladesh and South Korea. Concentrations 
(all corrected for background values) of IL-b (A); MIP-1b (B); MCP-1(C); and IL-b,MIP-1b, and MCP-1 
combined(D); or IP-10 (E) induced by stimulation with M. leprae WCSin 24-hWBA ofleprosy patients (TT/BT; 
n =10), HHC(n = 10), and EC (n = 10) from Bangladesh, or healthy controls (EC; n = 10) 
andtuberculosispatients (TB; n = 10) from SouthKorea. Medianvaluesper testgroup are indicatedbyhorizontal 
lines. Background values varied from50 pg/ml for IFN-g to 2000 pg/ ml for MIP-1b.  
Major obstacles in leprosy diagnostics are the lack of good surrogate markers for subclinical 
or latent M. leprae infection, as well as the long incubation time that hinder early detection of 
leprosy and its modes of transmission. Thus, to overcome inadequate leprosy diagnostics, the 
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development of rapid tests that can be applied in non-expert settings and allow identification 
of leprosy at early (subclinical) stages is high on the research agenda.  
In the present study we show that IFN- production induced by M. leprae-unique proteins can 
identify individuals highly exposed to M. leprae and therefore more at risk of developing 
disease and/ or transmitting the bacterium. Since an M. leprae resistant phenotype is 
generally believed to be associated with the emergence of a protective Th1-based response 
characterized by consistent secretion of IFN- in association with moderate amounts of pro-
inflammatory cytokines, we and others have previously used IFN- release assays (IGRAs) as 
a readout of cell-mediated immune responses (CMI) to investigate which M. leprae antigens 
can be useful for the diagnosis of leprosy [9;11;12]. This was partly based on the initial 
promising reports on QuantiFERON
®
-TB, an IGRAs for diagnosis of TB [28]. However, a 
recent meta-analysis showed that neither IGRA nor the tuberculin skin tests have high 
accuracy for the prediction of incident active TB in endemic areas [29]. Our study shows that 
this is also the case for leprosy since the positive IFN- responses measured in WBA after 
stimulation with M. leprae-unique antigens depended on the level of endemicity in the 
investigated area and was not specific for disease. Importantly, however, here we have 
identified M. leprae-unique proteins, in particular ML2478, which can be used with IFN- as 
a read-out in the context of various genetic backgrounds (African, Asian, and South 
American) to point out distinct degrees of M. leprae exposure even if these occur in 
individuals residing in distinct areas of the same city. Therefore, such M. leprae proteins, 
combined with IGRAs, can be relevant as new tools for predicting the magnitude of M. 
leprae transmission in a given population and for identification of individuals who are at risk 
of acquiring M. leprae infection and possibly developing leprosy. Besides these data for 
ML2478, which is a hypothetical unknown protein lacking transmembrane regions and 
weakly similar to a probable metallopeptidase from Streptomyces avermitilis (33% identity), 
similar data, were recently found by us using M. leprae-specific peptides instead of proteins, 
further support our findings (Martins et al. submitted; [18]. The M. leprae-specific IFN- 
response detected in this study in EC in areas hyperendemic for leprosy are consistent with 
earlier findings on the presence of M. leprae in nasal swaps of EC in Indonesia [30]. Thus, 
this indicates that a vast proportion of leprosy patients probably acquire M. leprae infection 
from unidentified infected individuals or subclinical leprosy cases in the community and not 
necessarily from diagnosed leprosy patients. 
The IP-10 production measured in WBA in this study displayed a pattern similar to that of 
IFN-, although the overall IP-10 concentrations were higher. Thus, our finding that IP-10 
can differentiate between M. leprae exposure levels in two Ethiopian EC groups, corroborates 
the potential of this cytokine as a biomarker for M. tuberculosis exposure/ infection [31]. In 
this respect it is noteworthy that IP-10 has also been shown to be a promising biomarker for 
TB in HIV
+
 individuals, as the use of IP-10 as a read-out, with or without IFN-, was reported 
to be much less influenced by CD4 cell count than the QuantiFERON
®
-TB Gold In-Tube 
[32]. Although IFN- is directly involved in inducing IP-10 production, IP-10 is produced 
primarily by monocytes and might be induced by CD4 T-cell- and IFN--independent 
pathways. Alternatively, the higher concentrations of IP-10 produced may render this 
biomarker less sensitive to the effect of immune suppression. 
 
The outcome of the immune response to M. leprae is determined by chemokines and 
cytokines that act as molecular signals for communication between cells of the immune 
system which renders them useful biomarkers predicting either protection or progression to 
disease. In this study, we identified secreted chemokines/ cytokines (IL-1, MIP-1 and 
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MCP-1) that, in contrast to IFN-, could discriminate in 24h WBA between patients (leprosy 
and TB) and healthy EC in the same endemic areas, thereby possibly reflecting differences 
between M. leprae exposure and pathogenic immunity against M. leprae.  
 
 
Figure 5. Multiplex cytokine analyses in whole-blood cultures from EC in Ethiopia. Concentrations (all 
corrected for background values) of IL-b (A), MIP-1b (B), MCP-1(C, E), IP-10(D, F)induced by stimulation 
with M. leprae WCS(A–D), or ML2478(E, F) in 24-h WBA of leprosy patients (TT/BT; n = 10), HHC(n = 10), 
and EC(n = 10) from Bangladesh, or healthy controls (EC; n = 10) and tuberculosis patients (TB; n = 10) from 
South Korea. Median values per test group are indicated by horizontal lines. Background values varied from ,50 
pg/ml for IFN-g to ,2000 pg/ml for MIP-1b.  
 
The chemokine that was very significantly increased in TT/BT leprosy patients compared to 
healthy EC from Bangladesh was MCP-1 (or CCL2). This molecule recruits monocytes, 
memory T cells and dendritic cells to sites of tissue injury and infection [33] and it has been 
suggested to play a role in maintaining the integrity of the granuloma in asymptomatic 
individuals with latent infection in high TB burden settings has been suggested [34]. For TB 
patients MCP-1 production by M. tuberculosis-stimulated PBMC was associated with TB 
disease severity [35]. On the other hand, for lepromatous leprosy (LL) patients MCP-1 was 
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found to be lower than for TB patients [36]. Similar data for tuberculoid leprosy patients have 
not been reported, yet the data in this study indicate that TT/BT patients are more inclined 
towards a phenotype resembling that of TB patients with elevated MCP-1 production. 
The second potential immunological biomarker we identified, MIP-1 (or CCL4), is a 
chemo-attractant for monocytes and can inhibit T cell activation by interfering with TCR 
signaling [37]. The exact role of MIP-1 in leprosy pathogenesis is still not clear. 
 
 
 
Figure 6. IFN-g/IL-10 ratio in M.leprae-stimulated WBA. Ratios of IFN-gconcentrations (corrected for 
background values) with respect to IL-10 concentrations (corrected for background values) induced by 
stimulation with M.lepraeWCS in 24-h WBA in individuals from Bangladesh (A) and South Korea (B).  
 
Thirdly, our data showed increased IL-1 concentrations in WBA of TT/BT compared to 
EC in Bangladesh. IL-1 is produced by activated macrophages, plays a major role in host 
resistance to M. tuberculosis [38] and is involved in the TLR2/1-induced vitamin D 
antimicrobial pathway leading to induction of the antimicrobial peptide defensin 4A. 
Recently, reduced expression of the IL1B gene was reported for lesions of LL patients who 
typically lack good cellular responses [39]. In view of our finding that TT/BT patients 
produce more IL-1 in response to M. leprae, this cytokine could be useful to indicate 
leprosy subtypes as well. Thus, although we can not absolutely explain the observed 
difference in IL-1, MIP-1 and MCP-1 secretion in the WBA in the various test groups we 
cannot rule out any effect of M. leprae-specific recall responses that may affect these innate 
responses [40]. 
 
In leprosy the quality and quantity of the innate and adaptive immune response, determine 
the outcome of infection: whereas the pro-inflammatory cytokine IFN- provides protection 
against mycobacteria, the anti-inflammatory cytokine IL-10 has been shown to be 
associated with dampening Th1 cells’ responses towards mycobacteria [41;42]. Besides 
measuring single cytokines, the ratios of such cytokines can provide important information 
since both pro- and anti-inflammatory cytokines play a role in protection from and 
pathogenesis of mycobacterial diseases and their balance may control or predict the 
eventual clinical outcome. The IFN-/ IL-10 ratio has been described to significantly 
correlate with TB cure [22-25]. Also, the IFN-/ IL-10 ratio positively correlated with TST 
induration suggesting that the ratio between PPD induced IFN- and IL-10 in peripheral 
blood may be important in controlling TST reactivity [43]. In this study IFN-/ IL-10 ratios 
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were higher for EC compared to either leprosy or TB patients, despite the lack of significant 
differences if only IFN- was measured. Thus, changes in the IFN-/ IL-10 ratio, especially 
when measured longitudinally in one individual, may provide information about potential 
disease development or response to treatment.  
 
Since the HIV burden in most leprosy endemic areas is quite severe, it should be analyzed 
whether IL-1, MIP-1, MCP-1, IFN- and IP-10 as well as the ratios of Th1/Th2 cytokines 
can be applied as biomarkers in immuno-compromised individuals. Therefore, we are 
currently investigating such potential biomarkers, in combination with M. leprae specific 
antigens, in HIV
+
 individuals as well as HIV
+
 leprosy patients.  
 
WBA using M. leprae antigens thus induce a ‘fingerprint’ of (the ratio of) Th1 or Th2 
cytokines that may, combined with detection of anti-PGL-I antibodies, be used to specify 
disease type in the leprosy spectrum. Recently, we reported the development of a robust, 
user-friendly lateral flow assay based on up-converting phosphor technology (UCP-LF) that 
allows simultaneous detection of cellular and humoral immune responses in one sample 
[44;45]. Using ML2478-stimulated WBA, this UCP-LF assay can now be used in poorly 
equipped laboratories to estimate levels of M. leprae exposure, by measuring both Th1 
(IFN-/ IP-10) and Th2 (IL-10) as well as anti-PGL-I IgM antibodies. Currently, the 
development of this rapid lateral flow assay for detection of IL-1, MIP-1 and MCP-1 is in 
progress. 
 
Since the majority of those exposed to M. leprae develop a protective immune response 
against the bacterium, large-scale, longitudinal follow-up studies, allowing intra-individual 
comparison of immune profiles in healthy controls from leprosy-endemic areas worldwide, 
will be essential to analyze whether the biomarkers identified here can be applied as tools 
for prediction of pathogenic immune responses to M. leprae. 
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Supplementary files 
Supplementary Figure S1A: IFN-γ responses in WBA from individuals in Bangladesh. IFN-γ production in 
response to recombinant proteins (ML0091, ML0811, ML2044 and ML2055) in 24 hour WBA of leprosy 
patients (TT/BT; n = 10), healthy household contacts (HHC; n =10) and endemic controls (EC; n=10) from 
Bangladesh. Background values were <50 pg/ ml. Median values for each group are indicated by horizontal 
lines.  
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Supplementary Figure S1B: IFN-γ responses in WBA from individuals in Bangladesh and South Korea. 
IFN-γ production in response to recombinant proteins (ML0009, ML0957, ML1976 and ML2531) in 24 hour 
WBA of leprosy patients (TT/BT; n = 10), healthy household contacts (HHC; n =10) and endemic controls (EC; 
n=10) from Bangladesh (prevalence = 2.45/ 10,000) or healthy controls (EC; n=10) and tuberculosis patients 
(TB; n=10) from South Korea (prevalence <1/10,000). For each group the number of IFN-γ responders (>100 
pg/ml) versus the total number of individuals in the group is indicated below the x-axis. Background values 
were <50 pg/ ml. Median values for each group are indicated by horizontal lines.  
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Supplementary Figure S2: Antibody responses in sera from healthy individuals in Bangladesh and South 
Korea. Reactivity of sera from endemic controls (EC; n=10) from Bangladesh and healthy controls (EC; n=10) 
from South Korea toward synthetic PGL-I antigen (ND-O-BSA; A), native M. leprae LAM (LepLAM; B) and 
recombinant protein ML2028 (Ag85B; C) by ELISA. Optical density readings were performed using a 1:200 
serum dilution. Median values for each group are indicated by horizontal lines.  
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Supplementary Figure S3: Comparison of cytokine production in 24h WBA. A: IFN-γ production 
(corrected for background levels) using 24 hour WBA versus 6 days LST in response to ML2478 recombinant 
protein (10 μg/ml) for 4 Brazilian leprosy patients () and two Dutch non endemic controls (▼).  B: Cytokine/ 
chemokine production (corrected for background levels) measured in ELISAs specific for IFN-γ, MCP-1, IL-1β 
and MIP-1β in response to ML2478 recombinant protein (10 μg/ml) in 24 hour WBA of one leprosy patient 
living in The Netherlands and Dutch non endemic controls (n= 3).   
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Abstract 
 
Background: Acute inflammatory reactions are a frequently occurring, tissue destructing 
phenomenon in infectious- as well as autoimmune diseases, providing clinical challenges for 
early diagnosis. In leprosy, an infectious disease initiated by Mycobacterium leprae (M. 
leprae), these reactions represent the major cause of permanent neuropathy. However, 
laboratory tests for early diagnosis of reactional episodes which would significantly 
contribute to prevention of tissue damage are not yet available. 
Although classical diagnostics involve a variety of tests, current research utilizes limited 
approaches for biomarker identification. In this study, we therefore studied leprosy as a 
model to identify biomarkers specific for inflammatory reactional episodes.  
Methods:  To identify host biomarker profiles associated with early onset of type 1 leprosy 
reactions, prospective cohorts including leprosy patients with and without reactions were 
recruited in Bangladesh, Brazil, Ethiopia and Nepal. The presence of multiple cyto-/ 
chemokines induced by M. leprae antigen stimulation of peripheral blood mononuclear cells 
as well as the levels of antibodies directed against M. leprae-specific antigens in sera, were 
measured longitudinally in patients.  
Results: At all sites, longitudinal analyses showed that IFN--, IP-10-, IL-17- and VEGF-
production by M. leprae (antigen)-stimulated PBMC peaked at diagnosis of type 1 reactions, 
compared to when reactions were absent. In contrast, IL-10 production decreased during type 
1 reaction while increasing after treatment. Of further importance for rapid diagnosis, 
circulating IP-10 in sera was significantly increased during type 1 reactions. On the other 
hand, humoral immunity, characterized by M. leprae-specific antibody detection, did not 
identify onset of type 1 reactions, but allowed treatment monitoring instead.   
Conclusions: This study identifies immune-profiles as promising host biomarkers for 
detecting intra-individual changes during acute inflammation in leprosy, also providing an 
approach for other chronic (infectious) diseases to help early diagnose these episodes and 
contribute to timely treatment and prevention of tissue damage.  
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Background 
 
Leprosy is a chronic, immunoregulatory infectious disease caused by Mycobacterium leprae 
that particularly affects the skin and peripheral nerves and often results in severe, life-long 
disabilities and deformities [1;2]. The number of new cases has plateaued at 220,000–
250,000 annually, but many linger undetected [3;4]. Leprosy remains endemic in Africa, 
South America and Asia and with increasing migration, new cases are detected in developed 
countries, where initial misdiagnosis is likely to occur [5-7].  
 
The inter-individual variability in clinical manifestations of leprosy closely parallels the 
ability of the host to mount an effective immune response to M. leprae. This is depicted by an 
immunological and clinical spectrum in those who progress to disease, ranging between two 
completely different poles i.e. tuberculoid (TT) and lepromatous (LL) leprosy [8]. Host 
resistance to M. leprae is associated with the emergence of a protective Thelper-1 (Th1)-
based response characterized by the secretion of the innate and adaptive cytokines IL-12p70, 
IFN-, lymphotoxin-/, and (moderate levels of) other pro-inflammatory cytokines such as 
TNF-. LL patients secrete predominantly anti-inflammatory mediators such as IL-10, 
accompanied by the absence of Th1-associated cytokines in response to M. leprae but 
characterized by high anti-M.leprae antibody titers. Conversely, TT patients produce 
exacerbated levels of pro-inflammatory cytokines, including those produced by Th17 rather 
than Th1, and frequently driven by strong innate immune activation resulting in the release of 
IL-1β and/or IL-6, TGF-β and IL-23 [9;10]. 
 
Although leprosy can be treated effectively with multidrug therapy (MDT), it is complicated 
by persisters [11] as well as acute inflammatory episodes called leprosy reactions. These 
immunological complications, occurring before, during and after MDT treatment in 30-50% 
of the patients, represent the major cause of leprosy-related neurological damage [12;13]. 
Two types of reactions are recognized: type 1 or reversal reactions (RRs) and type 2 or 
erythema nodosum leprosum (ENL). RRs are considered a delayed hypersensitivity reaction 
with characteristic infiltrations of skin and nerve lesions by CD4
+
 T-cells producing IFN- 
and TNF-α [14-16]. Up to 30% of leprosy patients are affected by RRs, which most 
commonly occur in borderline forms of leprosy (borderline-tuberculoid (BT), borderline-
borderline (BB), borderline-lepromatous (BL)) in which concomitant immunological 
fluctuations can generate significant neuropathology [17]. Prompt diagnosis and anti-
reactional treatment contributes to recovery significantly thus reducing risks for permanent 
tissue damage [18;19]. Unfortunately, reactions are frequently misdiagnosed due to decreased 
expertise within integrated health services [17]. Therefore, reliable tests for early diagnosis of 
RR could make huge differences in clinical outcomes. A major obstacle to developing such 
tests is the lack of dependable biomarkers for reactions across endemic populations. 
 
For the complex host immuno-pathogenicity of leprosy [2;14], assessment of multiple rather 
than single biomarkers is more informative of the hosts’ immune status. Therefore, we 
aimed to identify relevant host immune-biomarkers for early diagnosis of type 1 reactions. 
We recruited newly diagnosed leprosy patients longitudinally and studied M. leprae-specific 
cellular- and humoral immunity in blood of patients 1) in the absence of any clinical signs 
of reactions at least three months before reactions, 2) very early after clinical presentation of 
reactions and 3) after completion of treatment. Non-reactional patients (before and after 
treatment) as well as healthy individuals from the same area were analyzed similarly. To 
accommodate worldwide applicability, independent of the genetic and environmental 
background, this study was executed similarly in four distinct, prospective cohorts in Asia, 
Africa and South-America. 
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Materials and Methods 
 
General study-procedure. Recruitment took place in Bangladesh (International Centre for 
Diarrhoeal Disease Research Bangladesh, Dhaka), Brazil (National Reference Centre for 
Sanitary Dermatology and Leprosy, Uberlandia), Ethiopia (ALERT hospital and Health 
Centre,) and Nepal (Mycobacterial Research Laboratories, Kathmandu). Experiments were 
performed according to standard operating procedures and each site was provided with 
identical reagents. 
Study participants. Patients and endemic controls (EC) were recruited on a voluntary basis 
between February 2008-March 2013 (Table 1). Leprosy was diagnosed based on clinical, 
bacteriological and histological observations and classified by skin biopsies according to 
Ridley and Jopling [1]. Leprosy patients were treated according to WHO standards. Clinical 
monitoring for reactions was performed during monthly clinic visits. Clinical and 
demographic data was collected in clinical research forms (Supplementary file 2) and 
subsequently transferred in databases with special emphasis on standardizing data collection 
and definition of reaction between all cohorts [20;21]. For patients who presented with 
reactions the type, severity, skin- and/or nerve involvement, number of lesions and relapse 
were noted, according to state-of-the-art clinical expertise and international consensus 
scoring [21;22]. EC were assessed for the absence of clinical signs and symptoms of leprosy 
and TB. Staffs of leprosy- or TB clinics were excluded.  
TABLE 1 
Participating study sites and study groups
 
             
Site      Category
1
  Mean BI
2
 Sex ratio Age range Total
3
 
       (M/F)  (yr)    
Bangladesh  EC    na
4
  0.9    20-40  20 
 BL/LL   2.20  5       18-61  31 
 RR    1.68  2.5    21-63  20 
  
Brazil EC   na
4
  1.3    24-76  23 
 BL/LL   1.51  1       22-26  25 
 RR    1.95  3.3    25-68  20   
  
Ethiopia EC   na
4
  1.8   18-45  11 
 BL/LL   1.25  1.7   18-52  25
 
 RR   0.46  2.8    18-60  15 
  
Nepal EC   na
4
  3.6    19-28  20 
 BL/LL   2.96  2    35-58  13 
 RR   1.45  2.5    27-50  20 
            
1
EC: endemic control; BL/LL: borderline leprosy/ lepromatous leprosy; TT/BT: tuberculoid leprosy/ borderline 
tuberculoid leprosy; RR: reversal reaction (type 1 reaction);  
2
BI: bacterial index (mean);  
3
Total number of recruited individuals is indicated; samples for multiple time points were not always included. 
For multiplex cytokine analysis or UPLC-ESI-TOF MS a selected sample size was used for analysis.  
4
not applicable.   
 
Leprosy prevalence: Dhaka, prevalence: 2.45/10,000, new case detection rate (NCDR): 
0.31/10,000 (Annual Reports of Leprosy Control Institute & Hospital, Dhaka); Uberlandia, 
prevalence: 0.96/10,000, NCDR: 1,12/10,000 (National Disease Surveillance System, 
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Secretariat of Health Surveillance, Ministry of Health Brazil); Addis Ababa, prevalence: 
0.6/10,000 in 2010-2011, 0.4/10,000 in 2012, NCDR: 0.35/10,000 (FMOH reports); 
Kathmandu, prevalence: 1.1-0.79/10,000, NCDR: 1.67- 1.15/10,000 (Annual Report 2012-
2013, Leprosy Control Division, Department of Health Services, Kathmandu). 
Recruitment: Newly diagnosed, untreated leprosy patients without clinical reactions were 
enrolled and blood was drawn before MDT (t=0). Patients who presented reactions within 
three months of the start of therapy were excluded to avoid profile analyses of patients with 
latent reactions. If patients presented with reactions after more than three months of MDT, 
blood was drawn before initiation of anti-reactional therapy (t=x). Newly diagnosed leprosy 
patients who visited clinics with RR were recruited (t=x) but consequently lacked t=0 
samples. From all patients, blood was collected after MDT and/or steroid therapy (t=end). For 
patients with RR this was done at least one month after completion of steroid therapy to avoid 
assessment of the effect of steroids. All patients were assessed for the absence of reactions 
three months after t=end. For patients showing clinical signs of reactions within three months 
after t=end, this time point was excluded. In case patients died, moved or withdrew from the 
study, preventing follow-up, their samples were excluded. Blood was used for isolation of 
peripheral blood mononuclear cells (PBMC). Supernatants and sera were stored at -20C. 
Antigens. M. leprae recombinant proteins were produced as described [23]. M. leprae whole 
cell sonicate was provided through the NIH/NIAID “Leprosy Research Support” Contract 
N01AI-25469 
(http://www.beiresources.org/TBVTRMResearchMaterials/tabid/1431/Default.aspx). 
Cytokine/chemokine analysis. PBMC, freshly isolated from venous blood, were cultured for 
6 days with antigens as described [23]. IFN- was determined by ELISA (U-CyTech, Utrecht, 
The Netherlands) [24]. A positive, reference supernatant was provided to all laboratories. IL-
1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IFN-, IP-10, G-CSF, 
GM-CSF, MCP-1, MIG, MIP-1 and TNF in supernatants or sera were measured using the 
Bio-Plex-suspension-array-system (Bio-Rad,Veenendaal, NL)[23]. IFN-β was determined in 
undiluted sera (25ul) using Procartaplex IFN-β simplex-kit (eBioscience, Hatfield, UK) and 
CCL18 was determined (1:10 dilutions; 100l) by ELISA (DY394 DuoSet, R&D Systems, 
Minneapolis, MN) according to manufacturers’ instructions.  
Serology. Antibodies against ML2028 (Ag85B) and ND-O-BSA, a synthetic analogue of 
phenolic glycolipid I (PGL-I), were determined as described [25]. 
Ethics. This study was performed according to the Helsinki Declaration (2008 revision). 
Participants were informed about the study-objectives, the samples and their right to refuse to 
take part/ withdraw from the study without consequences for their treatment. Written 
informed consent was obtained before enrolment. All patients received treatment according to 
national guidelines. Ethical approval of the study-protocol was obtained through appropriate 
ethics committees: Ethical Review Committee of ICDDR,B  (#PR-10032; #PR-2007-069); 
Brazilian National Council of Ethics in Research (CONEP) and UFU Research Ethics 
Committee (#499/2008); National Health Research Ethical Review committee Ethiopia 
(NERC # RDHE/127-83/08); Nepal Health Research Council (NHR #751).  
Statistical analysis. Differences in cytokine concentrations were analysed with two-tailed 
Mann-Whitney U tests (unpaired samples) for non-parametric distribution and Wilcoxon 
matched-pairs signed rank test or paired t test for longitudinal analyses using GraphPad Prism 
version 5.01 for Windows (GraphPad Software, San Diego,CA, USA; www.graphpad.com). 
The statistical significance level used was p<0.05. 
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Results  
 
Recruitment of four prospective cohorts 
To identify biomarkers for early type 1 reactions, blood of newly diagnosed, untreated 
leprosy patients was obtained longitudinally in Bangladesh, Brazil, Ethiopia and Nepal 
(Table 1). The analysis included two samples of patients without reactions [1. before 
treatment (t=0); 2. after treatment (t=end)] and three of patients who developed RR during the 
study [1. in the absence of clinical signs of reactions, at least 3 months before RR diagnosis 
(t=0); 2. at RR diagnosis, before steroid-treatment (t=x); 3. after RR and at least one month 
after ending steroid-treatment (t=end)]. Since patients were frequently diagnosed with RR at 
their first clinic-visit, it became clear that it was not always feasible to include these first 
samples. Initially, patients who developed RR within 3 months of recruitment were excluded 
to avoid measuring markers for RR already at t=0.  Similarly, patients showing clinical signs 
of reactions within 3 months after ending MDT and/ or steroid treatment were excluded to 
prevent measuring biomarkers of RR at t=end. For longitudinal analysis (Fig. 1) only patients 
entering the study without reactions were utilized. Due to the low frequency of untreated 
cases without RR at their first clinic visits who developed RR during this study, we also 
included patients with RR at their first clinic visits (as initial RR cases) consequently lacking 
the first time point (t=0). Patients included in the analysis after database cleaning at each site 
are indicated in Table 1 and Figure 3 and 4. For healthy individuals from these areas with 
identical socio-economic background, one sample was collected. 
 
Longitudinal M. leprae-induced cytokine/chemokine production during reaction 
development 
First, we analysed M. leprae-induced cytokine production by blood cells of RR patients for 
whom valid samples were available at three time points (Bangladesh: n=3; Brazil: n=4; Nepal: 
n=3). All patients produced significantly higher IFN- and IL-17 at RR diagnosis than before 
or after treatment (Fig.1). Also, levels of IP-10, VEGF and IL-1β peaked at RR-onset 
(Fig.S2). In contrast, IL-10 was virtually not produced at RR diagnosis, compared to before 
diagnosis and after treatment. Cytokine responses to M. leprae-unique proteins, in particular 
ML2478 [23], corresponded well with responses to M. leprae (Fig.S1).  
Since cytokines modulate each other’s effects, we considered ratios as markers for disease-
status. Indeed, the differential cytokine production at RR onset was even more evident from 
the ratios of IFN-γ/IL-10 and IL-17/IL-10 (p=0.0032; p=0.0033; Fig.1), whereas IFN-γ/IL-10 
for patients who did not develop reactions remained similar before and after treatment 
(Fig.S3D) due to the simultaneous increase of both IFN- and IL-10 after MDT treatment in 
non-reactional patients (Fig. 3 and Fig. 4). The potential of cytokine ratios for discrimination 
between RR and its absence was also evident from the ROC (receiver operating 
characteristics) with AUC (areas under curve) ranging from 0,955 to 1. IP-10/IL-10 ratios 
showed a similar profile, with slightly less significance (AUC: 0.79; Fig.S3B-C). Thus, 
cytokine ratios proved valuable, RR-associated markers as well as markers for reactional 
treatment efficacy. 
 
Longitudinal serological analysis during reaction development 
For detection of M. tuberculosis infection [26] and to indicate M. leprae exposure [23;27], 
IP-10 was reported a useful marker. Notably, IP-10 is produced in large quantities facilitating 
its use in field-friendly test-platforms such as lateral flow [28]. IP-10 analysis of longitudinal 
sera of reactional patients showed increased levels during RR (Fig.2: p=0.0059; Fig.S4: AUC: 
0,79) consistent with previous studies [6;29]. Upon anti-reactional treatment, serum IP-10 
decreased (p=0.002; Fig.2A). In contrast, longitudinal sera from patients without reactions or 
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healthy donors, as control for RR-specificity, showed no significant difference in IP-10, 
clearly designating IP-10 as a serological marker for RR (Fig.2).   
 
The dynamics of CCL18 (chemokine (C-C motif) ligand 18) serum levels, elevated in 
lepromatous leprosy [30], were also investigated for patients experiencing reactions (Fig.2B), 
showing a decreasing trend at RR, increasing after treatment for most patients. CCL18 in 
healthy controls were much lower than for borderline lepromatous patients in line with recent 
findings [30].  
 
In view of the reduction of IL-10 during RR, these sera were also analysed for the presence of 
IL-10-inducing IFN-β [31]. Although no significant differences were detected at RR 
compared to before onset, IFN-β decreased significantly after treatment (p=0.006; Fig.S6).  
 
Cross-sectional analysis of cytokine production 
Cytokine profiles produced by blood cells cultured with M. leprae sonicate/ -proteins [23] 
were analysed cross-sectionally as well (Fig.3, S1, S2). In line with our longitudinal results, 
patients who developed RR produced significantly higher IFN- levels in response to M. 
leprae proteins at RR diagnosis than before onset of reaction or after reaction treatment 
regardless of their ethnic origin (blood at t=0 from Ethiopian RR patients was not available). 
As found previously for leprosy-endemic areas, EC produced high IFN- levels to M. leprae 
[23;27;32;33].  
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Figure 1. Longitudinal pattern of cytokine ratios for patients with reversal reaction (RR) IFN-γ, IL-17 and IL-10 production 
was induced by stimulation with M.leprae a. for 10 patients who developed RR during this study (Bangladesh:n=3; Brazil;n 
=4; Nepal:n =3) at leprosy diagnosis before MDT in the absence of any clinical signs of reactions and at least three months 
before reaction (before RR),at diagnosis of reaction before steroids (RR) or after MDT and RR, at least one month after end 
of steroids (after RR). IFN-γ/IL-10band IL-17/IL-10 c ratios and ROC (receiver operating characteristics) curves are shown. 
For calculations of ROC values, time points before RR versus at RR diagnosis (B, C middle panels) or at RR diagnosis 
versus after RR (B, C right panel) were considered  
 
IL-10 levels in response to M. leprae were again in striking contrast to IFN-γ levels (Fig.4). 
Virtually no responses were seen at RR diagnosis, compared to elevated IL-10 levels before 
diagnosis and after treatment. IP-10, IL-17, VEGF and to a lesser extent IL-1β levels 
followed those of IFN-, whereas G-CSF trended towards a decline at RR (Fig.S2). High 
levels of IL-5, IL-6, IL-8, MCP-1, MIP-1β, GM-CSF and TNF were observed for all groups 
but lacked a distinct longitudinal pattern, whereas induction of IL-2, IL-4, IL-7, IL-12p70 and 
IL-13 was low (data not shown).   
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Figure 2. Longitudinal serum analysis of patients with reversal reaction (RR) Levels of IP-10 a and CCL18 b in unstimulated 
sera derived from 10 leprosy patients (left panels) developing RR (Bangladesh: n =4;Brazil;n =3; Ethiopia:n =1;Nepal:n =2) 
in the absence of any clinical signs of reactions and at least three months before reaction (before RR),at diagnosis of reaction 
before steroids (RR) or after MDT and RR, at least one month after end of steroids (after RR), or from healthy Dutch 
controls (n= 10) at two sequential time points with six months intervals (right panels). For calculations of the ROC values, 
time points at least three months before RR and at RR diagnosis before steroids were considered. IFN-β levels for controls 
were not detectable  
 
Biomarkers to monitor treatment efficacy 
Besides biomarkers associated with reactions, biomarkers to monitor treatment efficacy 
provide practical tools as well. Thus, we analyzed the effect of treatment on immunemarkers: 
IFN- responses to M. leprae antigens of patients without reactions increased after treatment 
(Fig. 3), whereas IL-10 increased slightly, but not significantly with treatment (Fig.4). 
Treatment-induced increasing trends were also observed for VEGF, IL-1 and IL-17A levels 
(Fig.S2) thereby contributing to the biomarker profile for RR. As observed for RR patients, 
IFN- levels also increased in patients without RR after MDT treatment. In contrast to 
reactional patients, however, IL-10 levels were higher after MDT which renders the drop in 
IFN-/IL-10 ratio (Fig.1 and Fig.S3D) specifically associated with RR. 
 
Finally, cross-sectional screening of sera for the presence of antibodies to ND-O-BSA and 
ML2028 was performed (Fig.5 and Fig.S5). Anti-PGL-I IgM levels, but not anti-ML2028 
IgG levels were generally lowest in EC. In patients without RR, treatment significant 
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decreased antibodies (p = 0.0003 – 0.01), confirming that these serological markers add to 
host profiles useful to estimate treatment [25]. However, M. leprae-specific antibody 
detection did not identify RR, but allowed treatment monitoring (p = 0.0001. – 0.02; the 
Ethiopian cohort did not reach significance), suggesting that humoral immunity could serve 
as auxiliary tool for monitoring reactional treatment in addition to serum IP-10 and IFN-β as 
well as cytokine ratio’s.  
 
Figure 3. Longitudinal cross-sectional pattern of IFN-γ and IL-10 secretion. IFN-γ (Fig.3) or IL-10 (Fig.4) production 
(corrected for background values) in response to M. leprae sonicate (10 μg/ml) in 6day cultures of peripheral mononuclear 
cells (PBMC) of endemic controls (EC;▼), newly diagnosed leprosy patients without reactions (noRxn;) before treatment 
(t=0) and after treatment (t= end) and leprosy patients (•) in the absence of any clinical signs of reactions and at least 3 
months before RR (t=0), at RR diagnosis before steroids (t=x) or after MDT and RR (t= end), at least one month after end of 
steroids (after RR) inindividuals from Bangladesh, Brazil, Ethiopia, and Nepal. All patients were assessed for the absence of 
reactions three months after t =end. Background values were typically <50pg/ml. The number of individuals per group and 
the timepoint are indicated below the x-axis for each site  
 
Discussion 
 
Biomarkers as reliable correlates of disease complications and response to therapy are 
essential tools for early diagnosis of disease states in chronic infections. Generally, the 
performance of one biomarker can be significantly enhanced by using instead a custom-made 
grouping of independent biomarkers, called a profile or signature. In the current situation of  
leprosy elimination, the availability of sensitive and specific biomarkers that aid early 
diagnosis of leprosy reactions as well as monitor therapy, would be a strategic advantage 
enabling health care workers to identify, treat and possibly prevent these episodes at early 
stages, thereby reducing nerve damage. Since the immunopathology of leprosy, particularly 
in reactional states, is linked to temporal changes in the immune response to M. leprae, 
leprosy represents a uniquely suitable model to study immune-biomarker changes in relation 
to clinical disease manifestations.  
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Figure 4. Longitudinal cross-sectional pattern of IFN-γ and IL-10 secretion. IFN-γ (Fig.3) or IL-10 (Fig.4) 
production(corrected for background values) in response to M. leprae sonicate (10 μg/ml) in 6day cultures of peripheral 
mononuclear cells (PBMC) of endemic controls (EC;▼), newly diagnosed leprosy patients without reactions (noRxn;) 
before treatment (t=0) and after treatment (t= end) and leprosy patients (•) in the absence of any clinical signs of reactions 
and at least 3 months before RR (t=0), at RR diagnosis before steroids (t=x) or after MDT and RR (t= end), at least one 
month after end of steroids (after RR) in individuals from Bangladesh, Brazil, Ethiopia, and Nepal. All patients were 
assessed for the absence of reactions three months after t =end. Background values were typically <50pg/ml. The number of 
individuals per group and the time point are indicated below the x-axis for each site  
 
This is the first study in which cellular- and humoral immunity specific for M. leprae in 
leprosy patients within the three main continents reporting leprosy were monitored 
longitudinally during treatment. Although previous studies have analyzed circulating 
cytokines and chemokines [29] around the time of leprosy reactions, the addition of an M. 
leprae antigen-specific component, as utilized in this study provides more specificity to this 
approach.  
 
The data demonstrate translational importance since similar intra-individual trends were 
observed for development of RR in different endemic areas, allowing global application of 
these biomarkers in tests for early diagnosis of RR. In this respect, the importance of the 
combined effect of M. leprae-induced cytokine production (IFN-, IL-17, IP-10, IL-1β, 
VEGF), determined by their ratios versus IL-10, was highlighted, providing valuable tools for 
diagnosis of reactional states. 
 
The biomarker profiles identified in this study for RR can be used in blood-based diagnostic 
tests [28] to detect (intra-individual) changes during these acute inflammatory periods but 
also provide an approach for other chronic diseases with acute inflammatory states such as 
tuberculosis [34] and buruli ulcer [35] (paradoxical reactions) and Crohn’s disease [36;37], to 
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help early diagnose such episodes thereby contributing to timely treatment and prevention of 
disease-specific tissue damage. 
 
The acknowledged immunosuppressive role of IL-10 in lepromatous leprosy [38] as well as 
in M. leprae infected mice [39;40] was also evident from its reduction at RR-onset [41]. Thus, 
during RR the breakdown of regulation, in favour of inflammation, seems to underlie the 
aetiology of reactional tissue damage, whereas balanced ratios of these immune responses, as 
present in nonreactional leprosy patients, are protective against RR [42]. This is in line with 
the associations of IL-10 genetic variants with development of leprosy and leprosy reactions 
[6;43-46]. Suppression of IL-10 in a borderline tuberculoid-like murine model significantly 
augmented CD4/44
+
 and CD8/44
+
 longitudinal infiltrative responses specific to M. leprae 
antigens and permitted CD4
+
 T-cells to penetrate and fragment nerve [47], in line with our 
current field findings and supporting monitoring patient IL-10 levels in ratio to cytokines 
proven to escalate during RR as a potential early indicator of impending clinical RR.  
 
 
 
Figure 5. Humoral immunity to M. leprae antigens Antibodies against synthetic PGL-I (ND-O-BSA, a synthetic analog of 
the M. leprae-specific PGL-I) by ELISA. Sera were derived from Bangladesh, Brazil, Ethiopia, and Nepal and included 
endemic controls (EC;▼), newly diagnosed leprosy patients without reactions (noRxn;) before (t=0) and after treatment (t= 
end) and leprosy patients (•) in the absence of any clinical signs of reactions and at least 3 months before RR (t=0), at RR 
diagnosis before steroids (t=x) or after MDT and RR, at least one month after end of steroids (t= end).Optical density 
readings were performed using a 1:200 serum dilution. Median values for each group are indicated by horizontal lines. P-
values <0,05 indicate significant differences. The number of individuals per group and the timepoint are indicated below the 
x-axis for each site  
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As a second biomarker for RR in multiple ethnic backgrounds, increased serum IP-10 levels 
were identified, whereas CCL18, which is elevated in lepromatous leprosy [30], decreased at 
early RR in 6/10 patients who developed RR. Since CCL18 is secreted by dendritic cells 
upon recognition of M. tuberculosis [48] and has been implicated in differentiation of 
macrophages into an alternative phenotype [49] this suggests that decreased CCL18 levels 
lead to fewer alternatively activated macrophages and less T-cell regulation [6;50]. These 
data therefore indicate that new biomarker discovery approaches for RR also contribute to 
our understanding of the RR-associated immunopathologic mechanisms, suggesting new 
opportunities for therapeutic interventions.  
 
Since RRs are considered delayed hypersensitivity reactions caused by overreaction and/ or 
dysregulation of host defence mechanisms, conscientious (personalized) treatment 
monitoring is vital similar to other diseases with acute inflammatory states such as psoriasis 
and Crohn’s disease which share specific susceptibility genes with leprosy [51] [36]. Our data 
showed that pro-inflammatory cytokine/ IL-10 ratios, serum IP-10 can be used for monitoring 
treatment while not on steroids. Therefore, besides for early diagnosis of reactions, tests to 
monitor efficacy of treatment are useful as well, especially in the light of the reoccurrence of 
these episodes.  
 
To allow access to diagnostic test at resource-poor field settings, we recently developed low-
tech, robust lateral flow assays (LFAs) for (simultaneous) detection of inflammatory (IP-10) 
and regulatory (IL-10) immune responses together with anti-PGL-I IgM antibodies in short 
term whole blood assays [28;52]. In the light of the currently identified immune markers for 
RR, field-friendly LFAs measuring these cytokines for leprosy patients on MDT at each 
clinic-visit may be helpful to early detect RR if used for intra-individual testing. Thus, to 
provide a rapid test, the diagnostic potential of the cytokine ratios defined here, need to be 
determined in future studies using whole blood assays as well.  
 
Conclusions 
 
Type 1 or reversal reactions (RRs) are a major cause of leprosy-related nerve impairment and 
bear similarities with acute inflammation induced episodes in other (infectious) diseases. 
Since there is no laboratory test for the early diagnosis of these episodes, this multi-
continental, longitudinal study on the occurrence of RRs in leprosy patients, showed for the 
first time that both M. leprae-specific cellular- as well as humoral host immune-profiles, 
correlating with early onset of these inflammatory episodes, can be identified. Biomarkers 
associated with diagnosis or efficiency of treatment of type 1 reactions were identified based 
on intra-individual changes rather than single values. In particular, ratios of cytokines 
secreted by M. leprae stimulated blood cells as well as circulating cytokines in sera, 
contributed to these biomarker profiles. Thus, these profiles can be applied for the early 
diagnosis and to monitor reactional episodes and contribute to timely treatment and 
reduction/ prevention of tissue damage.  
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                            Figure 
S1: IFN-  in response to M.leprae-unique protein ML2478 in 6 day cultures of PBMC (see Figure 3). Simultaneously, 
PBMC were cultured with proteins: ML0009, ML0121, ML0141, ML0188, ML1601, ML1976, ML1989, ML1990, ML2283, 
ML2478, ML2531, ML2532 and ML2567 (data not shown).  
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Figure S2A (IP-10) 
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Figure S2B (TNF) 
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Figure S2C (IL-17) 
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 Figure S2D (VEGF) 
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Figure S2E (IL1-β) 
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Figure S2F (G-CSF) 
 
Figure S2: IP-10 (A), TNF (B), IL-17 (C), VEGF (D) , IL1-β (E) and G-CSF (F) production  in same cultures  as described 
in Figure S1.   
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Figure S3A-C 
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Figure S3:  IP-10 and IL-17 (A) after stimulation with M. leprae. IP-10/ IL-10 and IL-17/ IL-10 ratios are indicated (B, C).  
ROC curves were calculated for IP-10/ IL-10 and IL-17 /IL-10. Ratios for patients without reactions are shown as controls 
(D). 
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Figure S4:  IP-10 (A), IFN-β (B) and CCL18 (C) in sera. 
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Figure S5: Antibodies against M.leprae protein ML2028 in sera determined by ELISA. Optical density readings were 
performed using a 1:200 dilution. Median values are indicated by horizontal lines.   
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Figure S6: IFN-β in sera derived from patients developing RR in the absence of clinical signs of reactions and at least three 
months before reaction (before RR), at diagnosis of reaction before steroids (RR) or after MDT and RR, at least one month 
after end of steroids (after RR). For ROC values, timepoints at least three months before RR and at RR diagnosis before 
steroids were considered. IFN-β levels for controls were not detectable.     
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Abstract 
 
Background: Field-applicable tests detecting asymptomatic Mycobacterium leprae (M. 
leprae) infection or predicting progression to leprosy are urgently required. Since the 
outcome of M. leprae infection is determined by cellular- and humoral immunity, we aim to 
develop diagnostic tests detecting pro-/ anti-inflammatory and regulatory cytokines as well as 
antibodies against M. leprae. Previously, we developed lateral flow assays (LFA) for 
detection of cytokines and anti-PGL-I antibodies. Here we evaluate progress of newly 
developed LFAs for applications in resource-poor settings.  
Methods: The combined diagnostic value of IP-10, IL-10 and anti-PGL-I antibodies was 
tested using M. leprae-stimulated blood of leprosy patients and endemic controls (EC). For 
reduction of the overall test-to-result time the minimal whole blood assay time required to 
detect distinctive responses was investigated. To accommodate LFAs for field settings, dry-
format LFAs for IP-10 and anti-PGL-I antibodies were developed allowing storage and 
shipment at ambient temperatures. Additionally, a multiplex LFA-format was applied for 
simultaneous detection of anti-PGL-I antibodies and IP-10. For improved sensitivity and 
quantitation upconverting phosphor (UCP) reporter technology was applied in all LFAs. 
Results: Single and multiplex UCP-LFAs correlated well with ELISAs. The performance of 
dry reagent assays and portable, lightweight UCP-LF strip readers indicated excellent field-
robustness. Notably, detection of IP-10 levels in stimulated samples allowed a reduction of 
the whole blood assay time from 24h to 6h. Moreover, IP-10/IL-10 ratios in unstimulated 
plasma differed significantly between patients and EC, indicating the feasibility to identify M. 
leprae infection in endemic areas.  
Conclusions: Dry-format UCP-LFAs are low-tech, robust assays allowing detection of 
relevant cytokines and antibodies in response to M. leprae in the field. The high levels of IP-
10 and the required shorter whole blood assay time, render this cytokine useful to 
discriminate between leprosy patients and EC.  
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Author Summary 
 
Leprosy is one of the six diseases considered by WHO as a major threat in developing 
countries and often results in severe, life-long disabilities and deformities due to delayed 
diagnosis. Early detection of Mycobacterium leprae (M. leprae) infection, followed by 
effective interventions, is considered vital to interrupt transmission. Thus, field-friendly tests 
that detect asymptomatic M. leprae infection are urgently required.  
The clinical outcome after M. leprae infection is determined by the balance of pro- and anti-
inflammatory cytokines and antibodies in response to M. leprae. In this study, we developed 
lateral flow assays (LFA) for detection of pro-inflammatory (IP-10) vs. anti-inflammatory/ 
regulatory (IL-10) cellular immunity as well as antibodies against M. leprae and evaluated 
these in a field setting in Ethiopia using lightweight, portable readers.  
We show that detection of IP-10 allowed a significant reduction of the overall test-to-result 
time from 24h to 6h. Moreover, IP-10/IL-10 ratios in unstimulated plasma differed 
significantly between patients and EC, which can provide means to identify M. leprae 
infection. Thus, the LFAs are low-tech, robust assays that can be applied in resource-poor 
settings measuring immunity to M. leprae and can be used as tools for early diagnosis of 
leprosy leading to timely treatment and reduced transmission.   
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Introduction 
 
Leprosy, a curable infectious disease caused by Mycobacterium leprae (M. leprae) that 
affects the skin and peripheral nerves, is one of the six diseases considered by the WHO as a 
major threat in developing countries [1]. Despite being treatable, leprosy often results in 
severe, life-long disabilities and deformities [2] due to delayed- or misdiagnosis. 
Transmission of leprosy is clearly unabated as evidenced by the number of new cases, 10% of 
whom are children, that plateaued at nearly 250,000 each year since 2005 [1]. Continued 
transmission in endemic areas likely occurs from the large reservoir of individuals who are 
infected subclinically. Thus, early detection of  M. leprae infection, followed by effective 
interventions, is considered vital to interrupt transmission as highlighted by the WHO 2011-
2015 global strategy [3]. Despite this pressing need, field-friendly tests that detect 
asymptomatic M. leprae infection are lacking, nor are there any biomarkers known that 
predict progression to disease in infected individuals.  
 
Lateral flow assays (LFAs), are simple immunochromatographic assays detecting the 
presence of target analytes in samples without the need for specialized and costly equipment. 
Combinations of LFAs with up-converting phosphor (UCP) reporter technology are useful 
for detection  of a variety of analytes, e.g., drugs of abuse [4], protein and polysaccharide 
antigens from pathogens like Schistosoma and Brucella [5;6], bacterial and viral nucleic acids 
[7;8] and antibodies  against M. tuberculosis, HIV, hepatitis virus and Yersinia pestis [9–11]. 
The phosphorescent reporter utilized in UCP-LFAs is excited with infrared light to generate 
visible light, a process called up-conversion. UCP-based assays are highly sensitive since up-
conversion does not occur in nature, avoiding interference by autofluorescence of other assay 
components. Importantly, UCP-LF test strips can be stored as permanent records allowing re-
analysis in a reference laboratory. 
 
In leprosy, the innate and adaptive immune response to M. leprae matches the clinical 
manifestations as substantiated by the characteristic spectrum ranging from strong Th1 
immunity in tuberculoid leprosy to high antibody titers to M. leprae with Th2 cytokine 
responses in lepromatous leprosy [12]. In view of this spectral character, field-applicable tests 
for leprosy should allow simultaneously detection of biomarkers for humoral- as well as 
cellular immunity.  
 
Tests used in leprosy diagnostics include the broadly investigated serological assay detecting 
IgM against PGL-I [13;14]. Although this test is useful for detection of most multibacillary 
(MB) patients [15,16], as the antibody levels correlate well with the bacillary load, detection 
of anti-PGL-I Ab has limited value in identifying paucibacillary (PB) leprosy patients [17]. In 
areas hyperendemic for leprosy more than 50% of young schoolchildren surveyed had 
positive anti-PGL-I responses [18]. Still, the vast majority of individuals with a positive 
antibody titer will never develop leprosy [13]. With respect to cellular responses in leprosy 
diagnosis, studies have focussed on M. leprae-unique antigens which can probe T-cell M. 
leprae-specific responses resulting in the identification of M. leprae (-unique) antigens that 
specifically induced IFN- production in M. leprae infected individuals [19;20]. Combined 
with serology, the use of these IFN- release assays (IGRAs) provided significant added 
value since they identified the majority (71%) of PGL-I negative healthy household contacts 
in Brazil [21] while control individuals not exposed to M. leprae were IGRA-negative. 
Similar IGRAs allowed detection of the extent of M. leprae exposure along a proximity 
gradient in EC in one city in Brazil and in Ethiopia [22–24].  
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Although ELISA techniques, as used in IGRAs, are more widely applied than before, they 
still require laboratory facilities which are not available at all health centres in leprosy 
endemic areas. To accommodate ELISAs to field-applicable tests for leprosy diagnosis, we 
previously developed UCP-LFAs for detection of IFN- and IL-10 as well as antibodies 
against the M. leprae-specific phenolic glycolipid-I (PGL-I) for high-tech, laboratory-based 
microtiter-plate readers [25;26]. Since IFN-, the hallmark cytokine of Th1 cells, has 
generally been assessed as a biomarker to detect anti-mycobacterial immunity, we first 
developed a IFN--UCP-LFA [25]. Recently, IFN- induced protein 10 (IP-10) was found 
useful for detection of M. tuberculosis infection [27] and can also be used to indicate levels of 
M. leprae exposure and thereby the risk of infection and subsequent transmission [22;23]. 
Furthermore, since IP-10 is produced in large quantities, facilitating the use of simplified test 
platforms such as LFA [28], we investigated its potential as an alternative to IFN- for 
leprosy diagnosis. Accordingly, we developed quantitative, dry reagent UCP-LFAs for field-
detection of IP-10 and anti-PGL-I antibodies and evaluated these in a leprosy endemic area in 
Ethiopia. 
 
Materials and Methods 
 
Ethical statement. This study was performed according to ethical standards in the Helsinki 
Declaration of 1975, as revised in 1983. Ethical approval of the study protocol was obtained 
from the National Health Research Ethical Review committee, Ethiopia (NERC # 
RDHE/127-83/08) and The Netherlands (MEC-2012-589). Participants were informed about 
the study objectives, the required amount and kind of samples and their right to refuse to take 
part or withdraw from the study at any time without consequences for their treatment. Written 
informed consent was obtained from all study participants before venipuncture.  
Study participants. HIV-negative, newly diagnosed untreated leprosy patients and healthy 
endemic controls (EC) were recruited at the Armauer Hansen Research Institute (AHRI) in 
Addis Ababa, Ethiopia, The Leiden University Medical Center (LUMC) and the Erasmus 
Medical Center (EMC), The Netherlands from October 2011 until November 2012. Leprosy 
was diagnosed based on clinical, bacteriological and histological observations and classified 
by a skin biopsy evaluated according to the Ridley and Jopling classification [2] by qualified 
personnel. EC were assessed for the absence of signs and symptoms of tuberculosis and 
leprosy. Staff members working in the leprosy centers or TB clinics were excluded as EC. 
Mantoux-negative, healthy Dutch donors recruited at the Blood Bank Sanquin, Leiden, The 
Netherlands were used as nonendemic controls (NEC). None of these NEC had lived in or 
travelled to leprosy- or TB endemic areas, and, to their knowledge, had not experienced any 
prior contact with TB or leprosy patients.  
Recombinant proteins. M. leprae candidate genes were amplified by PCR from genomic M. 
leprae DNA and cloned using Gateway technology (Invitrogen, Carlsbad, CA) with 
pDEST17 expression vector containing an N-terminal histidine tag (Invitrogen) [29]. Purified 
recombinant proteins were produced as described [22;29] and contained endotoxin levels below 
50 IU per mg recombinant protein as tested using a Limulus Amebocyte Lysate (LAL) assay 
(Cambrex, East Rutherford, NJ). Recombinant proteins were tested to exclude protein non-
specific T cell stimulation and cellular toxicity in IFN- release assays using PBMC of in vitro 
PPD-negative, healthy Dutch donors recruited at the Blood Bank Sanquin, Leiden, The 
Netherlands. None of these controls had experienced any known prior contact with leprosy or 
TB patients.  
Whole blood assays (WBA). Within 3 hours of collection, venous heparinized blood (450 μl 
per well) was incubated in 48-well plates at 37°C at 5% CO2, 90% relative humidity with    
50 μl of antigen solution (100 g/ ml). After incubation periods of 1h, 4h, 6h or 24h (as 
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indicated), 150 l of supernatants were removed from each well and frozen in aliquots at –
20C until further analysis. 
Synthetic PGL-I and M. leprae whole cell sonicate (WCS). Synthetic PGL-I (ND-O-HSA) 
and M. leprae whole cell sonicate were generated with support from the NIH/NIAID Leprosy 
Contract N01-AI-25469 (available through the Biodefense and Emerging Infections Research 
Resources Repository listed at http://www.beiresources.org/TBVTRMResearch 
Materials/tabid/1431/Default.aspx). Disaccharide epitope (3,6-di-O-methyl--D-
glucopyranosyl(14)2,3-di-O-methylrhamnopyranoside) of M. leprae specific native PGL-I 
glycolipid was synthesized and coupled to human serum albumin (ND-O-HSA) as previously 
described by Cho et al. [30]. Inactivated (irradiated) armadillo-derived M. leprae whole cells 
were probe sonicated with a Sanyo sonicator to > 95% breakage.  
PGL-I ELISA.  IgM antibodies against M. leprae PGL-I were detected with natural 
disaccharide of PGL-I linked to human serum albumin (ND-O-HSA (500 ng/ well in 50 l) 
provided through the NIH/NIAID Leprosy Contract N01-AI-25469) as previously described 
[31]. Serum dilutions (50 l/ well; 1:800) were incubated at RT for 120 min in flat-bottomed 
microtiter plates (Nunc) coated with NDO-HSA. After washing diluted enzyme linked 
secondary antibody solution (anti-human IgG/IgM/IgA – HRP; Dako, Heverlee, Belgium; 50 
l/ well) was added to all wells and incubated at RT for 120 min. After washing diluted TMB 
solution (50 l/ well) was added to all wells and incubated in the dark for 15 min at RT. The 
reaction was stopped by adding 50 μl/ well 0.5 N H2SO4. Absorbance was determined at 
wavelength of 450 nm. Samples with a net optical density at 450 nm (OD) above 0.149 were 
considered positive. The ELISA performance was monitored using a positive and negative 
control serum samples on each plate.  
Cytokine ELISAs. For ELISAs 96 well Nunc MaxiSorp microtitre-plates were used and the 
presence of biotinylated antibody was detected enzymatically using streptavidin-HRP (horse-
radish peroxidase): IFN-  was determined using anti-IFN- coating Ab mAb mO-13-32-22 
(U-CyTech Biosciences, Utrecht, the Netherlands) and biotinylated anti-IFN- pAb pB-15-
43-13 (U-CyTech Biosciences) as detection Ab. Culture supernatants were diluted 1:2 in 
buffer (1% BSA/PBS) and the cut-off value to define positive responses was set beforehand 
at 100 pg/ml. The assay sensitivity level was 40 pg/ml. Values for unstimulated cell cultures 
were typically <20 pg/ml. IP-10 was determined using anti-IP-10 capture Ab (clone B-C50) 
and biotinylated anti-IP-10 detection Ab (clone B-C55; Diaclone, France) in culture 
supernatants diluted 1:100 with dilution buffer. The cut-off value to define positive responses 
was set beforehand at 2,000 pg/ml. The assay sensitivity level was 40 pg/ml. Values for 
unstimulated cell cultures of NEC were typically < 2,000 pg/ml. IL-10 was determined using 
anti-IL-10 mAb mO-13-10-12 (U-CyTech Biosciences) as coating Ab and biotinylated anti-
IL-10 pAb mB-15-10-26 (U-CyTech Biosciences) as detection Ab in culture supernatants 
diluted 1:2. The cut-off value to define positive responses was set beforehand at 100 pg/ml. 
The assay sensitivity level was 10 pg/ml. Concentration values for unstimulated whole blood 
were typically ≤ 10 pg/ml. 
Upconverting phosphor (UCP) conjugates and LF strips. UCP conjugates specific for 
cytokines IP-10, IL-10, IFN- were prepared following earlier described protocols [26], by 
conjugating 5 µg anti-IP-10 (BC-50; Diaclone), 20 μg anti-IL-10 mAb (coating mAb in 
ELISA, mO-13-10-12; U-CyTech) or 25 μg anti-IFN- (BB-1; Diaclone) per 1 mg 
carboxylated UCP particles, respectively. Wet UCP conjugates were stored at a concentration 
of 1 mg/ml at 4 °C. An UCP-IP-10 dry conjugate was made by drying 100 ng in a 5% sucrose 
matrix overnight at 37C in 0.65 ml U-shape polypropylene tubes (Ratiolab tubes for 96-well 
micro test plate, VWR International, Amsterdam, The Netherlands); dried materials were 
stored in aluminum foil bags (Lamigrip pouches Overtoom International, Den Dolder, The 
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Netherlands) with silica dry pellets at ambient temperature [6,32]. Reporter conjugates for 
detection of humoral immune response, an IgM- and Ig-specific UCP conjugates, were 
prepared as described earlier [9,26] by conjugation of 25 µg goat anti-human IgM (I0759; 
Sigma-Aldrich, Saint Louis, MO, USA),  protein-A (Repligen Corp.) or 
IgG/IgM/IgA/Kappa/Lambda–HRP (Dako), respectively. Wet conjugates were stored at a 
concentration of 1 mg/mL at 4 °C. Freeze dried pellets, so-called lyospheres, containing 100 
ng UCP
protein A
 conjugate were produced (Biolyph LLC, Hopkins, MN, USA) and stored in 
vacuum-sealed glass vials as described earlier [33]. LF strips (4 mm width) for IP-10, IL-10 
and IFN-γ were prepared with a test (T) line at 2.0 cm comprised of 50 ng anti-IP-10  BC-55 
(Diaclone), 700 ng anti-IL-10 mAb mO-10-10-28 (U-CyTech Biosciences) or 200 ng anti-
IFN- BG-1 (Diaclone) respectively. The antibody pairs were identical to those used for 
ELISA but not containing a biotin hapten. LF strips for cytokine detection were further 
provided with a goat anti-mouse pAb (M8642; Sigma-Aldrich) flow-control (FC) line of 
respectively 100 ng and 200 ng at 2.5 cm. LF strips for detection of antibodies against PGL-I 
were provided with 50 ng synthetic PGL-I (ND-O-HAS) on the test (T) line and 100 ng rabbit 
anti-goat IgG (G4018; Sigma-Aldrich) on the flow-control (FC) line. LF strips for IP-10 and 
PGL-I multiplex detection were prepared using the same compositions as the strips for the 
individual targets, but now were provided with two T- and two FC-capture lines. Capture 
lines were separated by 4 mm located at 1.5 (T1, IP-10), 1.9 (T2, PGL-I), 2.7 (FC1, goat anti-
mouse), and 2.3 cm (FC2, rabbit anti-goat).  
UCP-LFA for cytokine detection. The UCP-LFAs for cytokine detection (IFN-, IL-10, IP-
10) comprise two phases, designated solution phase and immunochromatography phase [26]. 
Solution phase: 10 µl of 100-fold diluted sample (translating to 0.1 µl undiluted sample) for 
IP-10 and 10 μl undiluted sample for IL-10 and IFN- is mixed with 90 μl High Salt Lateral 
Flow (HSLF) buffer (100 mM Hepes pH 7.2, 270 mM NaCl, 1% BSA (w/v), 0.5% Tween-20 
(v/v)) containing 100 ng specific UCP reporter conjugate and incubated for 60 min on a 
thermoshaker at 37 °C and 900 rpm. The immunochromatography phase: the above mixture 
is applied to cytokine specific LF strip and allowed to flow for at least 30 min. After 
immunochromatography, LF strips are scanned in a Packard FluoroCount microtiterplate 
reader adapted with an infrared laser. Upon IR excitation (980 nm), UCP reporter particles 
emit green light detectable using a 550 nm band pass filter. Results are displayed in 
histograms in relative fluorescence units (RFUs) measured at Test and Flow-Control lines, or 
as the ratio value between Test (T) and Flow-Control (FC) RFUs using Lateral Flow Studio 
software V 3.3.5 (QIAGEN Lake Constance GmbH). For strip analysis in Ethiopia a 
lightweight portable LF strip reader with UCP capability was used (UCP-Quant, an 
ESEQuant LFR reader custom adapted with IR diode; QIAGEN Lake Constance GmbH, 
Stockach, Germany) [6]. Best reproducibility is obtained when analyzing completely dry LF 
strips, whereas wet LF strips generate lower T and FC signals. Ratio values between wet- and 
dry-scanned strips are not significantly different when scanned with readers with sufficient 
sensitivity that contain a high power IR laser and an adjustable photo multiplier [34]. Since 
wet-format assays require a sonication step, not suitable for field applications [6], the IP-10-
UCP-LFA was adapted to allow implementation of dry reagents (dry conjugate and 
lyophilized buffer) similar as described for Schistosomiasis [6] and RSV [33]. Next, the dry-
format IP-10-UCP-LFA was transported to Ethiopia at ambient temperature and used by local 
staff after short instruction. In order to evaluate the field performance of these dry-format 
UCP-LFAs at the Ethiopian site, a lightweight dedicated UCP-LF strip analyzer was provided. 
UCP-LFA for anti-PGL-I antibody detection. For detection of anti-PGL-I IgM antibodies 
two protocols were used: a rapid sequential flow protocol without incubation using the 
UCP
protein-A
 or UCP
IgG/IgM/IgA/Kappa/Lambda
 conjugate, or a two phase protocol similar to the 
above described protocol for cytokine detection only using UCP
IgM
 instead of cytokine-
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specific UCP conjugates. The sequential flow protocol using the UCP
protein-A
 conjugate is 
referred to as consecutive flow (CF) as described [8;9;35]. The CF protocol comprised three 
sequential flow steps: first 40 µl of a diluted clinical sample (2.5% (v/v) in HSLF assay 
buffer), after 2 min followed by a wash step with 20 µl HSLF and a final flow after 5 min 
with 70 µl UCP-conjugate (100 ng in HSLF). Multiple strips can be handled simultaneously 
by prefilling 96 well ELISA microtitre-plates (Nunc MaxiSorp) with the appropriate three 
solutions and transferring LF strips from one well to the other.  Immunochromatography is 
allowed to continue for at least 30 min before LF strips are analyzed (see above). For the dry-
format UCP-LFA to detect anti-PGL-I antibodies, dry UCP
prot-A 
 reagent in the form of 
lyospheres [2] was used. 
UCP-LFA for simultaneous (multiplex) cytokine and antibody. Simultaneous detection of 
IP-10 and anti-PGL-I IgM was performed following the two phase protocol described above 
for cytokine detection. The solution phase comprised the incubation (60 min; 37 °C; 900 rpm) 
of 10 L 100-fold diluted sample (translating to 0.1 L of the original undiluted clinical 
sample) with 90 μl HSLF buffer containing 100 ng of the UCPIP-10conjugate (wet) and 100 
ng of the UCP
IgM
 conjugate. The immunochromatography phase was identical to that 
described for the cytokine-only testing protocol and allowed to continue for at least 30 min 
before analysis of LF strips (see above). Note that the above protocol may not be applicable 
when performing antibody detection with the UCP
protein-A
 conjugate due to unwanted 
interaction of protein-A with the UCP
IP-10
 conjugate [26]. 
Statistical analysis. Differences in cytokine concentrations between test groups were 
analysed with the two-tailed Mann-Whitney U test for non-parametric distribution using 
GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego California USA; 
www.graphpad.com). For correlations R
2
 was calculated with the Pearson correlation using 
GraphPad Prism version 5.01. The statistical significance level used was p0.05. 
 
Results 
 
Combined cytokine profiles in response to M. leprae antigens 
M. leprae unique antigens can be used to indicate M. leprae exposure using IFN- and IP-10 as 
read-outs [22;23;36]. Also, IFN- and IP-10 are associated with Th1-mediated protection against 
mycobacteria, whereas the anti-inflammatory cytokine IL-10 dampens Th1 cells’ responses 
[37–39]. In view of the high levels of IP-10 produced compared to IFN- [22;28] and since, in 
contrast to IFN-, IP-10 is not affected by low CD4 counts in TB patients with HIV [28], we 
investigated whether IP-10, as an alternative to IFN-, can be applied as a pro-inflammatory 
biomarker.  
 
To evaluate the combined diagnostic value of IL-10, IP-10 and IFN-, we first determined their 
concentrations by ELISAs in 24h WBA of 11 Ethiopian leprosy patients (9 BL, 2 BT) and 12 
EC. In addition, anti-PGL-I antibodies were determined for each individual as well (Figure 1). 
The IP-10 production measured in WBA displayed a pattern similar to that of IFN-, although 
the overall IP-10 concentrations were much higher: median levels of both cytokines in response 
to M. leprae and ML2478 in patients’ WBA were not significantly different from those for EC 
in this leprosy endemic area. These data are consistent with our previous findings, leading to the 
use of IFN-/ IP-10 production in response to ML2478 to determine the level of exposure to M. 
leprae irrespective of infection [22]. 
In contrast, IL-10 concentrations in response to ML2478 were significantly lower for EC 
(Figure 1C). Since the balance of pro- and anti-inflammatory cytokines in response to M. leprae 
regulates the clinical outcome after infection, diagnostic tests for leprosy measuring both types 
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of responses will be helpful in the decision on which individuals need (preventive) treatment. 
IP-10/IL-10 ratios for stimulated and unstimulated WBA samples demonstrated significantly 
different values between patients and EC, in particular for unstimulated samples (Figure 1D). 
Finally, detection of a biomarker for humoral immunity, anti-PGL-I antibody levels, 
demonstrated significantly higher titers for leprosy patients, further contributing to a 
discriminating profile between leprosy patients and EC in leprosy endemic areas (Figure 1E).  
 
Kinetics of cytokine production in WBA 
Since short overall test-to-result times are preferred for diagnostic assays, the supernatants of 
WBA of Ethiopian leprosy patients and EC were analyzed for the presence of IFN-, IL-10 
and IP-10 after 1h, 4h, 6h and 24h stimulation. For IFN- and IL-10, levels that varied 
significantly from unstimulated samples were only detected after 24h (data not shown). For 
IP-10, however, already after 6h significant production was observed in antigen stimulated 
samples (Figure 2). Important to note is that after 6h, IP-10 levels in ML2478-stimulated 
samples were significantly higher (p = 0.02) in patients compared to EC (Figure 2B), whereas 
no distinctive responses were observed for IFN- at that time point. PHA-induced IP-10 
levels were high for all individuals after 6h and substantial IP-10 levels were only detectable 
in M. leprae-stimulated samples after 24h. Thus, besides the higher levels of IP-10, also the 
shorter whole blood assay time required render IP-10 combined with ML2478 or as ratio with 
IL-10 directly in serum, a preferred pro-inflammatory biomarker to discriminate between 
leprosy patients and EC.  
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Figure 1. Combined cytokine profiles in response to M. leprae. Production of IFN- (A), IP-10 (B) and IL-10 (C) 
determined by ELISA, in response to medium (-), PHA, M. leprae WCS or the M. leprae-unique protein 
ML2478 in 24 h WBA for Ethiopian leprosy patients (n = 11: 2 BT (￮) and 9BL(●), and healthy endemic 
controls (EC; n = 12; □). For comparison between BT and BL, significant differences were found for M. leprae 
WCS (Mlep) induced IFN-c responses (p = 0.036) and ML2478 induced IL-10 responses (p = 0.035). D): IP-
10/IL-10 ratios are depicted for unstimulated samples after 24 h {LP (●) and EC (□)} or after 1 h WBA {LP () 
and EC (▼)}. (E): Anti-PGL-I antibodies for BL (￮) and BT () patients were detected by ELISA using natural 
disaccharide of PGL-I linked to HSA [31] (ND-O-HSA). Optical density (OD450) readings were performed 
using 1:800 serum dilutions. Median values per group are indicated by horizontal lines. The cut-off for 
positivity is indicated by the dashed horizontal line.  
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Development and evaluation of UCP-LFAs  
For detection of IFN-, IL-10 as well as antibodies against M. leprae PGL-I, we previously 
developed up-converting phosphor lateral flow assays (UCP-LFAs) [25;26]. Because of the 
potential of IP-10 to identify M. leprae infection in a shorter test-to-result time as well as the 
value of IP-10/IL-10 ratios, we now selected IP-10 for UCP-LFA development, using the 
wet-format for IL-10 described previously [26]. Validation of these IL-10 and IP-10 UCP-
LFA by comparison to ELISAs utilizing the same antibody pairs and antigen-stimulated 
WBA samples of non-endemic controls (NEC), demonstrated good correlations between 
UCP-LFAs and ELISAs for IP-10 and IL-10 (R
2
 0,854 and R
2
 0,816, respectively; Figure 3). 
 
In view of the greater stability in the field, dry assay format IP-10-UCP-LFA were produced 
and evaluated in Ethiopia as well: IP-10 values obtained in both wet and dry assays showed a 
good correlation (R
2
 0,790; Figure 4A) indicating the value for field application of the dry-
format IP-10-UCP-LFA. Similarly, the unstimulated WBA samples were locally (in Ethiopia) 
tested for the presence of antibodies against PGL-I as well. Quantitive analysis of the UCP
prot-
A
 ratios and ELISA OD values correlated well (R
2
 0.689; Figure 4B) indicating 100% 
agreement in respect to serological status of the samples (qualitative analysis).  
 
To further evaluate UCP-LF applications with this Ethiopian sample set, IL-10 levels of 84 
samples (21 patients, 3 stimuli and medium) were also tested, using the available wet-format 
IL-10-UCP-LFA in parallel with ELISA. Since the IL-10-UCP-LFA was used with 100-fold 
larger sample input than the IP-10 assay, some of the discrepancies observed for IL-10 
between ELISA and UCP-LF assay were probably due to particulate material present in 
WBA samples. Despite these differences, IL-10-UCP-LFA and ELISA correlated well (R
2
 
0,735; Figure 4C). 
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Figure 2. Kinetics of IP-10 production in WBA. (A): IP-10 concentrations produced in stimulated whole blood 
cultures of leprosy patients (upper panel; LP; n = 10: 5 BL (Ethiopia); 2 BT (Ethiopia); 3 BT (The Netherlands) 
and healthy endemic controls (lower panel; EC, n = 8) in response to M. leprae WCS (left panel; 10 mg/ml), M. 
leprae unique protein ML2478 (middle panel; 10 mg/ml) and PHA (right panel; 1 mg/ml). IP-10 concentrations 
were determined by ELISA after 1 h, 4 h, 6 h and 24 h antigen stimulation. Values on the y-axis are 
concentrations corrected for background values. (B): Comparison of IP-10 concentrations determined by ELISA 
after 6 h stimulation with ML2478 (10 mg/ml) of whole blood samples.  
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Figure 3. Correlation between ELISAs and UCP-LFAs. Levels of IP-10 (A) and IL-10 (B) in 24 h whole blood 
samples of 77 M. leprae (antigen), LPS and PHA stimulated WBA samples of Dutch healthy controls were 
simultaneously determined by ELISAs and wet-format UCP-LFAs. Left panels: results for ELISAs are indicated 
in pg/ml (ELISA) or as the ratio of the relative fluorescence units (RFUs) measured at Test and Flow-Control 
lines (UCPLFA). R
2 
equals the square of the Pearson correlation coefficient. Right panels: Spearman ranking.  
 
For direct comparison of single UCP-LFAs performance in a field- versus laboratory setting, 
the UCP-LF strips for IP-10 and anti-PGL-I antibodies analyzed in Ethiopia were sent to The 
Netherlands and re-analysed using a dedicated, high-tech UCP scanner, a Packard 
FluoroCount microtiter-plate reader adapted with an infrared laser (980 nm) capable to scan 
20 strips simultaneously. Comparison of ratios obtained in both tests showed an excellent 
correlations between both scanners (IP-10: R
2
 0,960 and PGL-I: R
2
 0,901; Figure 5), 
demonstrating that the UCP-LF strips can be stored as permanent record allowing re-analysis 
in a reference laboratory. Since leprosy endemic areas are often short of sophisticated 
laboratories, these results indicate that UCP-LFAs represent robust test suitable for resource-
poor settings. 
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Multiplex UCP-LFA for detection of IP-10 and anti-PGL-I antibodies 
IP-10 levels as well as anti-PGL-I antibody concentrations were present in high 
concentrations allowing reliable detection even with small amounts of serum thereby 
improving the robustness in field assays. To further simplify the use of the UCP-LFA for 
leprosy diagnostics in a field setting, we next developed a multiplex UCP-LFA for 
simultaneous detection of anti-PGL-I antibodies and IP-10 in whole blood samples, 
analogous to the earlier described anti-PGL-I/ IL-10 multiplex UCP-LFA [26]. The advantage 
of this specific chemokine/ antibody combination is that similarly diluted serum samples can 
be used, facilitating multiplex analysis of cellular and humoral immunity. For extensive 
comparison of single and multiplex UCP-LFAs Dutch leprosy patients’ WBA samples were 
used as well to accommodate for more samples. Multiplex UCP-LFA and the single UCP-
LFA for IP-10 and anti-PGL-I antibodies showed good correlations (R
2 
0,961 and 0, 897; 
Figure 6) demonstrating the applicability of this multiplex UCP-LFA. 
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Figure 4. Correlation between ELISAs and UCP-LFAs. Levels of IP-10 (A; n = 40), anti-PGL-I antibodies (B; n 
=22) or IL-10 (C; n =40) in WBA samples were simultaneously determined by ELISAs and UCP-LFAs in 
Ethiopia using dry-format (A, B) or wet format (C) UCP-LFAs. For cytokine analysis (A and C), samples of 
Ethiopian leprosy patients (2 BT and 8 BL) that were unstimulated or stimulated with M. leprae WCS, ML2478 
or PHA were used. For anti-PGL-I antibodies (B), samples of Ethiopian leprosy patients (2 BT and 8 BL) and 
healthy endemic controls (n = 12) were used. Left panels: results for ELISA are indicated in pg/ml (A, 
C)orOD450 (B) or as the ratio of the relative fluorescence units (RFUs) measured at Test and Flow-Control 
lines (UCP-LFA). R
2
 equals the square of the Pearson correlation coefficient. Correlation was calculated for 
samples with ELISA values higher than the cut-off threshold. Right panels: Spearman ranking. 
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Discussion 
 
Effective diagnostics are essential tools for the control, elimination and eradication of 
neglected diseases such as leprosy. Since leprosy endemic areas are often short of 
sophisticated laboratories, it is imperative to develop diagnostic tests for early detection of M. 
leprae infection that are suitable for field settings. The main requisite for such diagnostic 
tests is the selection of suitable biomarkers. WBA using M. leprae (-specific) antigens induce 
a ‘fingerprint’ of (the ratio of) pro- and anti-inflammatory cytokines that, combined with 
detection of anti-PGL-I antibodies, can be used as a biomarker profile for M. leprae infection. 
 
Figure 5. Performance of the portable lightweight UCP-Quant LF strip reader. Dry-format UCP-LFAs were 
performed for single detection of IP-10 and anti-PGL-I antibodies in an Ethiopian field setting (Figure 3). LF 
strips were analyzed using a portable reader (UCP-Quant). Subsequently, LF strips were shipped to The 
Netherlands and re-analysed using a dedicated lab-based FluoroCount microtiterplate reader (Packard) adapted 
for reading UCP-LF strips. Left panel: results are indicated as the ratio of the relative fluorescence units (RFUs) 
measured at Test and Flow-Control lines. R2 equals the square the Pearson correlation coefficient. Right panel: 
Spearman ranking. The grey box indicates samples scoring values below the specificity threshold. 
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Figure 6. Comparison between single and multiplex UCP-LFAs. UCP-LFAs were performed for single or 
multiplex detection of IP-10 (upper panel; n = 149 samples) and anti-PGL-I (lower panel; n = 115 samples) 
using M. leprae antigen-stimulated WBA samples of Dutch and Ethiopian leprosy patients. Simultaneous 
detection of IP-10 and anti-PGL-I IgM was performed following the two phase protocol using the UCP 
αIP-
10
conjugate and the UCP 
αIgM
 conjugate. Left panel: Results for UCP-LFAs are displayed as the ratio of the 
relative fluorescence units (RFUs) measured at Test and conjugate. Left panel: Results for UCP-LFAs are 
displayed as the ratio of the relative fluorescence units (RFUs) measured at Test and Flow-Control lines. R
2
 
equals the square of the Pearson correlation coefficient. Right panel: Spearman ranking. The grey box indicates 
samples scoring values below the specificity 
 
Notwithstanding the frequent use of IFN-, IP-10 represents an equally valid biomarker for 
pro-inflammatory responses to mycobacteria [22;23;27;36;40;41]. This chemokine is 
produced by various cell types, including monocytes/macrophages, and is involved in 
recruitment of lymphocytes and neutrophils to sites of inflammation. IP-10 can be used to 
differentiate between high and low M. leprae exposure levels [22] and it also provides a 
biomarker associated with type 1 reaction (T1R) in leprosy patients [42;43]. Moreover, IP-10, 
is much less influenced by CD4 cell count and, in contrast to IFN-,  can be used in HIV+ 
individuals [28]. Considering the similarities in IP-10 responses of M. leprae- and M. 
tuberculosis infected individuals, and the high concentrations in which it is produced, we 
developed a UCP-LFA for IP-10 and investigated its diagnostic potential for leprosy (this 
study) and TB in Africa (Corstjens et al., in preparation). Although most IGRAs require an 
antigen stimulation time of at least 24h, we here demonstrate that IP-10, in contrast to IFN-, 
already showed a significant divergence between Ethiopian leprosy patients and EC after 6h 
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stimulation with the M. leprae-unique protein ML2478. This considerably reduces the overall 
assay time and could conveniently provide a sample-to-result on the same day.  
 
Since host immunity and immuno-pathogenicity in response to M. leprae comprises 
multifaceted interactions between a diversity of cells secreting different molecules, it is rather 
unlikely that only a single compound is linearly correlated to protection or to disease 
progression [44]. Diagnostic tests that determine ratios of different types of cytokines will 
therefore be informative regarding disease development after M. leprae infection [19;45] as 
was previously illustrated by IFN-/ IL-10 and IFN-/ IL-17 ratios in Mtb infected individuals 
[46;47], but also for the development of T1R [42]. Relatedly, another valuable observation 
made here was the significant difference in IP-10/IL-10 ratios in sera of leprosy patients and 
EC, even without antigen stimulation. These data illustrate that the proportion of pro- to anti-
inflammatory cytokines is consistent with clinical outcome after infection. Consequently, 
over time changes in the IP-10/IL-10 ratio for one individual will provide relevant clinical 
information with respect to the outcome of infection.  
 
Dry-format UCP-LFAs are ideally suited for performance in the field and can be shipped and 
stored conveniently at ambient temperature and have prolonged shelf life of more than two 
years in African settings [6]. In this study we selected IP-10 and anti-PGL-I antibodies for 
field-evaluation of the dry-format UCP-LFA and development of dry-format UCP-LFA for 
more analytes is in progress. This evaluation showed that both dry-format UCP-LFAs were 
equally sensitive as ELISAs and could be applied in the concentration range of 100 
to >100,000 pg/ml. Also, the availability of affordable and portable UCP-LF strip readers 
showed suitability of the assay in field settings where ELISA equipment is not available or is 
more challenging to use. The LF strips were read with an easy to operate, portable reader that 
allows full instrument-assisted assay analyses avoiding operator bias. Due to the chemical 
stability of the assay components, the strips can be kept in patients’ files and read again after 
long periods of time.  
 
Besides the speed and ease of performance, another advantage of the UCP-LFA is that 
multiple analytes can be detected on the same LF-strip. Feasibility of multiplexed analysis 
was demonstrated previously for IL-10 and anti-PGL-I antibodies in spiked sera [26]. In this 
study multiplexing was successfully shown for IP-10 and anti-PGL-I antibodies in whole 
blood samples. Although the current UCP-LFA conditions for IL-10 quantitation demand a 
100-fold larger sample input than the IP-10 assay, a single strip allowing quantitative 
detection of IP-10, IL-10 as well as anti-PGL-I antibody detection is feasible. Revision of the 
position (distance from the sample pad) and antibody load of the test lines, would allow the 
use of 1 L samples instead of the currently applied 0.1 and 10 L for IP-10 and IL-10 
respectively. Moreover, multiplexing can be achieved by running two or more LF strips from 
a single sample in parallel as was for instance described for a simple multiple channel device 
running ten UCP-LF strips from a single sample [11].  
 
This study describes the first steps towards development of a UCP-LFA as a field test 
measuring pro- and anti-inflammatory cellular- as well as humoral immunity to M. leprae, 
thereby including read-outs for multiple classifications of the leprosy spectrum. Such tests 
can be useful tools in leprosy control programs for classification of leprosy and allow early 
diagnosis of leprosy or leprosy reactions, leading to timely treatment and reduced 
transmission.   
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Abstract 
 
Regulatory T (Treg) cells are known for their role in maintaining self-tolerance and balancing 
immune reactions in autoimmune diseases and chronic infections. However, regulatory 
mechanisms can also lead to prolonged survival of pathogens in chronic infections like 
leprosy and tuberculosis (TB). Despite high humoral responses against Mycobacterium 
leprae (M. leprae), lepromatous leprosy (LL) patients have the characteristic inability to 
generate T helper 1 (Th1) responses against the bacterium. 
In this study, we investigated the unresponsiveness to M. leprae in peripheral blood 
mononuclear cells (PBMC) of LL patients by analysis of IFN- responses to M. leprae before 
and after depletion of CD25
+ 
cells, by cell subsets analysis of PBMC and by 
immunohistochemistry of patients’ skin lesions. 
Depletion of CD25
+
 cells from total PBMC identified two groups of LL patients: 7/18 (38.8%) 
gained in vitro responsiveness towards M. leprae after depletion of CD25
+
 cells, which was 
reversed to M. leprae-specific T-cell unresponsiveness by addition of autologous CD25
+
 cells. 
In contrast, 11/18 (61.1%) remained anergic in the absence of CD25
+
 T-cells. For both groups 
mitogen-induced IFN- was, however, not affected by depletion of CD25+ cells.  In M. leprae 
responding healthy controls, treated lepromatous leprosy (LL) and borderline tuberculoid 
leprosy (BT) patients, depletion of CD25
+
 cells only slightly increased the IFN- response.  
Furthermore, cell subset analysis showed significantly higher (p = 0.02) numbers of FoxP3
+
 
CD8
+
CD25
+
 T-cells in LL compared to BT patients, whereas confocal microscopy of skin 
biopsies revealed increased numbers of CD68
+
CD163
+
 as well as FoxP3
+
 cells in lesions of 
LL compared to tuberculoid and borderline tuberculoid leprosy (TT/BT) lesions. Thus, these 
data show that CD25
+ 
Treg cells play a role in M. leprae-Th1 unresponsiveness in LL.  
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Author summary 
 
Leprosy is a curable infectious disease caused by Mycobacterium leprae (M. leprae) that 
affects the skin and peripheral nerves. It is manifested in different forms ranging from self-
healing, tuberculoid leprosy (TT) with low bacillary load and high cellular immunity against 
M. leprae, to lepromatous leprosy (LL) with high bacillary load and high antibody titers to M. 
leprae antigens. However, LL patients have poor cell mediated response against M. leprae 
leading to delayed clearance of the bacilli. A possible explanation for this bacterial 
persistence could lie in the presence of more regulatory cells at infection sites and in 
peripheral blood. This study shows the recovery of the cell mediated response by depletion of 
CD25
+
 cells in a subset of LL patients, while another patient subset was not affected similarly. 
Moreover, an increased frequency of FoxP3
+
 T cells together with anti-inflammatory 
macrophages was observed in LL patients’ skin biopsies. Thus, these data show that CD25+ 
Treg cells play a role in M. leprae-unresponsiveness in leprosy patients. 
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Introduction  
 
The human immune system strives to maintain the delicate balance between preventing host 
susceptibility to various pathogens and limiting immunopathology due to an exacerbated 
immune response to infections. Sub-populations of T-cells previously identified as suppressor 
T-cells and later as Treg cells are the major players in the regulatory network of the immune 
system [1,2]. Although the idea of suppressor T-cells was a key topic of research already in 
the 70’s and 80’s it was not successfully established because of poor cellular characterization, 
and it took until mid-1990’s before Treg cells were recognized as a different lineage [1]. More 
recently, studies clearly demonstrated the suppressive ability of this sub-population 
contributing to the re-acceptance of suppressor T-cell as a different T-cell lineage [3,4].  
 
Characterization of this T-cell sub-population has continued and currently the thymus-derived 
Treg cells (tTreg cells) and peripherally derived Treg cells (pTreg cells) [5] are the two widely 
accepted categories of Treg cells [1,6,7]. Both T-cell subtypes play a role in limiting immune 
reactions in autoimmune diseases and chronic infections [8–11]. In addition, CD39+ Treg cells 
have also been reported as a subset of the CD4
+
 CD25
high
FoxP3
+
 Treg cells in association with 
chronic infections like tuberculosis (TB) [12], hepatitis B (HBV) and in graft rejections 
[13,14] and the ability of CD8+ CD39+ Treg cells to suppress antigen specific CD4
+ 
proliferation clearly demonstrated the importance of this sub-population [15]. 
 
Leprosy is a chronic infectious disease leading to more than 200,000 new cases every year 
[16]. The remarkable inter-individual variability in clinical manifestations of leprosy closely 
parallels the hosts’ abilities to mount effective immune responses to M. leprae. This is clear 
from the well-known immunological and clinical spectrum in those who progress to disease 
ranging from polar T helper 1 (Th1) to Th2 responses. TT and BT show more dominant Th1 
responses which limit M. leprae growth resulting in clinical paucibacillary (PB) leprosy 
whereas, BL/LL patients demonstrate dominant Th2 responses as well as more permissive 
growth of M. leprae  resulting in clinical multibacillary (MB) leprosy. TT/BT patients in 
general show high cellular responses and low antibody titers to M. leprae antigens, and 
develop localized granuloma with often no detectable bacilli in their lesions. At the opposite 
pole, LL/BL patients are incapable to generate M. leprae specific Th1 cell responses, show 
high antibody titers to M. leprae antigens including PGL-I, with numerous bacilli and 
disorganized granuloma in their lesions. The borderline states of leprosy are immunologically 
unstable. The different outcomes of infection in leprosy are most likely caused by host 
defense mechanisms [17]. However, the mechanism underlying the M. leprae-specific T-cell 
anergy in LL patients is still not completely understood.  
 
In chronic bacterial or viral infections, evidence exists that Treg cells suppress effector T-cells 
(Teff cells) in order to limit damage to the host caused by the immune responses against 
pathogens [18]. In this situation, the regulatory activity of Treg cells may lead to prolonged 
survival of pathogens in the host [9,19]. As evidenced in a previous study, higher levels of 
CD4
+
CD25
+
FoxP3
+
 Treg cells were observed in active TB patients in the periphery compared 
to latently infected individuals and healthy controls [20,21]. Also, an increased number of Treg 
cells expressing FoxP3, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and glucocorticoid-
induced tumour-necrosis-factor-receptor-related protein (GITR) were reported in lymph 
nodes from children with tuberculosis lymphadenitis [22]. Similarly, in leprosy, higher 
numbers of Treg cells in PBMC from BL and LL patients stimulated with M. leprae cell wall 
antigen (MLCWA) were observed compared to TT/BT forms, indicating the possibility that 
Treg cells may have a role in persistence of M. leprae bacteria as well as unresponsiveness of 
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Th1 cells in BL/LL patients [23]. Recently, the mechanism of action of FoxP3 in CD4+CD25+ 
T cells derived from BL/LL leprosy patients  was shown to result from increased molecular 
interactions of FoxP3 with Histone deacetylases (HDAC7/9) in the nucleus of CD4
+
CD25
+
 T 
cells derived from BL/LL patients [24]. 
 
In the presence of pathogens, Treg cells can also be induced by certain macrophages as 
evidenced by the anti-inflammatory, CD163
+ 
macrophages, known as type 2 macrophages 
(mφ2), that exert a suppressive effect on Th1 responses [25,26]. On the other hand, IL-10 
induced phagocytosis of M. leprae by mφ2 without induction of microbicidal activity in LL 
lesions has been described [27] indicating the role of IL-10 producing Treg cells in the 
persistence of the pathogen within the host. Similarly, the presence of higher IL-10 
expression correlated with increased CD163 and indoleamine 2,3-dioxygenase (IDO) proteins 
in tissues and sera of LL patients further evidenced their potential [28]. 
 
In this study, we have investigated the functional role of CD25
+
 Treg cells in M. leprae 
unresponsiveness of LL patients as well as the frequency of CD25
+
 and FoxP3
+
 cells in the 
PBMC of leprosy patients. Additionally, lesions of LL and TT/BT patients were assessed for 
the presence of FoxP3
+
 cells and CD163
+
 macrophages (mφ2). 
 
Materials and Methods 
 
Ethical statement. Ethical approval of the study protocol was obtained from the National 
Health Research Ethical Review committee, Ethiopia (NERC # RDHE/127-83/08) and the 
Nepal Health Research Council (NHRC #751). Participants were informed about the study 
objectives, the required amount and kind of samples and their right to refuse to take part or 
withdraw from the study at anytime without consequences for their treatment. Written and 
Informed consent was obtained from study participants before enrollment.  
Study participants. The following HIV-negative individuals were recruited on a voluntary 
basis: newly diagnosed, non reactional leprosy patients from Ethiopia (ALERT hospital, 
Addis Ababa, Ethiopia) classified as LL (n=40) and TT/BT (n=16) and healthy endemic 
controls from health centers in Addis Ababa (EC; n=5); Treated, non reactional LL (n=6) and 
TT/BT (n=9) patients and EC (n=10) from Anandaban Hospital, (Kathmandu, Nepal); and 
non-endemic Dutch healthy controls (NEC; n=13). Leprosy was diagnosed based on clinical, 
bacteriological and histological observations and classified by a skin biopsy evaluated 
according to the Ridley and Jopling classification [17] by qualified microbiologists and 
pathologists. All patients were enrolled before treatment was initiated. EC were assessed for 
the absence of clinical signs and symptoms of tuberculosis and leprosy. Individuals working 
in health facilities were excluded as EC.  
PBMC Isolation, freezing and thawing. PBMC were isolated by Ficoll-Hypaque density 
gradient method, cells were washed and suspended in 20% fetal calf serum (FCS) in AIM-V 
(Invitrogen, Carlsbad, CA) and kept cool on ice, counted and frozen using a cold freshly 
prepared freezing medium composed of 20% FCS, 20% dimethyl sulphoxide (DMSO) in 
AIM-V. Cells were kept at -80 C for 2-3 days and transferred to liquid nitrogen until use. 
During thawing, cells were transported in liquid nitrogen to a water bath (37
o
C) for  30 to 40 
seconds until thawed half way and resuspended in 10% FCS in AIM-V (37
o
C) containing 
1/10,000 benzonase until completely thawed, washed 2 times (5-7 minutes each) and counted. 
The percentage viability obtained was > 75% and cells were incubated with anti-CD25 
magnetic beads or used for FACS analysis.  
CD25 
+
cell separation. Frozen PBMC were thawed, washed and incubated with 20µl of the 
CD25 micro beads II, human (Miteny Biotec, Bergisch Gladbach, Germany) in 80µl MACS 
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buffer (Phosphate-buffered saline (PBS) with 0.5% Bovine serum albumin (BSA) and 2mM 
EDTA) for 20 minutes at 4
o
C. Cells were washed and added to MS column attached to 
Magnetic Cell Sorter (MACS) (Milteny Biotec) where CD25
- 
cells were collected as flow 
through and the CD25
+ 
population was collected by detaching the column from the magnetic 
cell sorter. Cells were washed with MACS buffer and resuspended in AIM-V medium. The 
purity of the CD25
- 
and CD25
+
cell populations was > 80% (supplementary figure S2A and 
S2B).  
Lymphocyte stimulation tests (LST). Total PBMC (150,000 cells/well), CD25
-
 cells 
(150,000 cells/ well) or CD25
-
 cells with proportionally added CD25
+ 
cells (10,000 and/or 
25,000) were added in triplicate into 96 well U bottom tissue culture plates and cultured with 
M. leprae whole cell sonicate (WCS; 10 µg/ml), phytohaemagglutinin (PHA; 1 µg/ml) or 
AIM-V medium at 37
o
C with 5% CO2 and 70% humidity. After 6 days, supernatants were 
collected and kept frozen until used in ELISA. 
M. leprae whole cell sonicate (WCS). Irradiated armadillo-derived M. leprae whole cells 
were probe sonicated with a Sanyo sonicator to >95% breakage. This material was kindly 
provided by Dr. J.S. Spencer through the NIH/NIAID “Leprosy Research Support” Contract 
N01 AI-25469 from Colorado State University (now available through the Biodefense and 
Emerging Infections Research Resources Repository listed at 
(http://www.beiresources.org/TBVTRMResearch Materials/tabid/1431/Default.aspx). 
IFN- ELISA. IFN- levels were determined by ELISA (U-CyTech, Utrecht, The 
Netherlands) [29]. The cut-off value to define positive responses was set beforehand at100 
pg/ml. The assay sensitivity level was 40 pg/ml. Values for unstimulated cell cultures were 
typically < 40 pg/ml.  
Flow cytometry. After depletion, the total PBMC, CD25
-
 or CD25
+
 populations (25,000 to 
200,000 cells) were stained for CD3 (clone SK7, PerCP; Becton, Dickinson and Company, 
New Jersey, USA), CD4 (clone SK3, FITC; BD) and CD25 (PE; MACS) to check the purity.  
Frozen PBMC of patients and healthy controls (2 x 10
6
 cells/ml) were thawed, washed and 
treated with benzonase (10 U/ml, Novagen, Merck4Biosciences, Merck KGaA, Darmstadt, 
Germany) for 2 hours prior to in vitro stimulation with PMA (20ng/ml)/ionomycine (500 ng/ml) 
in the presence of 1 µg/ml anti CD28 (Sanquin, the Netherlands) and 1 µg/ml anti CD49d (BD 
Biosciences, Eerbodegem, Belgium). After 4 hours, Brefeldin A (Sigma Aldrich) was added at 
3 µg/ml and cells were left for an additional 16 hours in the incubator at 37
o
C with 5% CO2 and 
70% humidity. After live/dead staining with Vivid (Invitrogen, Life technologies, Merelbeke, 
Belgium), surface staining was performed for 30 minutes at 4°C with the labeled antibodies 
directed against: CD14-Pacific Blue, CD19-Pacific Blue (eBioscience), CD3-PE-TexasRed 
(Invitrogen, Life technologies), CD8-Horizon V500, CD4-Pe-Cy7, CD25-APC-H7 (all BD 
Biosciences, CD39-PE (Biolegend, ITK Diagnostics, Uithoorn, The Netherlands). Samples 
were washed, fixed and intracellular staining was performed using the intrastain kit (Dako 
Diagnostics, Glostrup, Denmark) with IFN-γ -Alexa700 (BD Biosciences), IL-10 APC 
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), and FoxP3 PE-Cy5 (eBioscience, 
Hatfield, UK) labeled antibodies. Cells were acquired on a FACS LSR Fortessa with Diva 
software (BD Biosciences, The Netherlands) and analyzed with FlowJo version 9.4.1 (Tree 
Star, Ashland, OR, USA). The full gating strategy for live CD4
+
 CD3
+ 
cells or CD8
+
 CD3
+ 
cells (supplementary Figure S1A and S1B) was performed in compliance with the most 
recent MIATA [30] guidelines according to the following procedure: events were first gated 
using a forward scatter area (FSC-A) versus height (FSC-H) plot to remove doublets. 
Subsequently, the events were subjected to a lymphocyte gate using a side scatter (SSC) 
followed by a live/dead gating. Then, live CD3
+ 
cells were gated and CD14
+
 and CD19
+ 
events were excluded from analysis using a dump channel. Finally, CD3 live cells were 
separated in to CD4
+
 and CD8
+
. After the gates for each function were created, we used the 
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Boolean gate platform to identify all functions within each cell preparation using the full 
array of possible combinations.  
Immunohistochemistry and confocal microscopy. Skin biopsies taken from leprosy lesions 
of LL (n=10) and TT/BT (n=4) patients were fixed in formalin and embedded in paraffin. 
Tissue sections with 4 m thickness were prepared using a microtome (LEICA RM 2165). 
The prepared tissues sections were stained for hematoxylin and eosine (H & E; images are 
shown in supplementary figure S3) and also used as previously described [31] for 
immunofluorescence staining. Tissue sections were deparaffinised and rehydrated using 
graded concentrations of ethanol to distilled water. Antigen retrieval was performed in 
boiling Tris-EDTA buffer (10mM Tris Base, 1mM EDTA Solution, 0.05% Tween 20, pH 9.0) 
for 12 minutes. After two hours of cooling at room temperature in antigen retrieval buffer, 
slides were washed twice in distilled water and twice in PBS, blocked for 15 min with 5% 
goat serum in PBS, washed again with PBS and stained with primary antibodies for FoxP3 
(1:100, mouse anti-human IgG1 Abcam; Cambridge, UK), CD8 (1:100 mouse anti-human 
IgG2b, Abcam), CD68 (mouse anti-human IgG2a AbD serotec/Bio-Rad; Veenendaal, The 
Netherlands), CD163 (1:400, mouse anti-human IgG1, Leica; Rijswijk, The Netherlands) and 
CD39 (1:100, mouse anti-human IgG2a, Abcam). Two antibodies were used per tissue 
section: FoxP3 with CD68, CD163, CD39 or CD8; CD68 with CD163 and CD39 with 
CD163. After overnight incubation at room temperature in the dark, sections were washed 
and incubated for 1 hour in the dark with secondary antibodies; goat-anti-mouse IgG1 
coupled with Alexa 488 (1:200) (Invitrogen, Bleiswijk The Netherlands), goat-anti-mouse 
IgG2a or goat-anti-mouse IgG2b with Alexa 546 (1:200) (Invitrogen). Tissue sections were 
then washed three times with PBS and mounted with Vectashield (DAPI, 4', 6-diamidino-2-
phenylindole; Vector Laboratories, Brussels, Belgium). Immunofluorescence of skin sections 
was examined and images were taken from 5 different fields per section using a Leica-TCS-
SP5 confocal laser scanning microscope (Leica Microsystems, Mannheim, Germany). 
Nucleated cells that positively stained for the specific marker were counted from five 
different fields per section by two laboratory persons independently. Average counts for each 
marker per section were compared for all samples.  
Statistical analysis. Differences in cytokine concentrations were analyzed with the two-
tailed Mann-Whitney U test or Wilcoxon signed rank test for non-parametric distribution 
using GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego California 
USA; www.graphpad.com) P-values were corrected for multiple comparisons. The statistical 
significance level used was p<0.05.  
 
Results 
 
Depletion of CD25
+
 cells enhanced pro-inflammatory response in LL patients  
To analyse the role of CD25
+
 cells in the production of IFN-, PBMC from Ethiopian LL 
patients (n=17) and Dutch healthy controls (n=12) were depleted of CD25
+
 cells and cell 
subsets with and without re-added CD25
+
 cells were stimulated with M. leprae WCS in 6 
days culture.  
 
PBMC from treated Nepali LL (n=6), BT (n=9) patients and EC (n=10) were depleted for 
CD25
+
 cells but only the total PBMC and CD25
-
cell subset were stimulated with M. leprae 
WCS. When compared according to clinical classification, there was a trend of higher IFN-  
production in PB compared to MB samples. IFN- production of total PBMC (undepleted 
fraction) from LL patients in response to M. leprae (WCS) was significantly lower (p = 0.001) 
compared to responses by PBMC from TT/BT patients, whereas IFN- responses to PHA 
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were high in both groups (Fig 1). These data further confirm the M. leprae-specific lack of 
cell mediated immunity (CMI) in LL patients.  
 
Analysis of IFN- production in response to M. leprae (WCS) by CD25- cells alone or CD25- 
cells (150,000 cells per well) supplemented with the CD25
+
 fraction (10,000 or 25,000 
cells/well) discriminated two groups of LL patients: those that produced IFN- in response to  
M. leprae after CD25
+
 cell depletion and those that did not (Fig 2A, 2B and 2E). Among the 
18 LL Ethiopian patients, 7 (38%) responded to M. leprae WCS after depletion of CD25
+
 
cells whereas they lacked any response in total PBMC. IFN- production in response to PHA 
in both groups was not affected by the depletion of or enrichment with CD25
+
 cells.  
 
In the LL patient group, in which recovery of IFN- responses was observed to M. leprae 
WCS after depletion of CD25
+
 cells, this could be reversed proportionally by the addition of 
CD25
+
 cells (Fig 2A). In the patient group in which CD25
+
 cell depletion did not reverse 
anergy to M. leprae, there was no effect observed by addition of CD25
+
 cells to the depleted 
fraction (Fig 2B). 
 
In similar analysis of treated leprosy patients (LL and BT) and endemic controls from a 
Nepali population, PBMC responded to M. leprae WCS in the presence of CD25
+
 cells and a 
slight increase in IFN- γ levels after CD25+ cell depletion was also observed (Fig 2C). 
Similarly, healthy Dutch controls (n=8) responding to M. leprae WCS before depletion of 
CD25
+
 cell showed a slight increase after depletion (Fig 2D left panel) as well, while other 
NEC (n=5) remained unresponsive after CD25
+
 cell depletion (Fig 2D right panel).  
 
FoxP3 expressing CD8
+
 CD25
+
 T-cell are more abundant in PBMC of LL  
For cell subset analysis, PBMC from Ethiopian LL (n=13), TT/BT (n=5) and EC (n=7) and 
Dutch healthy controls (NEC; n=4) were stained for surface and intra-cellular markers. The 
frequency of FoxP3
+
 CD8
+
CD25
+
 cells was significantly higher in PBMC of LL patients 
compared to TT/BT patients (p = 0.02) (Fig. 3). Although not statistically significant (p= 
0.05), we also observed a higher frequencies of FoxP3
+
 CD4
+ 
CD25
+
 T-cell in the LL group 
compared to the TT/BT patients (Fig. 3). In contrast, analysis of the frequency of IL-10 
producing CD4
+ 
CD25
+
 or CD8
+
CD25
+
 T-cell showed no significant differences between 
patients and healthy controls. The frequency of IL-10 production in CD4
+ 
CD25
+
 or 
CD8
+
CD25
+
 T-cell in general was very low in all groups.  
 
Mφ2 (CD68+ CD163+) and FoxP3+ cells are more frequent in skin lesions of LL patients  
Confocal analysis of two-colour immunofluorescence was used to localize specific cell 
markers in skin biopsies of Ethiopian LL (n=10) and TT/BT (n=4) leprosy patients. Higher 
number of CD68
+
 cells in LL lesions (p = 0.02) (Table 1, Fig.4A, 5A and B) indicated the 
presence of more infiltrating macrophages compared to TT/BT (Fig.5C and D). In addition, 
CD68
+
 CD163
+
 cells (mφ2) and FoxP3+ cells were present to a larger extent in LL patients’ 
lesions (p = 0.02) compared to TT/BT (Table 1 and Fig. 4B, 4C, 5C and 5D). With respect to 
the numbers of CD68
+
 CD163
+
 cells (mφ2) and FoxP3+ cells, differences were observed 
among the LL patients which could be explained by variations in the time elapsed since skin 
lesions were noticeable or by influence of other host factors. Although we found significantly 
higher frequency of CD8
+
FoxP3
+
 in PBMC, we could not clearly detect CD8
+
FoxP3
+ 
in skin 
lesions indicating CD4
+
FoxP3
+
 cells could play a regulatory role in these tissues. In addition, 
skin lesions were stained with CD39 combined with FoxP3 to localize CD39
+
FoxP3
+
 
regulatory T-cells. However, in most skin tissues, CD39
+
 cells were not detected except for 
two LL skin tissues in which CD39 and FoxP3 positivity was observed simultaneously in 
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macrophage-like shaped cells (Fig 4E). Thus, these results indicate the induction of more 
FoxP3
+
 but not CD39
+
 Treg cells in LL patients’ skin lesions probably by the presence of 
type 2 macrophages.  
 
Discussion 
 
Decreased M. leprae-specific T-cell mediated immunity is the hall mark of lepromatous 
multibacillary leprosy and can be assessed by in vitro unresponsiveness to M. leprae 
(antigens) or clonal anergy [2,23,32]. In this study, we confirm the M. leprae-specific 
unresponsiveness by the absence of IFN- responses to M. leprae WCS.   
 
 
Figure 1. IFN- responses to PHA and M. leprae whole cell sonicate (WCS) by PBMC of TT/BT (n=7), BB/BL 
(n=9) and LL (n=16) patients. Median values for each group are indicated by horizontal lines. 
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Figure 2. IFN- responses of total PBMC, CD25- cells and CD25- cells supplemented with CD25+ cells from LL 
patients. (A) representatives for the group responding to M. leprae after depletion of CD25
+
 cells (n = 7); (B) 
representatives for the group not responding to M. leprae after depletion of CD25
+
 cells (n = 11); (C) LL005 and 
LL010 representatives for Nepali treated LL patients (n=10), BT004 and BT006 representatives for Nepali 
treated BT patients (n=7) and EC020 and EC023 representatives for Nepali EC (n=10) before and after 
depletion of CD25
+
 cells; (D) NEC001 and NEC002 representatives for healthy Dutch controls (n=10) after 
depletion of CD25
+
 cells with and without response to M. leprae WCS; (E) Dot plot graph showing IFN- 
responses of both groups of Ethiopian LL patients  in dot-plot graph. Medium indicates AIM-V medium used in 
the assays as negative control. In 2A and 2B: for LL001, CD25-25000 and for LL052 and LL053, CD25-10000 
were not done. 
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Figure 3. T-cell subset analysis of PBMC from LL, TT/BT and the control group consisting of EC and NEC 
showing the frequencies of FoxP3 expressing T-cells and IL-10 producing FoxP3
+
 T-cells.  
 
Figure 4. Immunohistochemical analysis of skin lesions of LL (n=10) and BT patients (n=4) showing the 
number of  (A) CD68
+ 
cells (B) CD68
+
 CD163
+
 cells and (C) FoxP3
+
 cells. 
 
Several studies have investigated the possible causes leading to hyporesponsiveness in LL 
patients such as formation of foamy macrophages in presence of IL-10 [27], cholesterol 
dependent dismantling of HLA-DR raft in macrophages of BL/LL [33] and other factors, 
including Treg cells. Some of these studies on Treg cells have shown their presence and role 
either in the periphery or in skin lesions through measuring Treg associated markers, mainly 
CD25, TGF-β, CTLA4, IL-10, and FoxP3 [23,24,34,35, 45]. Recently, Teles et al. showed 
higher expression of IFN- and the downstream vitamin D-dependent antimicrobial pathway 
related genes including CYP27B1 and VDR (Vitamin D receptor) in TT/BT as well as an 
increased IL-10 expression induced by IFN-β in LL lesions [36]. Some reports have revealed 
the limitations of the available Treg markers due to their lack of specificity [37–39]: CD25, for 
example, is expressed on activated T and B cells and is not exclusively found on Treg cells. 
However, noting that CD25 is still a crucial marker for Treg cells in the unstimulated situation, 
we performed depletion of CD25
+
 cells from unstimulated PBMC to isolate the Treg cells and 
demonstrated their involvement in M. leprae-specific unresponsiveness in LL patients.   
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The BL/LL patients are known for their poor CMI and this is commonly assessed by 
measuring IFN- responses to M. leprae WCS. The total PBMC of the LL patients were 
analysed along with the CD25
+ 
depleted and enriched fraction for their IFN- responses to M. 
leprae WCS and was negative. However, the depletion of CD25
+
 cells from total PBMC of 
LL patients showed an enhanced pro-inflammatory response as measured by the level of IFN-
 in response to M. leprae WCS in some but not all patients. Two distinct groups of LL 
patients were identified after depletion of CD25
+ 
cells; 38% (7/18) of the LL patients showed 
enhanced IFN- responses in the CD25- population while the remaining 62% of the LL 
patients did not respond to M. leprae WCS at all. The recovered IFN- production in the first 
group was reversed by addition of CD25
+
 cells, clearly indicating that this CD25
+
 cell 
population conferred the unresponsiveness in these LL patients. However, we did not stain 
the CD25
+
 cell populations with FoxP3 which could have allowed more detailed 
characterization as CD25
high
 FoxP3 or CD25
low
 FoxP3 sub-populations which might have 
explained differences between the responders and non-responders. Nonetheless, the presence 
of non-responding LL patients after depletion of CD25
+
 cells indicates  that CD25
+
 Treg cells 
do not represent the sole factor responsible for T-cell anergy in LL leprosy. As the Th1 arm is 
responsible for killing and clearing bacilli, there could have been enormous damage to tissues 
in BL/LL patients where high load of bacilli and antigens are available. However, the 
presence of Treg in these patients represents one important factor that can avoid tissue damage 
but, on the other hand, creates a convenient environment for bacilli to survive through 
suppression of Th1 response. In addition, the significant IFN- production observed in treated 
LL patients in our study before depletion of CD25
+
 T cells showed how treatment and 
thereby the level of bacillary load can influence the Th1 response and Treg.  Similar findings 
were reported for TB patients with recovered IFN- production and reduced number of Treg 
cells after treatment [21,40]. The slight increases observed in IFN- production after depletion 
of CD25
+
 T cells in treated LL and BT patients and in EC tested in the depletion experiments 
could also indicate the regular presence of Treg cells to maintain homeostasis in the host. 
However, the overall ratio of CD25
+
 Treg cells to effector T cells will be crucial in 
determining the outcome of M. leprae infection in the host. 
 
Previous studies which aimed at identifying potential factors for M. leprae-specific 
unresponsiveness in LL used the addition of IL-2 [2,41–43] or anti-DQ monoclonal 
antibodies [44] or offered isolated antigenic fractions of M. leprae. Interestingly, each of the 
studies similarly identified two groups of LL patients, in one of which M. leprae 
unresponsiveness could be reversed. This indicated that the unresponsive phenotype in LL 
patients is likely mediated through the collective effects of various molecules. The more 
recent observation of cholesterol-dependent dismantling of HLA-DR raft and an increased 
membrane fluidity in BL/LL patients which causes a major defect in antigen presentation 
provides additional evidence for the presence of multiple different factors leading to T-cell 
anergy [33]. Thus, M. leprae specific unresponsiveness/anergy in LL patients very likely is a 
complex phenomenon mediated by multiple host and pathogen associated factors, one of 
which is represented by Treg cells.  
 
Several studies have reported on the ex vivo frequency of Treg cells in peripheral blood of LL 
and TT/BT patients in unstimulated or M. leprae antigens stimulated PBMC [23,35]. Attia et 
al. showed, elevated frequencies of circulating Treg cells (CD4
+
CD25
high
FoxP3
+
) in TT 
patients [35] whereas Palermo et al., showed that PBMC stimulated with M. leprae antigen 
for 6 days in culture had significantly higher number of Treg cells (CD4
+
 CD25
+
FoxP3
+
) in 
LL patients [23]. Recently, Saini et al., further confirmed the importance of Tregs in LL non-
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responsiveness by measuring TGF-  producing CD4
+
 CD25
+
FoxP3
+
 cells in stimulated 
PBMC culture [45]. In this study, we analysed the frequency of Treg cells in PBMC briefly 
activated with PMA/ionomycin. The frequency of CD4
+
 CD25
+
FoxP3
+
 cells was higher in 
LL compared to BT but not statistically significant (Fig 3). However, with the visible 
difference observed between LL and BT and with the evidences from previous studies, their 
presence and role in BL/LL patients cannot be denied. For example, the recent molecular 
analysis of FoxP3 in CD4
+
CD25
+
 T cells nuclei has revealed that the FoxP3 interaction with 
histone deacetylases drives the immune suppression by CD4
+
 CD25
+
 Tregs in BL/LL unlike in 
other forms of leprosy [24]. 
 
On the other hand, the frequency of CD8
+
 CD25
+
FoxP3
+
 cells found in this study was 
significantly higher in LL (Fig 3). This suggests that FoxP3
+
 CD8
+
 CD25
+
 Treg cells may also 
play a role in unresponsiveness in LL although not specifically analyzed for their functional 
role in our depletion experiments. Although lower in frequency compared to the CD4
+
 
CD25
+
FoxP3
+
, Saini et al., also reported higher numbers of CD8
+
 CD25
+
FoxP3
+
 in LL 
compared to BT but without induction of TGF-β [45]. Most studies focused on CD4+ 
CD25
+
FoxP3
+
 in leprosy [23,35]. In contrast one study on LL lesions showed the presence of 
increased numbers of CD8
+
 T cells with suppressive type in LL indicating the importance of 
CD8
+
 Treg cells in leprosy [46]. In addition few other studies identified CD8
+
 Treg as a 
potential suppressive sub-population [47,48]. Recent evidence from an in vitro study also 
revealed CD8
+
 Treg cells (CD8
+
 LAG-3
+ 
FoxP3
+
CTLA-4
+
) induced by matured plasmacytoid 
dendritic cells (pDC) with suppression activity on allo-reactive T memory cells [49]. In our 
opinion, the CD8
+
 Treg population is not sufficiently studied in leprosy and we believe 
further analysis of this population in all forms of leprosy in periphery and lesionary tissues 
will be vital.  
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Figure 5. Immunohistochemical analysis (Original magnification, 400x; image size 359m x 359 m) of skin 
lesions. Sequential skin sections from LL (n = 10) and BT (n = 4) patients were stained with mAb specific for 
CD68 (red) and FoxP3 (green) [A, B, E, F], for CD68 (red) and CD163 (green) [C, D] and CD39 (red) [G]. 
Representatives LL [A, B, C, D, and G] and BT [E, F,] patients are shown.  
Insets represent 1500x magnification of FoxP3
+
 cells [A, B]; 800x magnification of CD68
+
 CD163
+
 [C, D]; 
1000x magnification of CD39
+ 
cells [G]. 
 
The low IL-10 frequency measured by FACS analysis in all groups did not allow detection of 
significant differences among groups as expected in view of the crucial role of IL-10 as an 
anti-inflammatory cytokine in the unresponsiveness in LL patients [27,36]. This could be due 
to the short PMA/ionomycin stimulation inherent to the procedure for ex vivo determination 
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of the frequency of CD25
+
 cells. However, 6 days stimulation of PBMC from BL patients 
with M. leprae induced high levels of IL-10 [50].  
 
Although, it will not be easy to generalize or conclude on frequencies and numbers of CD4
+
 
CD25
+
FoxP3
+
 Treg cells in different forms of leprosy since the experimental procedures used 
in each study vary, most of the studies including ours, point to the presence of increased 
numbers of Treg cells in LL patients either in periphery as well as lesions. Detailed 
characterization of Treg cell subsets in large cohorts of leprosy patients as well as the ratio to 
effector T cells may provide additional insights in this area.  
 
The dominant presence of CD163
+
 macrophages in LL lesions [27,28] and the significantly 
higher expression of IL-10 and CTLA4 in LL tissues have been reported previously [25]. The 
role of Treg cells (FoxP3
+ 
GITR
+
 CD25
+
) and their induction by CD163
+
 anti-inflammatory 
human macrophages was demonstrated in vitro since CD4
+
 T-cells gained a potent 
regulatory/suppressor phenotype and functions after activation by mφ2 [25]. In the current 
study, we show the presence of significantly higher number of CD68
+ 
CD163
+cells (mφ2) in 
the vicinity of FoxP3
+
 cells in LL lesions compared to TT/BT lesions. These findings support 
the involvement of both cell types in the induction and/or maintenance of M. leprae directed 
Treg cells in LL lesions. 
 
Since a suppressive effect of CD4
+
CD39
+
FoxP3
+
 Treg cells was described in TB patients [12], 
we also analysed the frequency of CD39
+
FoxP3
+
 cells in PBMC but observed no differences 
between LL and TT/BT patients except for few LL skin lesions, in which macrophage-shaped 
CD39
+
 cells were observed. A recent study has shown that CD39 expression on macrophages 
has an important role in self-regulation mechanism during inflammation [51]. These cells 
may also play a similar role in LL patients but this has to be further analysed. 
 
In summary, this study clearly show that CD25
+
 Treg cells play a role in unresponsiveness in 
LL, and that there are two subtypes of M. leprae unresponsive LL patients. Furthermore, the 
co-existence of Treg cells with mφ2 in LL lesions further supports the potential role of these 
regulatory cell subsets at the site of infection.  
 
Acknowledgements 
 
The authors gratefully acknowledge Dr. Nigel Savage (Dept. of Infectious Diseases, LUMC) 
for expert-advice on tissue staining. We thank Yonas Fantahun, S/r Genet Amare, Selfu 
Girma, Dr Mihret and Dr. Saba M. Lambert from AHRI/ALERT, Ethiopia and Murdo 
Macdonald, Bishwa Sapkota and Chaman Ranjit from MLR, Anandaban Hospital, Nepal for 
the support in the recruitment and sample collection process. AHRI, LUMC and MLR are 
members of the IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) 
Consortium.  
Chapter 6 
 
 
190 
 
References 
 
 1.  Sakaguchi S, Wing K, Miyara M (2007) Regulatory T cells - a brief history and perspective. Eur J 
Immunol 37 Suppl 1: S116-S123. 10.1002/eji.200737593 [doi]. 
 2.  Ottenhoff TH, Elferink DG, Klatser PR, de Vries RR (1986) Cloned suppressor T cells from a 
lepromatous leprosy patient suppress Mycobacterium leprae reactive helper T cells. Nature 322: 462-464. 
10.1038/322462a0 [doi]. 
 3.  Modlin RL, Mehra V, Wong L, Fujimiya Y, Chang WC, et al. (1986) Suppressor T lymphocytes from 
lepromatous leprosy skin lesions. J Immunol 137: 2831-2834. 
 4.  Mutis T, Cornelisse YE, Datema G, van den Elsen PJ, Ottenhoff TH, et al. (1994) Definition of a human 
suppressor T-cell epitope. Proc Natl Acad Sci U S A 91: 9456-9460. 
 5.  Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S,et al. (2013) Regulatory T cells: 
recommendations to simplify the nomenclature. Nat Immunol 14: 307-308. ni.2554 [pii];10.1038/ni.2554 
[doi]. 
 6.  Mills KH (2004) Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4: 841-855. 
nri1485 [pii];10.1038/nri1485 [doi]. 
 7.  Belkaid Y (2007) Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 7: 875-888. 
nri2189 [pii];10.1038/nri2189 [doi]. 
 8.  Nouri-Aria KT, Durham SR (2008) Regulatory T cells and allergic disease. Inflamm Allergy Drug 
Targets 7: 237-252. 
 9.  Sanchez AM, Yang Y (2011) The role of natural regulatory T cells in infection. Immunol Res 49: 124-
134. 10.1007/s12026-010-8176-8 [doi]. 
 10.  Dons EM, Raimondi G, Cooper DK, Thomson AW (2012) Induced regulatory T cells: mechanisms of 
conversion and suppressive potential. Hum Immunol 73: 328-334. S0198-8859(11)00602-1 
[pii];10.1016/j.humimm.2011.12.011 [doi]. 
 11.  Belkaid Y, Tarbell K (2009) Regulatory T cells in the control of host-microorganism interactions. Annu 
Rev Immunol 27: 551-589. 10.1146/annurev.immunol.021908.132723 [doi]. 
 12.  Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, et al. (2009) Characterization of regulatory T cells 
identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. Clin Exp Immunol 156: 
463-470. CEI3908 [pii];10.1111/j.1365-2249.2009.03908.x [doi]. 
 13.  Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, et al. (2010) Expression of CD39 by human 
peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 10: 
2410-2420. 10.1111/j.1600-6143.2010.03291.x [doi]. 
 14.  Tang Y, Jiang L, Zheng Y, Ni B, Wu Y (2012) Expression of CD39 on FoxP3+ T regulatory cells 
correlates with progression of HBV infection. BMC Immunol 13: 17. 1471-2172-13-17 
[pii];10.1186/1471-2172-13-17 [doi]. 
 15.  Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SA (2013) CD39 is involved in 
mediating suppression by Mycobacterium bovis BCG-activated human CD8 CD39 regulatory T cells. 
Eur J Immunol . 10.1002/eji.201243286 [doi]. 
 16.  2013 Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec 88: 365-379. 
 17.  Ridley DS, Jopling WH (1966) Classification of leprosy according to immunity. A five-group system. Int 
J Lepr Other Mycobact Dis 34: 255-273. 
 18.  Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN (2007) Regulatory T cells and human disease. 
Clin Dev Immunol 2007: 89195. 10.1155/2007/89195 [doi]. 
 19.  Gravano DM, Vignali DA (2012) The battle against immunopathology: infectious tolerance mediated by 
regulatory T cells. Cell Mol Life Sci 69: 1997-2008. 10.1007/s00018-011-0907-z [doi]. 
 20.  Wergeland I, Assmus J, Dyrhol-Riise AM (2011) T regulatory cells and immune activation in 
Mycobacterium tuberculosis infection and the effect of preventive therapy. Scand J Immunol 73: 234-242. 
10.1111/j.1365-3083.2010.02496.x [doi]. 
 21.  Ribeiro-Rodrigues R, Resende CT, Rojas R, Toossi Z, Dietze R, et al.(2006) A role for CD4+CD25+ T 
cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 144: 25-34. 
CEI3027 [pii];10.1111/j.1365-2249.2006.03027.x [doi]. 
 22.  Rahman S, Gudetta B, Fink J, Granath A, Ashenafi S, et al. (2009) Compartmentalization of immune 
responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory t 
cells in the granulomatous lesions. Am J Pathol 174: 2211-2224. S0002-9440(10)61080-2 
[pii];10.2353/ajpath.2009.080941 [doi]. 
 23.  Palermo ML, Pagliari C, Trindade MA, Yamashitafuji TM, Duarte AJ, et al. (2012) Increased expression 
of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am J Trop Med Hyg 86: 
878-883. 86/5/878 [pii];10.4269/ajtmh.2012.12-0088 [doi]. 
                                                                                                                                                      Tregs in leprosy
             
191 
 
 24.  Kumar S, Naqvi RA, Ali R, Rani R, Khanna N, et al. (2013) CD4+CD25+ T regs with acetylated FoxP3 
are associated with immune suppression in human leprosy. Mol Immunol 56: 513-520. S0161-
5890(13)00170-3 [pii];10.1016/j.molimm.2013.04.015 [doi]. 
 25.  Savage ND, de BT, Walburg KV, Joosten SA, van MK, et al. (2008) Human anti-inflammatory 
macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound 
TGFbeta-1. J Immunol 181: 2220-2226. 181/3/2220 [pii]. 
 26.  Verreck FA, de BT, Langenberg DM, van der Zanden L, Ottenhoff TH (2006) Phenotypic and functional 
profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to 
microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol 79: 285-293. 
jlb.0105015 [pii];10.1189/jlb.0105015 [doi]. 
 27.  Montoya D, Cruz D, Teles RM, Lee DJ, Ochoa MT, et al. (2009) Divergence of macrophage phagocytic 
and antimicrobial programs in leprosy. Cell Host Microbe 6: 343-353. S1931-3128(09)00311-4 
[pii];10.1016/j.chom.2009.09.002 [doi]. 
 28.  Moura DF, de Mattos KA, Amadeu TP, Andrade PR, Sales JS, et al. (2012) CD163 favors 
Mycobacterium leprae survival and persistence by promoting anti-inflammatory pathways in lepromatous 
macrophages. Eur J Immunol 42: 2925-2936. 10.1002/eji.201142198 [doi]. 
 29.  Geluk A, van der PJ, Teles RO, Franken KL, Prins C, et al. (2008) Rational combination of peptides 
derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. 
leprae infection. Clin Vaccine Immunol 15: 522-533. 
 30.  Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, et al. (2012) T cell assays and 
MIATA: the essential minimum for maximum impact. Immunity 37: 1-2. S1074-7613(12)00291-9 
[pii];10.1016/j.immuni.2012.07.010 [doi]. 
 31.  Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, et al. (2008) Human leukocyte antigen class I, 
MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines 
survival of cervical cancer patients? Clin Cancer Res 14: 2028-2035. 14/7/2028 [pii];10.1158/1078-
0432.CCR-07-4554 [doi]. 
 32.  Ottenhoff TH, Elferink DG, de Vries RR (1984) Unresponsiveness to Mycobacterium leprae in 
lepromatous leprosy in vitro: reversible or not? Int J Lepr Other Mycobact Dis 52: 419-424. 
 33.  Kumar S, Naqvi RA, Khanna N, Rao DN (2011) Disruption of HLA-DR raft, deregulations of Lck-ZAP-
70-Cbl-b cross-talk and miR181a towards T cell hyporesponsiveness in leprosy. Mol Immunol 48: 1178-
1190. S0161-5890(11)00091-5 [pii];10.1016/j.molimm.2011.02.012 [doi]. 
 34.  Massone C, Nunzi E, Ribeiro-Rodrigues R, Talhari C, Talhari S, et al. (2010) T regulatory cells and 
plasmocytoid dentritic cells in hansen disease: a new insight into pathogenesis? Am J Dermatopathol 32: 
251-256. 10.1097/DAD.0b013e3181b7fc56 [doi]. 
 35.  Attia EA, Abdallah M, Saad AA, Afifi A, El TA, et al. (2010) Circulating CD4+ CD25 high FoxP3+ T 
cells vary in different clinical forms of leprosy. Int J Dermatol 49: 1152-1158. 10.1111/j.1365-
4632.2010.04535.x [doi]. 
 36.  Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, et al. (2013) Type I interferon suppresses 
type II interferon-triggered human anti-mycobacterial responses. Science 339: 1448-1453. 
science.1233665 [pii];10.1126/science.1233665 [doi]. 
 37.  Corthay A (2009) How do regulatory T cells work? Scand J Immunol 70: 326-336. SJI2308 
[pii];10.1111/j.1365-3083.2009.02308.x [doi]. 
 38.  Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, et al. (2012) Defining a functionally 
distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol 42: 
1893-1905. 10.1002/eji.201242444 [doi]. 
 39.  Moncrieffe H, Nistala K, Kamhieh Y, Evans J, Eddaoudi A, et al. (2010) High expression of the 
ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one 
regulatory and one memory T cell population. J Immunol 185: 134-143. jimmunol.0803474 
[pii];10.4049/jimmunol.0803474 [doi]. 
 40.  Jackson-Sillah D, Cliff JM, Mensah GI, Dickson E, Sowah S, et al. (2013) Recombinant ESAT-6-CFP10 
Fusion Protein Induction of Th1/Th2 Cytokines and FoxP3 Expressing Treg Cells in Pulmonary TB. 
PLoS One 8: e68121. 10.1371/journal.pone.0068121 [doi];PONE-D-12-25094 [pii]. 
 41.  Haregewoin A, Longley J, Bjune G, Mustafa AS, Godal T (1985) The role of interleukin-2 (IL-2) in the 
specific unresponsiveness of lepromatous leprosy to Mycobacterium leprae: studies in vitro and in vivo. 
Immunol Lett 11: 249-252. 0165-2478(85)90175-0 [pii]. 
 42.  Ottenhoff TH, Wondimu A, Reddy NN (1990) A comparative study on the effects of rIL-4, rIL-2, rIFN-
gamma, and rTNF-alpha on specific T-cell non-responsiveness to mycobacterial antigens in lepromatous 
leprosy patients in vitro. Scand J Immunol 31: 553-565. 
 43.  Ottenhoff TH, Converse PJ, Gebre N, Wondimu A, Ehrenberg JP, et al. (1989) T cell responses to 
fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be 
Chapter 6 
 
 
192 
 
overcome in vitro by stimulation with fractionated M. leprae components. Eur J Immunol 19: 707-713. 
10.1002/eji.1830190421 [doi]. 
 44.  Ottenhoff TH, Walford C, Nishimura Y, Reddy NB, Sasazuki T (1990) HLA-DQ molecules and the 
control of Mycobacterium leprae-specific T cell nonresponsiveness in lepromatous leprosy patients. Eur J 
Immunol 20: 2347-2350. 10.1002/eji.1830201027 [doi]. 
 45.  Saini C, Ramesh V, Nath I (2014) Increase in TGF-beta Secreting CD4(+)CD25(+) FOXP3(+) T 
Regulatory Cells in Anergic Lepromatous Leprosy Patients. PLoS Negl Trop Dis 8: e2639. 
10.1371/journal.pntd.0002639 [doi];PNTD-D-13-01037 [pii]. 
 46.  Modlin RL, Hofman FM, Taylor CR, Rea TH (1983) T lymphocyte subsets in the skin lesions of patients 
with leprosy. J Am Acad Dermatol 8: 182-189. 
 47.  Joosten SA, van Meijgaarden KE, Savage ND, de BT, Triebel F, et al. (2007) Identification of a human 
CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. 
Proc Natl Acad Sci U S A 104: 8029-8034. 0702257104 [pii];10.1073/pnas.0702257104 [doi]. 
 48.  Joosten SA, Ottenhoff TH (2008) Human CD4 and CD8 regulatory T cells in infectious diseases and 
vaccination. Hum Immunol 69: 760-770. S0198-8859(08)00149-3 [pii];10.1016/j.humimm.2008.07.017 
[doi]. 
 49.  Boor PP, Metselaar HJ, Jonge S, Mancham S, van der Laan LJ, et al. (2011) Human plasmacytoid 
dendritic cells induce CD8(+) LAG-3(+) Foxp3(+) CTLA-4(+) regulatory T cells that suppress allo-
reactive memory T cells. Eur J Immunol 41: 1663-1674. 10.1002/eji.201041229 [doi]. 
 50.  Geluk A, van Meijgaarden KE, Wilson L, Bobosha K, van der Ploeg-van Schip JJ, et al. (2013) 
Longitudinal Immune Responses and Gene Expression Profiles in Type 1 Leprosy Reactions. J Clin 
Immunol . 10.1007/s10875-013-9979-x [doi]. 
 51.  Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, et al. (2013) TLR stimulation initiates a CD39-
based autoregulatory mechanism that limits macrophage inflammatory responses. Blood 122: 1935-1945. 
blood-2013-04-496216 [pii];10.1182/blood-2013-04-496216 [doi]. 
 
 
                                                                                                                                                      Tregs in leprosy
             
193 
 
Supplementary File 1A. Gating strategy for live CD4
+
CD3
+
 cells or CD8
+
CD3
+
 cells in 
PBMC  
 
 
 
Sup. Fig S1A. Ungated events were first gated using a forward scatter area (FSC-A) versus height (FSC-H) plot 
to remove doublets. Subsequently, the events were subjected to a lymphocyte gate by gated through a side 
scatter (SSC). Subsequently, live CD3
+
cells were gated by live/dead staining using Vivid (Invitrogen, Life 
technologies) as a marker for viability and CD14
+
 or CD19
+
 events were excluded from analysis using a dump 
channel. Finally, CD3
+
 live cells were separated into CD4
+
 and CD8
+
. 
 
Supplementary File 1B. Gating strategy for IL-10 and FoxP3 expression in CD4
+
CD3
+
 cells 
or CD8
+
CD3
+
 cells   
 
 
Supp. Fig. S1B After the gates for each function were created, we used the Boolean gate platform to identify all 
functions within each cell population using the full array of possible combinations FACS LSR Fortessa as 
shown here for IL-10 and FoxP3 expression in CD4
+
 T cells. 
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Supplementary File 2A. Dot plot analysis of bulk (total) PBMC, CD25 depleted and  
CD25 positive population of a representative LL patient (LL053). 
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Supp. Fig S2A.After separating the CD25 negative and CD25 positive cell population using Magnetic cell sorter, fractions of 
each cell population including the bulk (total) PBMC were analysed for their expression of CD3, CD4 and CD25. Here the 
data are presented in dot plots. 
Supplementary File 2B. Zebra plots of bulk (total) PBMC, CD25 depleted and CD25 positive 
population of a representative LL patient (LL053). 
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Supp. Fig. S2B. After separating the CD25 negative and CD25 positive cell population using Magnetic cell sorter, fractions 
of each cell population including the bulk (total) PBMC were analysed for their expression of CD3, CD4 and CD25. Here 
the data are presented in zebra plots. 
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Supplementary File 3. Hematoxylin and Eosin staining of four representative LL patients 
(original magnification X100). 
 
     
 
      
 
 
Supp. Fig. S3. Tissue sections from paraffin embedded biopsy samples of leprosy patients were stained for H&E. Here 
images of H&E staining of four representative LL patients are presented. 
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Abstract 
 
The host immune response against Mycobacterium leprae (M. leprae) determines the type 
and severity of the disease. Early detection of leprosy and asymptomatic M. leprae infection 
is key to reducing transmission. We have developed diagnostic tools based on cellular 
immune responses to M. leprae antigens. However, coinfections with HIV or helminths may 
reduce the host immune response to M. leprae thereby possibly hampering diagnosis of 
infected cases in tests based on anti-mycobacterial cellular immunity. This study 
characterized the immune profiles of HIV- or helminth coinfected leprosy patients in order to 
estimate the effect of coinfection in immunodiagnostic tools. Production of selected host 
biomarkers from peripheral blood mononuclear cells (PBMC) stimulated with M. leprae 
whole cell sonicate (WCS) and mRNA expression level of 76 genes was measured. 
Similar T helper 1 (Th1) and Th2 responses were measured in WCS stimulated PBMC of 
leprosy patients with HIV coinfection and matched leprosy patients without HIV infection.   
In non-reaction BL/LL patients with and without helminth infection, the IFN- production 
was similar in both groups but the reductive effect of helminth coinfection in patients with 
T1R suggests the interference of helminth driven Th2 responses.  
mRNA expressions of IL15 (p=0.0001), CTLA4 (p=0.003) and TLR10 (CD290) (p=0.0001) 
were significantly higher in HIV coinfected patients than in non-HIV patients, whilst 
ZNF532 expression was significantly lower (p =0.002). In BL/LL patients with and without 
helminth coinfection, similar mRNA expressions were observed for all 76 genes tested. 
In summary, the similarity in immune responses in leprosy patients with and without HIV 
and helminth coinfections allows the use of identified immune- and transcriptomics 
biomarkers in diagnostic tests irrespective of patients’ coinfection status. However, in 
patients with reactions, helminth infections may mask the severity of the reaction in Th1-
based diagnostic tests, which warrants further investigations in larger/ longitudinal cohorts. 
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Author Summary 
 
Early detection of leprosy is the main strategy to reduce transmission. Recently, we have 
developed diagnostic tools based on cellular immune responses of the host to M. leprae 
antigens. HIV or helminth coinfections in leprosy patients may interfere and hamper the 
diagnostic potential of these new tools.  Therefore, in this study, the immune profiles of 
coinfected leprosy patients were characterized and compared with non coinfected leprosy 
patients to estimate the effect of coinfection in immunodiagnostic tools. 
Similar host immune responses were measured in both HIV co-infected and non-coinfected 
leprosy patients. The IFN- production in helminth co-infected patients without T1R (type 1 
reaction) was similar with that of non coinfected patients. However, a reduced IFN- 
production was measured in helminth coinfected patients with T1R.  
mRNA expressions for majority of the genes were similar except for a few genes namely 
IL15 CTLA4 and TLR10 (CD290) which were found significantly higher in HIV coinfected 
patients and ZNF532 expression was significantly lower.  In BL/LL patients with and without 
helminth coinfection, similar mRNA expressions were observed for all genes tested. 
In summary, the similar immune responses shown in this study for both groups allows the use 
of identified host biomarkers in diagnostic tests irrespective of patients’ coinfection status. 
However, further investigations in larger/ longitudinal cohorts are warranted in helminth 
coinfected patients with reaction. 
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Introduction 
 
Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae) and 
about 200,000 new cases of leprosy are reported by the WHO every year [1]. The disease 
manifestation has a wide spectrum which ranges from the tuberculoid form with high cell 
mediated immunity (CMI) and low number of bacilli to the lepromatous form with poor CMI 
and high bacillary load [2]. Host immunity determines the clinical manifestation after 
infection with M. leprae.  However, coinfections may interfere with host immunity, thereby 
determining clinical manifestations either by up regulating or down regulating the different 
arms of immunity [3;4].  
 
Over the last three decades, HIV has killed millions through increasing susceptibility of 
infected people to many opportunistic infections. Mycobacterial infections are among these 
opportunistic threats, and tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) is 
the leading cause of death among HIV infected individuals [5;6]. After initiation of anti 
retroviral therapy (ART), diseases like TB may manifest as a result of immune reconstitution 
inflammatory syndrome (IRIS) which is an exaggerated immune reaction against re-current 
or unrecognized sub-clinical infections [7].  
 
Similarly, increased manifestation of leprosy, especially of the lepromatous form, was 
predicted in HIV infected patients taking ART [8;9]. In contrast to the expectations, the 
impact of HIV has not worsened the leprosy situation, although some patients on ART are 
being diagnosed as new leprosy cases [10]. Few studies have analysed some clinical, 
immunological and pathological parameters [11-14]. Most of these features in M. leprae-HIV 
coinfected patients were reported to be similar compared to patients with one infection, 
indicating that each disease progresses independently [15].  
 
The occurrence of type 1 leprosy reactions (T1R) in association with anti-retroviral therapy 
(ART) initiation was reported and is often considered as immune reconstitution inflammatory 
syndrome (IRIS) in M. leprae-HIV coinfected patients on ART [11;14;16-20]. In a non-HIV 
leprosy patient with T1R, our group has previously shown increased expression of 
cytotoxicity-associated genes granzyme A (GZMA), granzyme B (GZMB) and perforin 1 
(PRF1) [21]. In M. leprae-HIV coinfected patients, increased frequency of CD8
+
 T cells was 
also reported as a potential triggering factor for the occurrence of T1R along with increased 
production of PRF and GZMB compared to non-HIV leprosy patients [22]. Therefore, in this 
study, we compared the mRNA expressions of these and other related genes in both groups of 
patients. 
 
Coinfection with intestinal parasites, mainly helminthic infections are known to elicit   
immune modulation characterized by up-regulating Th2 responses in the infected host [23-
28]. In mycobacterial infections like TB, studies have shown the effect of helminth 
infestation through weakening Th1 immunity [29]. Moreover, poor immunogenicity induced 
by BCG vaccination was also observed in helminth infested groups compared to de-wormed 
groups in an Ethiopian cohort [30;31]. There are also evidences for Omega-1 (with 
glycosylation and ribonuclease activity) secreted by Schistosoma mansoni eggs in 
conditioning dendritic cells in priming Th2 responses [32;33]. In addition, helminthic 
infections are common in HIV infected people [34]. The presence of intestinal helminths in 
leprosy patients may potentially facilitate the progression of M. leprae infection to more 
severe forms of leprosy [35]. Significant association of lepromatous leprosy (LL) with 
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helminths and higher production of Th2 type cytokines such as IL-4 and IL-10, were reported 
in coinfected patients [35;36]. 
 
Our group has selected specific M. leprae proteins and identified host biomarkers such as 
IFN-, IP-10, MIP-1β, MCP-1, IL-1β, IL-6 for detection of M. leprae infection and/ or 
exposure in different groups including leprosy patients, household contacts and endemic 
controls [37-40]. These biomarkers are currently applied in development of field friendly 
rapid diagnostic tests. Assessing the effect of coinfections on these biomarkers is essential for 
the interpretation of these tests in leprosy patients with coinfections. 
 
In this study, we analysed immune responses to M. leprae antigens in HIV or helminth 
coinfected Ethiopian leprosy patients to assess the effect of these coinfections on host 
immune biomarkers. 
 
Materials and Methods 
 
Ethical statement. This study was performed according to the Helsinki Declaration (2008 
revision). Ethical approval of the study protocol was obtained from the National Health 
Research Ethical Review committee, Ethiopia (NERC # RDHE/127-83/08). Participants were 
informed about the study objectives, the required amount and kind of samples and their right 
to refuse to take part or withdraw from the study at anytime without consequences to their 
treatment. Written and informed consent was obtained from study participants before 
enrollment. Pre- and post counseling for HIV testing was performed by the recruiting nurse 
and patients identified as HIV-positive were referred to ALERT ART clinic.  
Study participants. During 2009 and 2012 M. leprae-HIV coinfected patients (n=21) and 
leprosy patients without HIV (n=256) were enrolled in this study.  Leprosy was diagnosed 
based on clinical, bacteriological and histological observations and classified by a skin biopsy 
evaluated according to the Ridley and Jopling classification [2] by qualified microbiologists 
and pathologists. All patients were enrolled before initiation of MDT antibiotic treatment for 
leprosy infection or steroid treatment for leprosy associated inflammation or reactions.  or 
steroid. The HIV test was done using KHB (Shanghai kehua Bioengineering CO-Ltd, 
Shanghai, China) and if positive a second test was performed using STAT-PAK™ (Chembio 
HIV1/2, Medford, New York, USA). Stool samples were prepared using the direct stool 
smear (wet smear) protocol and examined under microscope within 30 min for the presence 
of ova, cysts and parasites. Patients with positive microscopic result were further categorized 
into patients with helminth and protozoan infection. 
PBMC isolation, freezing and thawing. PBMC were isolated by density gradient method 
using Ficoll-paque, cells were washed and suspended in 20% fetal calf serum (FCS) in AIM-
V (Invitrogen, Carlsbad, CA) and kept cool on ice, counted and frozen using a cold freshly 
prepared freezing medium composed of 20% FCS, 20% dimethyl sulphoxide (DMSO) in 
AIM-V. Cells were kept at -80 C for 2-3 days and transferred to liquid nitrogen until use. 
During thawing, cells were transported in liquid nitrogen to a water bath (37
o
C) incubated for  
30 to 40 seconds until thawed half way and resuspended in 10% FCS in AIM-V (37
o
C) 
containing 1/10,000 benzonase until completely thawed, washed twice (5-7 minutes each) 
and counted.  
M. leprae Whole Cell Sonicate (WCS). Irradiated armadillo-derived M. leprae whole cells 
were probe sonicated with a Sanyo sonicator to >95% breakage. This material was kindly 
provided by Dr. J.S. Spencer through the NIH/NIAID “Leprosy Research Support” Contract 
N01 AI-25469 from Colorado State University (now available through the Biodefense and 
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Emerging Infections Research Resources Repository listed at 
http://www.beiresources.org/TBVTRMResearch Materials/tabid/1431/Default.aspx). 
Lymphocyte stimulation tests (LST). PBMC (200,000 cells/well) were added in triplicate 
into 96 well U bottom tissue culture plates and cultured with M. leprae whole cell sonicate 
(WCS; 10 µg/ml), phytohaemagglutinin (PHA; 1 µg/ml) or AIM-V medium at 37
o
C with 5% 
CO2 and 70% humidity. After 6 days, supernatants were collected and kept frozen until used 
in ELISA. 
IFN- ELISA. IFN- levels were determined by ELISA (U-CyTech, Utrecht, The 
Netherlands) [41]. The cut-off value to define positive responses was set beforehand at100 
pg/ml. The assay sensitivity level was 40 pg/ml. Values for unstimulated cell cultures were 
typically < 40 pg/ml.  
Multiple cytokine and chemokine assays. The concentrations of 12 analytes (IL-1, IL-10, 
IL-12p70, IL-17, IFN-, IP-10 (CXCL10), G-CSF, GM-CSF, MCP-1 (CCL2), MIP-1 
(CCL4), VEGF and TNF) in supernatants from 6 days LST were measured using the Bio-
Plex suspension array system powered by Luminex xMap multiplex technology (Bio-Rad 
Laboratories, Veenendaal, The Netherlands) and analyzed using the Bio-Plex Manager
TM
 
software 6.0 (Bio-Rad laboratories, Veenendaal, The Netherlands). The assay protocol 
described in Bobosha, K et al., 2012 was followed [42]. 
PGL-I ELISA.  IgM antibodies against M. leprae PGL-I were detected with natural 
disaccharide of PGL-I linked to BSA (ND-O-BSA (0.01 ng/ well) provided through the 
NIH/NIAID Leprosy Contract N01-AI-25469) as previously described [43]. Serum dilutions 
(100 l/ well; 1:300) were incubated at 37°C for 90 min in flat-bottomed microtiter plates 
(Nunc) coated with NDO-BSA. After washing diluted enzyme linked secondary antibody 
solution (100 l/ well) was added to all wells and incubated at 37°C for 30 min. After 
washing diluted TMB solution (100 l/ well) was added to all wells and incubated in the dark 
for 15 min at RT. The reaction was stopped by adding 100 μl/ well 0.5 N H2SO4. Absorbance 
was determined at wavelength of 450 nm. Samples with a net optical density at 450 nm (OD) 
above 0.199 were considered positive. The ELISA performance was monitored using a 
positive and negative control serum sample on each plate. 
PAXgene whole blood RNA isolation. PAXgene tubes were stored at -80C and shipped to 
LUMC. Total RNA from venepuncture PAXgene blood collection tubes was extracted and 
purified using the PAXgene Blood RNA kit (BD Biosciences) including on-column DNase 
digestion according to the manufacturers’ protocol. The RNA yield from 2.5 ml of whole 
blood was determined by a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE) and ranged from 4.2 to 8.5 μg of total RNA (average 6.02 ± 1.5 μg) with an 
average OD260/280 ratio of 2.0 ± 0.04.  
Dual color Reverse Transcription Multiplex Ligation-dependent Probe Amplification 
(dcRT-MLPA) assays. dcRT-MLPA assay was performed as described previously [44]. 
Briefly, for each target-specific sequence, a specific RT primer was designed that is 
complementary to the RNA sequence and located immediately downstream of the probe 
target sequence. Half-probes consisted of chemically synthesized oligonucleotides and right 
hand half-probes were 5’ phosphorylated to facilitate ligation. As a positive control, 
chemically synthesized oligonucleotides were used that were complementary to the RNA 
sequence and encompassed the combined target-specific sequences of the left and right hand 
half-probes. Primers and probes were purchased from Sigma-Aldrig Chemie (Zwijndrecht, 
The Netherlands) and MLPA reagents from MRC Holland (Amsterdam, The Netherlands). 
To avoid detection of contaminating DNA fragments, all target sequences have an exon 
boundary near the probe ligation site. Also, splice variants and SNPs present in the mRNA 
were taken into account. Trace data were analyzed using GeneMapper software package 
(Applied Biosystems, Warrington, UK). The areas of each assigned peak (in arbitrary units) 
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were exported for further analysis in Microsoft Excel spreadsheet software. Signals below the 
threshold value for noise cut-off in GeneMapper (log2 transformed peak area ≤ 7.64) were 
assigned the threshold value for noise cut-off. Results from target genes were calculated 
relative to the average signal of the reference gene, GAPDH, present within the gene sets. 
Following normalization of the data, signals below the threshold value for noise cut-off (peak 
area ≤ 7.64) were again assigned the threshold value for noise cut-off. To monitor assay 
performance, a negative control (without RNA), a positive control (using synthetic template 
oligonucleotides as hybridization templates) and a commercial Human Universal Reference 
RNA (Clontech, Palo Alto, CA, USA) were included on each 96-well plate. dcRT-MLPA 
experiments for RNA samples of all time points were performed simultaneously.  
Statistical analysis. Data were analyzed with the two-tailed Mann-Whitney U test for non-
parametric distribution using GraphPad Prism version 5.01 for Windows (GraphPad Software, 
San Diego California USA; www.graphpad.com). The statistical significance level used was 
p<0.05.  
 
Results 
  
T1R in M. leprae-HIV coinfected patients  
to assess the effect of HIV coinfection, we recruited, 10 male and 10 female HIV coinfected 
leprosy patients with age range of 18 to 50 including 16 BB/BL/LL patients and 4 BT. The BI 
ranged from 0 to +4 (Table 1).  
 
Table 1. M. leprae-HIV coinfected patients’ demographic and clinical status 
 
 Lep-HIV                   
Coinfected  Sex Age Rxn Status BI 
PGL-I 
(OD450) ART status*  
CD4 
count 
1 Lep HIV 002 M 39 T1R BT 0 0.02 ART  242 
2 Lep HIV 011 F 23 T1R BT 0 0.018 ART 90 
3 Lep HIV 008 F 18 T1R BT 0 0.103 Not received 581 
4 Lep HIV 001 M 40 T1R BB 0 0.726 ART NA 
5 Lep HIV 006  F 35 T1R BB 0 0.2 ART 21 
6 Lep HIV 018 F 50 T1R BB 0 0.027 Not received 247 
7 Lep HIV 004  M 25 T1R BL 0 0.096 ART/IRIS 206 
8 Lep HIV 009 M 36 T1R BL 0 0.068 ART 86 
9 Lep HIV 012 F 30 T1R BL 0 0.599 ART 332 
10 Lep HIV 014 M 38 T1R BL 0 0.981 Not received 359 
11 Lep HIV 016 M 28 T1R BL 0 0.08 Not received 216 
1 Lep HIV 017 F 39 T1R BL 0 0.042 Not received 218 
13 Lep HIV 019  F 26 T1R BL 2 2.183 ART 216 
14 Lep HIV 020 M 30 T1R BL 0 0 ART 144 
15 Lep HIV 007 F 30 T2R BL 0 0.612 ART 109 
16 Lep HIV 003 M 30 T2R LL 3 0.091 Not received 238 
17 Lep HIV 025 M 38 T2R LL 2 1.375 Not received 375 
18 Lep HIV 015 M 34 No rxn BT 0 0.026 Not received 565 
19 Lep HIV 021   F 40 No rxn LL 4 ND Not received 59 
20 Lep HIV 005 F 24 No rxn LL 3.3 1.375 ART 425 
Rxn: leprosy reaction; T1R: type 1 reaction; T2R: type 2 reaction  
*: at diagnosis of leprosy 
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The patients who were referred from the ART clinic at ALERT were all on ART (11/20), 
whereas the other patients who were first diagnosed for leprosy had not received ART (9/20).  
T1R was diagnosed in 14 out of 20 (70 %) and T2R in 3 out of 20 (15 %) (LL= 2 and BL= 1). 
Only 3 patients did not have reactions (LL=2 and BT=1) at the time of leprosy diagnosis. 
Among the HIV coinfected patients on ART; 9/11 (69.2%), and among those naive to ART 
5/9 (30.7%) had a clinical T1R. The CD4 count ranges from 21 to 425 cells/µl in patients on 
ART and ranges from 59-581 cells/ul in patients naïve to ART.  
 
Similar cytokine responses in non-HIV and HIV coinfected leprosy patients 
To assess the influence of HIV infection on recently identified potential biomarkers for early 
diagnosis, cytokine/chemokine responses against M. leprae WCS in both HIV uninfected and 
HIV coinfected leprosy patients were analysed. As shown in Figure 1, the IFN-γ responses to 
M. leprae WCS measured by ELISA in both groups were found similar.  
The IFN- responses to PHA in both groups were higher in general compared to responses to 
M. leprae WCS. Also, the IFN-  response in non-HIV leprosy patients to PHA was 
significantly, though slightly, higher (p =0.045) compared to that in those infected with HIV 
(Figure 1).  
 
Fig 1: IFN-γ responses of PBMC from HIV coinfected (n=13) and non-coinfected leprosy patients (n=13) stimulated with M. 
leprae Whole Cell Sonicate (WCS) and PHA positive control in 6 days culture. 
 
Similarly, the 11 analytes (IL-1, TNF, IL-12p70, IL-17, IL-10, IP-10 (CXCL10), MCP-1 
(CCL2), MIP-1, G-CSF, GM-CSF and VEGF) measured in supernatants of 6 days PBMC 
culture were also found similar in both groups (Figure 2) affirming the possibility to use the 
previously identified host biomarkers as diagnostic markers in  non-HIV as well as HIV 
coinfected individuals. 
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Fig 2: Multiple cytokine and chemokine responses of PBMC of HIV coinfected (n=18) and non-coinfected leprosy patients 
(n=15) stimulated with M. leprae Whole Cell Sonicate (WCS).   
 
Increased mRNA expression of IL15 and CTLA4 in HIV coinfected leprosy patients 
mRNA expression of 76 target genes involved in innate and adaptive immunity or associated 
with leprosy [21] were analysed in both HIV-coinfected (n=20) and HIV-uninfected  leprosy 
patients (n=20). Only a few genes showed significant differences between both groups of 
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leprosy patients. Significantly higher CD4 (p <0.0001) and CD8 (p <0.002) mRNA 
expression levels were measured in non-HIV and HIV coinfected respectively (Figure 3). The 
expressions of IL15 (p =0.0001), CTLA4 (p =0.003) and TLR10 (CD290) (p =0.0001) were 
found significantly higher in HIV coinfected leprosy patients (Figure 3).  In contrast, ZNF532 
mRNA expression was found significantly higher (p =0.002) in non-HIV patients. The 
expression of all other tested genes including IL1β, CCL4, CCR7 and VDR did not show 
significant differences between the two groups. 
 
 
Fig 3: mRNA expression of 11 target genes in peripheral blood of HIV coinfected (n=20) and non-coinfected leprosy 
patients (n=20). 
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Comparable frequency of helminth coinfection in MB and PB leprosy patients 
Leprosy patients were recruited consecutively at ALERT hospital and tested for helminth 
infestation where 218 BL/LL and 38 BT patients were included from 2009 – 2013. Among 
these patients, 54 out of 218 BL/LL patients (24.7%) and 6 out of 38 (15.7%) BT patients 
were found coinfected with parasites; helminths (51.6%) and protozoans (48.3%) (Table 2).  
 
Table 2. Type and distribution of parasites in leprosy patients         
M/F: Male –Female ratio; BT: Borderline tuberculoid; BL: Borderline lepromatous 
 
The most frequent protozoans were Giardia lamblia and Entamoeba histolytica and the most 
frequent helminths were Ascaris lumbricoides and hookworm. Helminth infected BL/LL 
patients were 27 out of 218 (12.4%) and BT were 4 out of 38 (10.5%). 
 
Helminth coinfection suppresses the Th1 response in leprosy patients with T1R 
As shown in Figure 4, the IFN-γ (hallmark cytokine for Th1 immunity) production in non-
reactional BL/LL patients with and without helminths in response to M. leprae WCS were 
low (less than 100 pg/ml) and no difference was observed between the BL/LL patients with 
and without helminths. However, when PBMC of BL/LL patients (n=4) with T1R not treated 
with steroids were stimulated with M. leprae WCS, patients free of helminth infestation 
showed significantly higher (p=0.028) IFN-γ responses than those coinfected with helminths 
(n=4).  
Stool result # of 
patients 
% Sex ratio 
(M/F) 
Age range 
(yrs) 
Type of leprosy Reaction 
(No/Yes) 
Cyst of Giardia lamblia 8 3.13 5/3 18-55 BL/LL 4/4 
Cyst of Giardia lamblia and Entamoeba histolytica 1 0.39 1/0 33 BL 1/0 
Cyst of Entamoeba histolytica 9 3.50 6/3 24-46 BL/LL 5/4 
Trophozoites of Giardia lamblia 7 2.72 6/1 20-55 
BL/LL (5) 
BT (2) 4/3 
Trophozoites of Giardia lamblia and Entamoeba 
histolytica 1 0.39 1/0 18 LL 1/0 
Trophozoites of Entamoeba histolytica 3 1.17 2/1 29-40 BL/LL 1/2 
Larvae of Strongyloides stercolaris 4 1.56 4/0 22-28 BL/LL 1/3 
Ova of Ascaris lumbricoides 10 3.89 7/3 18-47 BL/LL 7/3  
Ova of Enterobius vermicularis 1 0.39 1/0 31 BL 1/0 
Ova of hookworm 10 3.89 8/2 18-46 
BL/LL (6) 
 BT (4) 6/4  
Ova of Hymenolepis nana 1 0.39 0/1 21 BL 1/0 
Ova of Taenia Spp 2 0.78 1/1 25-29 BL/LL 0/2 
Ova of Trichuris trichiura 1 0.39 0/1 18 LL 1/0 
Ova of Trichuris trichiura and Ascaris lumbricoides 2 0.78 2/0 25 LL 2/0 
No parasites 196 76.26 133/63 18-65 
BL/LL (164)    
BT (32) 97/89 
Total 256           
       
Protozoans 29 48.3 
    
Helminths 31 51.6 
    
       
Parasites 60 23.35 
    
No parasites 196 76.26 
    
 
256 100 
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Fig 4: IFN-γ responses of PBMC of helminth coinfected and non-coinfected leprosy. Patients stimulated with M. leprae 
Whole Cell Sonicate (WCS) in 6 days culture A. patients without reaction: no helminth n=9 and helminth infested n=8 B. 
patients with T1R: no helminth n=4 and helminth infested n=4 
 
Similar mRNA expressions of leprosy associated genes in patients with and without 
helminth  
The mRNA expression of 76 genes associated with innate and adaptive immunity were 
assessed using dcRT-MLPA [41] in whole venous blood of BL/LL patients without helminth 
(n=11) and coinfected with helminth (n=11). The mRNA expressions in both groups were 
found similar. In figure 5, the mRNA expression levels for a selection of 27 genes are shown. 
 
 
  
                                                                                                                                                Coinfections in leprosy 
 
209 
 
 
                           
Fig 5: mRNA expression of 27 target genes in peripheral blood of BL/LL patients without helminths 
(n=11) and with helminths (n=11). 
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Discussion 
 
Coinfections in leprosy have not been studied intensively although some reports have shown 
coinfections as risk factors for leprosy reactions (both type 1 and 2) [45;46]. Reports on the 
occurrence of TB in HIV patients who are naïve to ART as a result of diminished CD4
+
 T 
cells [47;48] and in those who are on ART as IRIS [7] prompted the leprosy research 
community to evaluate HIV-infection in leprosy patients [13;17;18;49-51]. HIV coinfection 
was reported previously to occur in any form of leprosy [11] and a strong association of ART 
with the occurrence of T1R was shown in several studies [11;12;17;22] including this study. 
ART is known to restore CD4
+
 T cell numbers but also drives an excessive and tissue 
destructive inflammation in some individuals [52]. This inflammatory environment may 
facilitate the occurrence of T1R in M. leprae-HIV coinfected patients. However, taking into 
consideration that T1R represents a common phenomenon that occurs in 30-50% of leprosy 
patients at any time before, during or after MDT, the interference or influence of ART needs 
to be investigated. In addition, studies on the interaction of various factors including ART, 
MDT, steroids, reactions, leprosy forms and various immune cells including T cells, dendritic 
cells and macrophages will certainly generate valuable information which could be used in 
management of coinfected patients in general and specifically those with T1R.  
 
The clinical and histopathologcial features of leprosy in HIV coinfected patients did not 
differ from non-HIV leprosy patients in our study, as also evidenced by previous studies 
[15;49] except the above discussed ART and T1R association. No differences were observed 
in immune responses against M. leprae WCS as measured by different cytokines/chemokines 
suggesting the feasibility of the use of the newly identified diagnostic biomarkers in 
coinfected patients as well. Still, helminths-induced Th2 response may suppress stronger Th1, 
which could become evident upon treatment with anti-helminth prophylaxis. Therefore, 
further longitudinal studies are required to monitor the effect on anti-M.leprae responses 
effected by treatment. 
 
Lower CD4:CD8 ratio [14] and an increased CD8
+
 memory T cells in HIV coinfected 
patients with T1R [22] were reported previously. In our study,   mRNA expression levels in 
whole blood of CD4 was significantly lower (p<0.0001), whereas CD8 expression was 
significantly higher (p<0.002) in HIV coinfected leprosy patients. In addition, IL15 and 
TLR10 were higher expressed in coinfected and ZNF532 was higher expressed in leprosy 
patients without HIV. IL-15 is known as a pleiotropic cytokine dominant in lesions of TT/BT 
patients [53;54]. Increased IL15 mRNA expression in coinfected patients may be associated 
with the Th1 dominated immune response as a result of ART and/or T1R. Toll like receptors 
(TLR) are important in triggering inflammatory and adaptive immune responses in a host 
invaded by pathogens. A recent study revealed that TLR10 shares microbial derived agonists 
of TLR1 and also requires TLR2 for innate immune recognition [55]. Although not 
particularly demonstrated for TLR10, there is evidence that HIV infected individuals in 
general show pro-inflammatory responsiveness to TLR agonists [56]. Therefore, the 
significantly increased TLR10 mRNA expression (p =0.0001) in the leprosy HIV coinfected 
patients demonstrated in this study, indicates its potential as a biomarker for HIV infection in 
leprosy patients. Zinc fingers in general are interaction modules that bind to different 
compounds including nucleic acids, proteins and small molecules [57]. There is insufficient 
information particularly on Zinc Finger 532 (ZNF532) function and the significantly higher 
mRNA expression (p =0.002) shown in non-HIV patients in this study calls for further 
investigation in this domain. There are few recent reports on Zinc finger nucleases, which are 
generated by fusing Zinc finger DNA-binding domain to a DNA cleavage as therapy for HIV. 
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Therefore, our finding on ZNF532 may have relevance in future diagnostic or therapeutic 
research in HIV.  
 
On the other hand, in non-helminth and helminth coinfected leprosy patients, the comparable 
mRNA expressions may implicate the minimal interference of helminth but assessing the 
protein expression levels is warranted. Decreased Th1 responses in presence of helminths in 
leprosy patients was reported previously [35]. In this study, the majority of helminth 
coinfected and non-helminth leprosy patients were BL/LL patients and showed comparable 
Th1 responses because the cellular immune responses in both groups were low, in line with 
the general phenomenon in BL/LL patients. Importantly, however, we were able to show the 
effect of helminths in leprosy patients with T1R as their IFN- responses were significantly 
lower compared to non-helminthic leprosy patients with T1R. This suggested interference of 
helminth infestation and domination of helminth driven Th2 type response in patients with 
reaction as T1R generally induces a dominant Th1 type responses. Furthermore, since delay 
in clearance of bacilli is a major issue in BL/LL patients, the risk of helminth infection in 
further delaying the bacterial clearance and whether de-worming puts patients at risk of 
developing T1R have to be investigated in longitudinal studies to develop proper 
management algorithms of coinfected patients and potentially adapt diagnostic tests. 
 
In general, characterization of host immune profiles in coinfected patients is relevant for the 
validation of newly developed diagnostic tools.  In this study, the previously identified 
biomarkers for early diagnosis such as IP-10, CCL4 and CCL2 [58;59] were evaluated and 
comparable responses were observed in mono- and coinfected groups indicating the potential 
use of these biomarkers in both groups. Therefore, it is essential for future biomarker 
screenings or diagnostic tool development for leprosy to consistently include patients who are 
infected with other microbes besides M. leprae and thereby account for the interference of 
coinfections.  
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Summary 
 
Globally more than 200,000 people develop leprosy every year and 2-3 million people live 
with leprosy associated disabilities. Despite the availability of efficient multi drug therapy, 
leprosy has continued affecting many individuals, including children because of the 
uninterrupted transmission in the population. Untreated MB cases as well as non-
symptomatic M. leprae infected individuals in the population are believed to be the major 
sources of M. leprae infection and transmission. The currently available clinical and 
laboratory diagnostics methods have limitations for detection of PB patients and 
asymptomatic, M. leprae infected individuals at high risk of developing the disease. In 
addition, leprosy reactions are the major causes of disabilities and occur as a result of host 
immunological responses against whole bacilli and/or its antigens before, during or after 
treatment. However, no tools are available to predict leprosy reactions. 
The availability of the whole genome sequence of M. leprae has opened the opportunity to 
understand the pathogen and the disease more than ever. In silico identification of unique M. 
leprae genes and production of the encoded recombinant proteins have broadened the 
possibilities to develop diagnostic tools, in particular for early detection of infection which 
eventually helps to reduce transmission.  
In vitro assessment of recombinant M. leprae proteins and synthetic peptides for their 
immunogenicity and specificity in populations with different genetic backgrounds by 
measuring cell mediated immunity has shown the presence of potential antigens. Further in 
depth analysis of the host immune responses against these unique antigens in leprosy patients, 
their close household contacts and healthy endemic controls is of immense importance in 
development of new diagnostic tools. Therefore, field friendly tests for early detection are 
currently developed at the LUMC using through identification of M. leprae antigens and host 
biomarkers with diagnostic potential. 
Thus, this thesis focuses on the selection and evaluation of immunogenic M. lepraeunique 
proteins and peptides thereof as well as identification of potential host biomarkers for 
detection of M. leprae infection and early diagnosis of leprosy reactions.  
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General Discussion 
 
In search of immunogenic, M. leprae unique antigens  
 
The leprosy elimination goal will only be achieved if the ongoing transmission within the 
endemic populations is abrogated. Untreated MB cases as well as certain M. leprae infected 
individuals in the population are believed to be the major sources of M. leprae infection and 
transmission. Early detection of leprosy still remains the core strategy of WHO [1], leprosy 
control programs and researchers in the field. In addition, various strategies are designed to 
block transmission by identification of M. leprae infected individuals. In order to develop 
tests that allow detection of infection, about 200 candidate M. leprae antigens were screened 
for induction of cellular or humoral responses in leprosy endemic populations. These 
candidate antigens were selected based on analysis of the whole genome sequence of M. 
leprae [24] .  The host immune response to M. leprae, characterized by both cell mediated 
immunity (CMI) and humoral mediated immunity (HMI) is the main factor that determines 
disease outcome in leprosy. PB patients mostly develop CMI whereas MB patients develop 
predominantly HMI.  Therefore, both types of immune responses need to be determined 
infield applicable tests. 
 
CMI based antigen selection  
The studies described in this thesis aimed at the identification of specific and immunogenic M. 
leprae antigens (proteins and peptides) for eventual application as diagnostic tools. This was 
accomplished by performing extensive screening of antigens in leprosy endemic populations 
with different genetic backgrounds from Asia, Africa and Latin America as well as from very 
low and non-endemic populations in South Korea and The Netherlands, respectively [27]. 
Being a stable cytokine, it is used as read out in T cell in vitro assays as well as in 
commercialized diagnostic kits like QuantiFERON TB Gold and T Spot TB tests. The level 
of IFN-γ secreted by immune cells in response to the M. leprae proteins and synthetic 
peptides was used as readout for preliminary selection of immunogenicity of M. leprae-
specific candidate antigens [8;26;27] (chapter 2). Subsequently, promising candidate 
diagnostic antigens were analysed in leprosy patients, their household contacts and endemic 
controls for their potential to induce additional biomarkers besides IFN-γ (chapter 3 and 
chapter 4). Subsequently, the application of such biomarkers in field-friendly diagnostic tests 
was investigated (chapter 5).  
 
Among several antigens tested, the “hypothetical proteins” ML2478 and ML0840 were able 
to discriminate between the likely levels of infection as judged by their ability to induce high 
IFN- responses in TT/BT, HHC and EC living in high endemic areas as compared to healthy 
controls from non-endemic area [25]. Similarly, responses to ML1601, a group IV 
hypothetical protein with less than 30% identity in most mycobacterial species discriminated 
groups according to their level of M. leprae exposure [7] (Chapter 3). Few other research 
groups have explored such potential M. leprae antigens based on CMI [19;20;38;48;53]. So 
far, ML2478 and ML1601were reported as promising and we have studied these further for 
the development of diagnostic tools. 
 
Considering the potential of peptides to induce  more specific T cell responses by avoiding T 
cell cross reactivity to conserved stretches of amino acids in the protein, several M. leprae 
peptides and pools thereof were tested for their ability to induce recall CMI [17;18;28;53]. 
Due to the inherent highly polymorphic HLA-restriction of antigen presentation to T cells, 
multiple peptides would be required in order to cover populations with different genetic 
  
 
Chapter 8 
218 
 
backgrounds. Most of the M. leprae peptides and peptide pools induced very low IFN-γ (in 
the range of 50 to 100 pg/ml concentration) in all study groups [8;27] as described in this 
thesis (chapter 2). Especially in whole blood assays (WBA), the level of IFN-γ barely 
exceeded the background levels, thus rendering these peptides not useful for application in 
diagnostic tools. Previously, addition of co-stimulants including cytokines (IL-2, IL-7, IL-12, 
IL-18 and IL-23) and antibodies (anti-IL-10, anti CD49d, anti CD28 and anti-CD40) were 
tested by our group to enhance peptide-induced IFN-γ responses. Mannosylation of peptides 
was also investigated. IL-12 was the only co-stimulus which enhanced M. leprae specific 
IFN-γ response in WBA [29]. However, further studies using IL-12 at a low concentration in 
an endemic area in Ethiopia showed that this cytokine also induced some individual-specific 
background responses when used in combination with M. leprae unique peptides in WBA, 
thereby excluding this strategy as a dependable assay for selection of immunogenic peptides 
(Bobosha et al., unpublished data). Aabye et al. investigated a simple strategy to enhance 
CMI by incubating cell cultures at temperatures ranging from 38 - 41°C mimicking the fever 
temperature known for increased inflammatory responses in vivo. Those cell cultures 
incubated at 39°C showed enhanced immune responses to Mtb antigens (peptides of TB10.4 
and peptides in the QuantiFERON-TB Gold test) and mitogen (PHA), especially in 
individuals with low responses at base line [2]. Thus, evaluation of such simple boosting 
techniques may also enhance the weak in vitro responses against M. leprae specific peptides.  
 
The other approach described in chapter 3 of this thesis is in silico discovery of 
promiscuously binding HLA class I and class II epitopes, which should highly enrich for 
relevant peptides [38]. Among the 29 in silico selected HLA class I (n=21) and class II (n=8) 
peptides derived from virulent proteins group IV.A 
(sanger.ac.uk/Projects/M_leprae/Ml_gene_list_hierarchical.shtml), we identified two peptides 
of ML2055 (p35: IPASVSAPA and p42: LAIAVVASA), by measuring IFN-γ, that were able 
to differentiate endemic controls living in areas with high versus low leprosy endemicity [5]. 
Similarly, a study conducted in Brazil identified 58 additional peptides following a similar in 
silico prediction approach. IFN-γ responses to these selected peptides and their pools showed 
interesting differences as to their level of exposure to M. leprae and/or bacillary load among 
healthy controls from hyper endemic areas, close HHC of MB patients and HHC of PB 
patients which is also supported by the anti-PGL-I IgM values of each group [38]. 
HMI based antigen selection 
High humoral and poor cell mediated immunity is a typical feature of MB patients and is an 
indication of the failure to contain M. leprae infection. Clinically, it is relatively simple to 
diagnose MB patients without performing tests such as the anti-PGL-I IgM assays which are 
mainly used in epidemiological studies [49]. As mentioned in chapter 1 of this thesis, 
humoral responses against most M. leprae antigens studied so far are more potent in detecting 
MB patients. However, the potential of humoral responses in monitoring treatment outcome 
and in assessing possible incipient disease in close household contacts [54] requires further 
exploration. In this thesis, we showed that HMI as estimated by IgM responses against PGL-I 
can be combined in a field friendly assay with CMI responses as described in chapter 5 
indicating the applicability of combined approach in diagnostic test development.  
 
Potential host biomarkers relevant in leprosy diagnosis and prediction of reactions 
In leprosy, the cytokine- and chemokine environment at the sites of infection is a major 
determinant influencing outcome of the disease. For instance, higher IL-15 production in 
leprosy lesions drives the differentiation of monocytes to pro-inflammatory macrophages 
(Mφ1) which is typical feature of TT/BT patients. Instead, higher IL-4 and IL-10 leads to 
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differentiation of monocytes towards anti-inflammatory macrophages (Mφ2) in MB patients 
[41;42]. IFN-, the hallmark cytokine produced by Th1 cells, induces the differentiation of 
Mφ1 and expression of microbicidal pathways.  
 
Several host chemokines and cytokines other than IFN-γ were also analyzed in other 
populations, using multiplex assays [5;25;45]. IP-10, IL-1β, IL-6, TNF- and MCP-1 were 
able to differentiate healthy controls residing in relatively high (EChigh) and low (EClow) 
leprosy endemic areas (Chapter 3), suggesting an ability to detect differences in the levels of 
M. leprae exposure. Of interest, a heterogeneous IL-1β response was found within the 
household contacts group [5;25]; this might suggest that some individuals in this group may 
induce protective versus pathogenic immune responses to M. leprae. Similarly in TB, IP-10, 
MCP-1 and IL-4 were among the potential biomarkers reported for detection of latent or 
active TB, disease progression or protection.  Such markers could be important in treatment 
monitoring or in vaccine development [3;11;31;33;40;46]. Therefore, investments in larger-
scale longitudinal follow-up studies [44], allowing intra-individual comparison of immune 
profiles of healthy controls as well as household contacts from leprosy-endemic areas 
worldwide, will be essential to evaluate which biomarkers correlate with true progression to 
disease and thus can be used as predictive tools. Some of these biomarkers (such as IP-10 and 
MIP-1β) are abundantly produced and can be measured easily from small amounts of samples 
or from shortly stimulated WBA. This makes them attractive candidates for development of 
simple and rapid field friendly diagnostic tests.  
 
Tools for early detection or prediction of leprosy reactions are highly relevant and a key goal 
in leprosy research, since these could be instrumental in reducing severe complications and 
disabilities in leprosy patients. In a recent longitudinal study by our group, an increased 
production of cytokines: IFN-, IP-10, CCL9, IL-17A and VEGF (vascular endothelial 
growth factor) and a decrease in IL-10 and GCSF was reported in patients with active T1R in 
response to M. leprae (whole cell sonicate) as compared to time points prior to the onset of 
the reaction. Upregulated mRNA expressions of VEGF and cytolytic proteins like GRMA, 
GRMB and PRF1 in T1R were also detected [30]. In other multicenter longitudinal studies by 
our group, the ratios of cytokines such as IFN-/IL-10 and IL-17/IL-10 appeared as potential 
tools for predicting T1R in leprosy patients [34] (Chapter 4). In line with this, high 
expression of TNF-α mRNA and protein in nerves and lesions [35] and over expression of 
VEGF and its receptor KDR in lesions [23] of patients with T1R were reported previously. 
Elevated IL-13, IL-6 and IL-10 [4] in lesions of T1R and decreased IL-13, IL-10 and sIL-6R 
in patients on steroid [32] and also increased IP-10 in plasma of T1R patients [50;55] showed 
the importance of these host biomarkers in leprosy reactions, suggesting utility in diagnostic 
platforms and possibly also in monitoring the efficacy of clinical reaction management. 
Further intensive longitudinal assessment of patients at multiple time points before, during 
and after reactions will reveal more biomarkers for prediction of reactions.   
 
The biomarkers discussed in this thesis (IFN-, IP-10, MCP-1, MIP-1β, IL-1β and others) are 
expressed by either innate cells (monocytes, macrophages, DCs, NK cells, ILCs) or adaptive 
immune (T) cells. A recent study in mice demonstrated that during re-exposures or re-
infections, memory T cells secrete IFN- which induces a cascade of innate cells to produce 
different cytokines and chemokines to control the infection [52]. This example illustrates the 
synergy of innate and adaptive immunity in controlling infections.  Future in depth analysis 
of which cells produce the biomarkers discovered in our work will provide new insights into 
the cellular networks and mechanisms involved.  These can be further studied to obtain 
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relevant information on these and new biomarkers that could in turn be analysed for 
improved diagnosis of M. leprae infection, leprosy reactions, and predictive capacity.  
 
Application of up-converting technology in development of leprosy diagnostic tools 
The development of rapid diagnostic tests that detect M. leprae infection is an urgent topic. 
As a study in India reported, inadequate monitoring of a policy of ‘new case validation’ in 
which treatment was not initiated until the primary diagnosis had been verified by a leprosy 
expert, may have led to approximately 26% of suspect cases awaiting confirmation of 
diagnosis 1–8 months after their initial primary health care visit [51]. This clearly shows the 
need for rapid leprosy diagnostic kits applicable in field settings where there is scarcity of 
leprosy experts.  
 
In recent studies, up-converting phosphor technology (UPT) has been applied in diagnostics 
via detection of various analytes derived from the host or pathogen. Similarly, the application 
of UCP-LFA for T-cell based responses or in combination with humoral responses was 
previously optimized for leprosy to measure IFN-, IL-10 and anti PGL-IgM [12] and more 
recently also IP-10 [6] (Chapter 5). The abundant IP-10 response against M. leprae specific 
antigen ML2478, which allows differentiating highly exposed individuals from those with 
low exposure, provided a rationale for optimizing the UCP-LFA for IP-10. Along with this, 
the possibility of detecting IP-10 already 6 hrs after stimulating with ML2478, the 
reproducibility of readings in dry and wet UCP-LF format using portable and bench readers 
makes it a highly promising candidate for POC test development [6]. The possibility of 
measuring both humoral and cell mediated responses against M. leprae on the same UCP-LF 
strip is an additional advantage that may simplify diagnosis of leprosy. Currently, the IP-10, 
IFN- and anti-PGL-I IgM based UCP-LFA is being field-tested in several endemic areas in 
Asia and Africa in combination with clinical follow-up of leprosy patients and their contacts.  
In addition, several other cytokines and chemokines are under investigation for application in 
the UCP-LFA platform in order to allow multiplex formats of different T cell subset-related 
cytokines as well as antibodies. A similar UCP-LFA test was also field-tested for its utility in 
TB diagnosis in five African countries [13], which further corroborated the value and 
robustness of this assay. 
 
Regulatory T cells contribute to non-responsiveness in Lepromatous patients 
The T cell non responsiveness in LL patients is mediated by multiple host and pathogen 
factors. We have shown regulatory T cells as a major factor for the non-responsiveness in at 
least one third of LL patients using a functional assay [9] (Chapter 6). In addition, the co-
presence of significantly higher number of FoxP3 positive cells with CD163
+
 Mφ2 in LL 
lesions shown in this thesis [9], and the higher number of CD163
+ 
[41] and increased IL-10 
and CTLA-4 in lesions of LL reported previously [43] further strengthens the role of 
regulatory T cells in leprosy. The presence of high frequency of CD8
+
 T regs in peripheries of 
LL patients as shown in ours and in another recent study [47] certainly indicates the need for 
functional characterization of this T reg population at infection sites and in the systemic 
circulation. In TB, the suppressive role of CD8
+
CD39
+
 T reg cells has been shown previously 
[10]. Increasing basic understanding of pathogenic mechanisms in leprosy will facilitate the 
design of treatments that can boost the CMI and down regulate the regulatory function to re-
establish normal function of macrophages and T cells in MB patients which eventually 
facilitate bacterial clearing from the host.   
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Co-infections in leprosy 
The impact of HIV has not worsened the leprosy situation as predicted [36;37]. However, 
manifestation of sub-clinical leprosy infection in some patients on anti-retroviral therapy 
(ART) was observed [37] although it is difficult to clearly show the onset of the infections, 
whether the HIV infection precedes leprosy or the other way round. The number of co-
infected patients in our study was small but among them the majority (66.6%) were patients 
with T1R and a strong association of ART and T1R was observed as described in chapter 7 
and was found similar with previous reports [15;39]. However, this association has to be 
further investigated in larger groups of patients on ART or naïve to ART in longitudinal 
studies.   
 
Characterization of immunological profiles in co-infected individuals is also important to 
generate information for the development of new diagnostic tools that can be used in both 
groups, in addition to what it might add in better understanding the co-existence of the two 
infections. In this thesis, significantly higher mRNA expression of CD8
+
 T cells in co-
infected patients is reported (chapter 7) and in previous study, in addition to the higher 
frequency of CD8
+
 T cells, their role in triggering T1R was reported in co-infected patients 
[14]. Therefore, further detailed investigations of immune cells derived from co-infected and 
leprosy patients without HIV are required for better understanding of the influence of one 
infection on the other and to generate information useful for management of co-infected 
patients. 
 
Another common co-infection is infection with helminthes. In TB, helminth infestation 
upregulates Th2 responses and weakens Th1 immunity induced e.g. by BCG vaccination 
[21;22] which may play a role in delayed clearance of the bacilli. In our study, the majority of 
patients were BL/LL patients (n=218). However, comparable percentages of BL/LL (12.4%) 
and BT (10.5%) patients tested positive for helminthes, unlike a previous study that showed 
higher (22.8%) helminth infection in MB compared than PB (6.8%) [16]. Although our 
findings require further analyses in a larger sample size, high IFN-γ responses against M. 
leprae WCS in helminth-free leprosy patients with T1R were measured as compared to 
helminth co-infected BL/LL patients with T1R. This indicates a skewing of helminth driven 
Th2 responses over Th1 also during T1R.  We hypothesize that this Th2 biased immune 
response may further delay the clearance of the bacilli in these patients. De-worming could 
be an option in regaining the Th1 type response in these patients to facilitate the bacterial 
clearance but may aggravate on the other hand the severity of the T1R.  These issues need to 
be investigated urgently before they can be applied in patient management. 
 
Conclusions and recommendations 
 
The achievements in leprosy control in the last three decades are remarkable, especially the 
replacement of life-long treatment dapsone with MDT and the global decline of leprosy 
prevalence. However, the incidence of leprosy registered every year in some countries such 
as India, Bangladesh, Brazil and Ethiopia has become stable because of the ongoing 
transmission within the endemic population. 
  
The major known sources of M. leprae infection are untreated MB patients and the non-
symptomatic sub-clinically infected individuals, although the nine-banded armadillos has  
also been reported as a source of infection in places where these animals are living close to 
humans [56]. The existence of some environmental reservoirs such as soil and water is also 
not resolved yet [57]. The established clinical investigation and the lab assessments including 
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AFB staining, the PGL-I based ML-Flow and LID-1 (See page 7) based rapid tests are more 
appropriate in identifying MB patients. However, developing diagnostic tests capable of 
identifying patients with few clinical signs and sub-clinically infected non-symptomatic 
individuals is by far more important in reducing leprosy transmission. 
   
Measuring IP-10 in whole blood assays briefly stimulated with the immunogenic and specific 
protein ML2478 and peptides of ML1601 has been found relevant in differentiating groups of 
individuals by level of their M. leprae exposure. IP-10 in UCP-LF assays is reproducible in 
different settings and preparations in dry or wet format and can be measured in combination 
with the humoral anti-PGL-I IgM in the same assay. Other biomarkers including MCP-1, 
MIP-1β and IL-1β were also found to have potential in differentiating groups by level of 
exposure or infection. In addition, the ratios of IFN-/IL-10 and IL-17/IL-10 were found 
relevant in predicting reactions. The identified antigens and biomarkers here in this thesis 
have to be further validated in larger sample sizes focusing on higher numbers of HHC. 
Studies are ongoing by our group in Asian and African countries to facilitate the application 
of biomarker tests in active case detection and in contact tracing in control programs. 
Furthermore, detailed analysis of the source and role of the identified cytokines and 
chemokines in the immunopathogenesis of leprosy will be relevant and will include study of 
the interactions of host immune cells with M. leprae in diverse host genetic backgrounds. It is 
also obvious that co-infections in HIV-positive patients are high and helminthes are common 
in people with low economic or living status. Therefore, including leprosy patients with co-
infections as study populations in every step in the diagnostic tool development process is 
important to ensure the applicability of the diagnostic tools in these groups of people.  
 
Our studies started with the screening of hypothetical (unknown functions) but unique M. 
leprae candidate antigens, assessing their immunogenicity in populations in different 
continents that covered large host background genetic and environmental diversity. We next 
used the most promising antigens to develop a simple and rapid diagnostic test format for 
early detection of infection, and of disease onset, including type-1 leprosy reactions. 
However, our studies also led to major questions on exposure vs infection: does a high pro-
inflammatory response in highly exposed individuals represent a signature of protective 
immunity, or a risk of developing disease? Such questions can only be answered by 
longitudinal assessment of well defined M. leprae exposed cohorts at different endemic sites.     
 
Finally, as all research activities in leprosy involve vulnerable groups, it is crucial that a 
strong public awareness program is installed to avoid stigma, to facilitate research and 
develop reliable tools relevant for leprosy control.  
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Lepra is een chronische infectieziekte veroorzaakt door Mycobacterium leprae. Wereldwijd 
leven er 2-3 miljoen mensen met lepra en ervaren de permanente, bijbehorende handicaps. 
Daarnaast ontwikkelen er jaarlijks meer dan 200.000 mensen deze ziekte. Ondanks de 
beschikbaarheid van effectieve antibiotica (multidrug treatment), worden als gevolg van de 
aanhoudende transmissie van de leprabacterie, veel mensen, waar onder kinderen, getroffen 
door lepra. Aangenomen wordt dat onbehandelde multibacillairepatiënten als ook M. leprae 
geïnfecteerde individuen zonder klinisch-zichtbare symptomen de belangrijkste bronnen van 
besmetting zijn. De momenteel beschikbare klinische- en serologische laboratoriummethoden 
zijn niet geschikt voor detectie van paucibacillaire patiënten en (nog) asymptomatische, M. 
leprae geïnfecteerde individuen die een hoog risico lopen op het ontwikkelen van de ziekte. 
Ook bestaan er geen diagnostische testen om leprareacties, de belangrijkste oorzaak van 
zenuwschade bij lepra, te voorspellen. 
 
In silico identificatie van genen die uniek zijn voorM. leprae en productie van de 
bijbehorende eiwitten heeft de mogelijkheden om diagnostische testen te 
ontwikkelenaanzienlijk uitgebreid, in het bijzonder voorde vroegdiagnostiek van infectie. 
Dergelijke testen kunnen uiteindelijk aanzienlijk bijdragen aan vermindering vantransmissie.  
Door middel van in vitroscreening van de specifieke cellulaire immuniteit van recombinante 
eiwitten en synthetischepeptiden van M.lepraein populaties met verschillende genetische 
achtergronden, zijn diverse antigenen geïdentificeerd met diagnostisch potentieel. Uitgebreid 
onderzoek naar de cellulaire immuunresponsetegen deze unieke antigenen bij leprapatiënten, 
hun huisgenoten en gezonde personen uit hetzelfde, lepra-endemische gebiedzijn van immens 
belang bij de ontwikkeling van nieuwe diagnostische testen. 
Dit proefschrift bespreekt de selectie en evaluatie van immunogene,M. leprae unieke eiwitten 
en peptiden, alsmede identificatie van gastheer biomarkers met als doel de detectie van M. 
leprae infectie en vroegdiagnostiek van lepra en leprareacties.  
 
Het meten van de hoeveelheid van het chemokine IP-10 in bloed,na 24 uur stimulatie met de 
specifieke M.lepraeeiwitten ML2478 en ML1601 (of hun bijbehorende peptiden), kan 
worden gebruikt om de mate van blootstelling aan M. leprae, en hiermee het risico op infectie, 
te bepalen in verschillende populaties. 
Aangezien klinieken in gebieden waar lepra voorkomt veelal niet beschikken over high-tech 
apparatuur, moeten diagnostische testen voor detectie van leprareacties gebruiksvriendelijk 
zijn. Om een gebruiksvriendelijke test voor het meten van IP-10 in veld situaties te 
ontwikkelen, werden er UCP-LF assays ontwikkeld en getest in diverse, verschillende 
populaties in lepra endemische gebieden. Deze testen bleken robusten reproduceerbaar voor 
gelijktijdige bepaling van zowel de hoeveelheid  IP-10 (cellulaire immuniteit) als het aantal 
antilichamen (humorale immuniteit) tegen M. leprae PGL-I 
Daarnaast werden andere biomarkers, waaronder MCP-1, MIP-1β en IL-1β,gevonden die 
gebruikt kunnen worden om de mate van infectie te helpen vaststellen.  
Een belangrijk aspect bij het bepalen van biomarkers is dat niet de absolute hoeveelheid maar 
de verhoudingen van verschillende markers correspondeert methet optreden van ziekte. In dit 
proefschrift wordt dit beschreven voor de ratio IFN-/IL-10 en IL-17/IL-10 bij type 1 lepra 
reacties.  
 
Aangezien bij het ontstaan van lepra meerdere factoren een rol spelen, is het duidelijk dat niet 
één maar meerdere biomarkers moeten worden toegepast in nieuwe diagnostische testen voor 
lepra en M. leprae infectie. Daarom zullen de in dit proefschrift beschreven biomarkers 
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verder moeten worden gevalideerd in grote aantallen contacten van leprapatienten. Hierbij is 
het vooral van belang dat de bepaling van de markers longitudinaal (op meerdere tijdstippen) 
plaats vindt omdat de intra-individuele verandering in biomarker ratios van belang is bij de 
diagnostiek van lepra. 
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